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Abstract 
NMR spectroscopy of tissue samples can be integrated with more conventional biofluid 
NMR spectroscopy to provide a comprehensive metabolic profile. The aim of this project is 
to integrate and interpret a combination of NMR and conventional toxicological data from 
urine, plasma and liver samples obtained over various time points during hepatotoxicity 
studies in the rat. The combined studies provided insights into the mechanisms and also 
sites of toxic damage. This integrated interrogation of the complex data sets also give a 
more holistic approach to the study of time-related toxic effects in the intact rat system and 
allow characterisation of key metabolic effects during toxic insult. High-resolution Magic 
Angle Spinning 1H NMR spectroscopy has therefore been used to investigate the 
biochemical composition of rat liver tissue samples and the data integrated with the results 
of biofluid NMR spectroscopy, clinical chemistry and histopathology to provide a 
comprehensive and sequential view of altered metabolism and toxicity using allyl formate, 
chlorpromazine and thioacetamide as model hepatotoxicants in the first instance. The NMR 
data were analysed collectively using a combination of pattern recognition techniques to 
describe the integrated metabolic effects in the whole system. Chemometric methods based 
on principal components analysis and partial least squares analysis were used to identify 
key features and biochemical correlations between the data sets. In addition, time- 
dependent metabolic variations in the treated-animals were obtained by means of 
multivariate mean trajectory approach. 1H MAS NMR of intact tissue provided a 'snap 
shot' of the endogenous perturbations in the organ at a particular time. In addition, 1H 
NMR spectroscopy of the biofluids enabled sequential monitoring of the biochemical 
changes following treatment, reflecting the altered metabolism in the whole organism. The 
analysis identified toxin-induced changes in liver, plasma and urine metabolic profiles 
which are related to choline metabolism, glucose homeostasis and energy metabolism 
represented by changes in liver TMAO, glucose and lipid levels, changes in plasma glucose 
and lipid levels and changes in urinary TMAO and tricarboxylic acid cycle intermediates 
i. e. succinate, citrate and 2-oxoglutarate. These studies demonstrated the varied applications 
of NMR-based metabonomic techniques in toxicological studies and that the integrated 
metabonomic approach is a powerful method for investigating complex biological systems. 
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Chapter 1. Introduction 
1.1 Background 
The use of medicines and drugs dates back in time as far as the first Egyptian dynasty of 
3 100 B. C. Discovery of the majority of these early drugs has been a trial-and-error process 
and serendipitous. The endeavour to optimize drug discovery and to rationalise the process 
has led to the concept of quantitative structure- activity relationships and brings about the 
progressive replacement of the highly serendipitous process to a process dominated by new 
technology. The process of bringing a new drug to market is very expensive and time 
consuming. It has been estimated that the cost to bring a drug to market successfully is now 
USD$800 million and takes about 10 to 15 years (DiMasi, 2001). The introduction of 
combinatorial chemistry and the setting up of library-based synthesis programmes has 
brought about the rapid generation and discovery of possible lead compounds and this 
therefore increases the pressure on the drug safety evaluation process. The knowledge of 
the toxicology of the drug candidate is vital in determining which candidate to be selected 
for development. However, complete toxicology testing for large numbers of lead 
compounds has proven to be both impractical (due to timescale) and costly. Therefore it is a 
prudent approach to reject unsuitable lead compounds in the early stage of development, 
and new ways of minimising such attrition are needed. The incorporation of screens that 
allow rational selection and optimisation of these molecules based on pivotal characteristics 
such as the way in which the candidate drug is metabolised (drug metabolism) or absorbed 
in in-vitro and in-vivo models coupled with pharmacological and preliminary toxicological 
data will enable identification of major metabolic imperfections in these molecules. These 
criteria will then form the basis for the decisions to advance one candidate into 
development over another (Ball and Borman 1998). 
In-vivo toxicity testing is still regarded as the most comprehensive approach. The use of 
results from in-vitro testing is rather restricted. The use of in-vitro data for assessment and 
classification of toxicity is usually in the early stages of a toxicology study to screen out 
most toxic compounds e. g. an Ames test to determine if a chemical is a mutagen. This is 
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simply because the results generated in in-vitro studies do not mirror the total effects 
observed within standardized animal testing due to the complexity of living animals. In- 
silico toxicology, also known as computational toxicology involves the use of computer 
technology and informatics to analyse, model and estimate the chemical toxicity based on 
structure-activity relationships (Mathews et al. 2000). This technology can be used to 
estimate effective dose related to toxicological end point. However, the use of in-silico 
technology is limited by the current existing knowledge on toxicological data and can never 
provide a definitive toxicity assessment. The Food and Drug Administration (FDA) does 
not recognize the use of in-silico toxicological information in regulatory submissions. This 
is simply due to the fact that in-silico technology generates unreliable prediction of toxicity, 
poor coverage for FDA-regulated substances and incorrect logic with respect to FDA 
hazard identification practices (Mathews et al. 2000). 
Disease biology is complex and drug development must be driven by insights into 
biological responses (Butcher et al. 2004). Understanding the relationships between genetic 
factors, the risks of developing major diseases and the molecular basis of drug efficacy and 
toxicity is a fundamental problem in modem biology (Nicholson et al. 2004). System 
biology approach aims to integrate multivariate 'omics-generated' biological data, to better 
describe and understand interactions in complex biological systems and ultimately to 
develop predictive models of human diseases (Nicholson et al. 2004, Butcher et al. 2004, 
Nicholson and Wilson 2003). The challenges of modelling mammalian biological 
complexities have been described recently by Nicholson et al. in a fascinating review (Nat. 
Biotechnol. 22,1268 - 1274,. October 2004). The relationships between 'endogenous' 
metabolic processes (coded in the genome and intrinsic to cellular function) and 
'xenobiotic' (foreign compound) metabolism are poorly understood, especially with respect 
to environmental factors (Nicholson and Wilson 2003). Metabonomics as part of the 'omics 
trinity' (genomics, proteornics and metabonomics) promise to, at least partially, provide a 
means of modelling these interactions. 
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1.2 Overview of the project 
The studies on which this project is based were split into two distinct phases. In phase one, 
four model hepatotoxins were individually dosed to rats. In phase two, four Pfizer 
compounds of known toxicity were individually dosed. However, only three of the phase 
one model hepatotoxins are presented in this thesis as one of the hepatotoxins, isoniazid, do 
not produce any liver toxicity. The overall aim was to use the phase one data to build 
models of hepatotoxicity, which would then be used in characterising any hepatotoxicity in 
the phase two compounds. All the studies were conducted on male Sprague-Dawley rats 
housed individually in metabolic cages. Majority of this project will focus on integrating 
the NMR-generated metabonomic data of both biofluids and liver tissues as well as 
histopathological and clinical chemistry data to give a global view on the effects of model 
hepatotoxins in mammalian system. 
The highly complex and information-rich NMR spectra necessitate the use of computer- 
based pattern recognition data reduction and mapping techniques to assist in spectral 
interpretation. Chernometric methods based on principal components analysis and 
projections to latent structures by means of partial least squares analysis were used to 
identify key features and biochemical correlations between the data sets. In addition, time- 
dependent metabolic variations in the treated-animals were obtained by means of 
multivariate statistical batch processing and mean trajectory approaches. This enabled 
sequential monitoring of the biochemical changes following treatment, reflecting the 
altered metabolism in the whole organism. 
The general layout of this thesis is outlined below in Figure 1.1. 
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1.3 Research Aims and objectives 
The overall aim of this project was to investigate the use of Magic Angle Spinning Nuclear 
Magnetic Resonance (MAS-NMR) spectroscopy to identify hepatotoxin-induced changes 
in the liver of experimental animals and to integrate and correlate these changes with the 
corresponding NMR spectroscopic data generated from urine and blood plasma and with 
the findings of histopathology and clinical chemistry. 
The specific objectives are: 
1. To measure and analyse MAS-NMR spectra of liver tissue samples from rats dosed 
with a range of liver toxins acting by different mechanisms. 
2. To compare and contrast the NMR results obtained from the liver tissue and 
biofluid samples. 
3. To compare and contrast the spectroscopic and conventional toxicological data. 
4. To integrate spectroscopic data from liver, blood plasma and urine samples to 
provide a more complete understanding of hepatotoxin-induced biochemical 
changes. 
5. To develop chernometric models based on the MAS NMR spectra of liver tissue, 
which can be used for detecting and quantifying hepatoxicity of chemical 
compounds. 
6. To identify metabolic biomarkers in liver tissue common to all hepatotoxins and 
those which allow distinction of the various types of hepatotoxic changes. 
To improve the understanding of the mechanisms of action of hepatotoxic 
compounds. 
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1.4 The Liver 
1.4.1 Structure andfunction 
The liver (Fig. 1.2) is situated below the diaphragm in the abdominal cavity. It is the largest 
organ of the body representing about 2-3% of body weight in mammals. The liver is 
subdivided into two lobules, which consist of lobes. The primary cells in the liver are the 
hepatocytes and the Kupffer cells. The liver is a highly active, multi- functional organ, 
which plays a major role in maintaining homeostatic control in the body and controls of a 
multitude of metabolic activities essential for the regulation of blood composition. The liver 
performs a large variety of functions including excretory and detoxification functions, 
cholesterol metabolism, exocrine and endocrine functions, and digestive functions. 
Figure 1.2 The liver and hepatic lobules (adapted from 
http: //www. bioloevmad. com/master. html? http: //www. bioloi! ymad. com/Kidneys/Kidn 
evs. htm). 
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The liver is served by two blood supplies, with the hepatic portal vein supplying 75% of the 
hepatic blood, and the hepatic artery, which supplies the remainder. Venous blood from the 
intestine, stomach, pancreas and spleen converges into the portal vein thus supplying the 
liver with nutrients, and the hepatic artery supplies oxygenated blood to the liver. The 
structural unit of liver, the hepatic lobules, are hexagonal in shape. At the peripheries of 
the lobules are the portal triads consisting of a portal vein, a hepatic artery and a bile duct. 
The portal vein divides into branches of interlobular veins surrounding the hepatic lobules 
(Fig. 1.2). Blood passes through these vessels between the liver cells (sinusoids) to the 
centre of the lobule. The hepatic artery also branches and accompanies the portal veins 
between the lobules. Hepatic arterial blood enters the sinusoids in the liver where it mixes 
with the blood from the portal vein. Sinusoids are highly fenestrated vascular channels. 
They are lined with endothelial cells bounded by hepatocytes and Kupffer cells. The 
endothelial cells are flat, non-phagocytic cells, which remove lipoproteins, glycoproteins 
and sugars from the blood. The Kupffer cells are macrophages, which remove old blood 
cells from spaces in between the endothelial cells and hepatocytes. Blood flow through the 
sinusoids is emptied into the central vein in each lobule. These central veins coalesce to 
form hepatic veins, which leave the liver and empty into the vena cava. 
The biliary system consists of channels and ducts that transfer bile from the liver to the 
small intestine. Bile is a product of hepatocytes. Hepatocytes are arranged in 'plates' 
surrounding the sinusoids. The basal part of adjacent hepatocytes is joined together to form 
canaliculi (the first channel in the biliary system). This is the intercellular space between 
the adjacent hepatocytes. Hepatocytes secrete bile into the canaliculi. Bile flows parallel to 
the sinusoids but in the opposite direction to the flow of blood. The bile drains into the bile 
ducts, which are lined with epithelial cells. The bile ducts are situated in close proximity to 
the end branches of both portal vein and hepatic artery. Small bile ducts merged into bigger 
ducts eventually forming the common bile duct. 
The hepatic acini are the functional unit of the liver. The acinus consists of a unit bounded 
by two portal triads and a central vein. The hepatocytes in each acinus are divided into 
three concentric elliptical zones that correspond to the distance from the arterial blood 
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supply (Fig 1.3). There are metabolic differences in each zone as those hepatocytes closest 
to the arterioles, zone 1 or periportal region, are the best oxygenated followed by zone 2 or 
mediolobular region and finally zone 3 or centrilobular region. This arrangement also 
means that cells in the center of the acinus (zone 1) are the first to encounter and potentially 
absorb blood-borne toxins absorbed into portal blood from the small intestine. 
Consequently, a variety of pathological processes lead to lesions that reflect acinar structure 
i. e. periportal necrosis or centrilobular necrosis. 
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Figure 1.3 Hepatic acinus and hepatocytes (adapted from 
htti): //arbl. cvmbs. colostate. edu/hbooks/Dathphvs/dii! estion/liver/histo acinus. html . 
1.4.2 Carbohydrate Metabolism 
The liver is capable of producing glycogen, the principal storage polysaccharide, by 
glycogenesis and of degrading the stored glycogen by glycogenolysis. An individual's 
metabolic status determines whether glycogen synthesis or glycogen degradation 
predominates. Liver glycogen is the only source for homeostatic control of the blood 
glucose level, since only the liver is equipped with the enzyme glucose-6-phosphatase that 
converts gluco se-6 -phosphate to glucose. In the liver, approximately 10% of the glucose of 
glycogen is available for immediate enzymatic release because of the highly branched 
glycogen structure (Kaplan and Pesce, 1989). Liver glycogen storage is dynamic in nature, 
functioning as a source of glucose for all parts of the body except muscle. Increased 
demand for glucose will normally be met by an increase in glycogenolysis. However, 
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gluconeogenesis enables a continued supply of glucose when the body's store of glycogen 
is depleted under strenuous conditions by producing glucose-6-phosphate from amino 
acids, lactate and glycerol. 
1.4.3 Bile Formation 
Bile acids are the major metabolic product of cholesterol. Bile acids synthesis from 
cholesterol is a multi-enzyme coordinated process (Palmeira and Rolo, 2004). In this 
pathway, the addition of hydroxyl groups, reduction of double bonds and the oxidation of 
the side chain, form a soluble end product from cholesterol. Hydroxylation is always on one 
side of the molecule resulting in an amphipathic molecule having a hydrophobic tail on one 
side and a hydrophilic tail on the other. However, different bile acids have varying degree 
of hydrophobicity and hydrophilicity determined by their physicochernical and biochemical 
properties (Pah-neira and Rolo, 2004). The major bile acids in humans are cholic, 
chenodeoxycholic, lithocholic and deoxycholic acids. These four major bile acids differ 
only in the number and position of hydroxyl groups that are attached to the steroid nucleus 
with cholic acid having three hydroxyl groups, both chenodeoxycholic and deoxycholic 
acids having two hydroxyl groups and lithocholic acid has only one (Figure 1.4). 
The bile acids which are synthesised within the hepatocytes are called primary bile acids 
i. e. cholic and chenodeoxycholic acids. These bile acids are further conjugated with glycine 
or taurine to form glycol- or tauro-conjugated bile acids, which are then secreted by the 
liver into the bile. Regulation of bile acids synthesis is determined by the amount of bile 
acids returned from the intestine to the liver. Biosynthesis decreases as more bile acids are 
reabsorbed (Montgomery et al. 1996). Bile acids biosynthesis is also controlled by the 
amount of cholesterol ingested. An increase in cholesterol consumption will lead to an 
increase in bile acids synthesis. Therefore, continuous conversion of cholesterol into bile 
acids in the liver is vital in preventing the body from having a cholesterol overload. 
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Figure 1.4 Schematics of bile acids synthesis (adapted from Montgomery et al. 1996). 
Conjugated primary bile acids are either secreted by the liver directly into the duodenum 
via the common bile duct or stored temporarily in the gall bladder. Bile is secreted into the 
intestine to emulsify lipids, a process necessary for hydrolysis and absorption of dietary fat. 
Secretion of bile acids from the liver and the emptying of the gallbladder are controlled by 
the hormone hepatocrinin and cholecystokinin respectively. Deoxycholic and lithocholic 
acids are both secondary bile acids. They are formed through the action of intestinal 
bacterial enzymes on the primary bile acids in the intestine. The process involves the 
deconjugation of the primary bile acids followed by the C-7 dehydroxylation of the primary 
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bile acids by intestinal bacteria. Secondary bile acids are also conjugated with glycine or 
taurine to form corresponding glyco- and tauro-conjugates. 
1.4.4 Enterohepatic Circulation 
Although bile acids are secreted in large quantities into the intestine, only a small amount 
of the bile acids secreted are lost from the body. About 95% of bile acids secreted into the 
duodenum are reabsorbed back into the blood circulation through the ileum. The venous 
blood from ileum empties into the portal vein, which passes through the sinusoids to the 
liver. Here, the bile acids are extracted by the hepatocytes surrounding the sinusoids. These 
extracted bile acids are then resecreted into the canaliculi. The whole process is termed 
'Enterohepatic Recirculation' (Figure 1.5). 
Enterohepatic recirculation is the process by which a drug is reabsorbed in the 
gastrointestinal track after biliary excretion. A drug that is excreted in the bile enters the 
intestine after storage in the gallbladder. A major prerequisite for such a process is the 
conjugation of the drug by a phase II biotransformation in the liver and the excretion into 
the bile of the resulting conjugate (glucuronide, glycoside, sulfate). This conjugate may 
then be enzymatically hydrolyzed by intestinal microflora in the gastrointestinal track 
releasing the parent drug for reabsorbtion into the portal circulation. Biliary secretion and 
intestinal reabsorption may continue until the drug is ultimately eliminated from the body 
via renal or fecal excretion or other routes of disposition. Hence, enterohepatic circulation 
may result in unusually long persistence of drug in the body, and may influence such 
pharmacokinetic parameters as the drug half-life, the area under the plasma level versus 
time curve (AUQ and possibly estimates of bioavailability. 
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Figure 1.5 Enterohepatic Recirculation (adapted from Chan et aL 2004). 
1.4.5 Metabolism and Detoxification 
As the liver is one of the major points of entry to the tissues of the body, it is one of the 
primary sites of metabolism and elimination of most xenobiotics. The liver removes mostly 
water-insoluble drugs, which are bound to albumin, from the blood plasma. It then converts 
the water-insoluble drugs to a more water-soluble form, which may be excreted into bile 
and eliminated via the gastrointestinal tract. The process of enhancing the water solubility 
of xenobiotics is termed biotransformation. B iotrans formation of xenobiotics is mostly 
accomplished by liver microsomes which contain a family of enzymes that oxidise various 
chemicals such as carcinogens, drugs and steroids. These microsomal systems are termed 
mixed-function oxidases consisting mainly of cytochrome P-450 mono-oxygenases and 
flavin-containing mono - oxygenase s. Many of the biotrans formation reactions such as 
epoxidation, hydroxylation, dehalogenation and oxidative dearmnation are catalysed by 
these mixed-function oxidases. Metabolism of xenobiotics by mixed-function oxidases is 
classed as Phase I metabolism. Phase 1 metabolism normally involves the alteration of 
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foreign molecules simply by the addition of a functional group. These can then be 
conjugated in Phase 2 metabolism. 
Phase 2 metabolism involves mainly conjugation with readily available polar endogenous 
compounds such as glucuronic acid and sulphate, to the functional group present on the 
foreign molecule or those introduced by Phase 1 metabolism. This renders the whole 
molecule more polar and thus more water-soluble, facilitating excretion and reducing the 
likelihood of toxicity. Another important route of Phase 2 metabolism is glutathione 
conjugation. This is because it involves the removal of reactive intermediates. Glutathione 
is a tripeptide found in many mammalian tissues especially in the liver. It plays a major 
protective role in the body as it is a scavenger for reactive compounds of various types, 
combining at the reactive centre in the molecule therefore reducing the toxicity (Timbrell 
2002). The sulphydryl group of glutathione acts as a nucleophile which either displaces 
another atom or attacks an electrophilic site. Consequently, glutathione may react either 
chemically or in enzyme-catalysed reactions with a variety of compounds which are either 
reactive or are electrophilic metabolites produced in Phase 1 reactions. The reactions may 
be catalysed by one of a group of glutathione transferases located in the soluble Eraction of 
the cell. The resulting conjugate may be either excreted into the bile unchanged or 
metabolised farther,, via Phase 3 reactions, to yield an N-acetylcysteine conjugate. A 
detailed description of the underlying principles of biochemical toxicology has been 
extensively covered in numerous publications (Timbrell 2000, Gibson & Skett 1994) 
1.5 Common Liver Diseases Associated with Drug Toxicity 
The effects of hepatotoxins may be highly reproducible whereby upon a single exposure or 
repeated exposure to the hepatotoxin, the liver consistently shows signs of 
hepatic injury. 
Such toxins include chloroform, carbon tetrachloride, tetracycline, and anti cancer drugs. 
On the other hand, the effects of a hepatotoxin can be idiosyncratic whereby 
it produces a 
toxic response in only a tiny proportion (e. g. 1 in 10000) of animals or 
humans. Halothane 
is such an example where the damage could be due to the phenotypic susceptibility of a 
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particular animal. However, this project will focus on identification of reliable and 
consistent hepatotoxins. 
Liver damage may arise from either single or repetitive exposure to hepatotoxins. The main 
types of acute liver damage that may occur are necrosis (cell death), steatosis (fatty liver) 
and cholestasis (obstruction of bile flow) leading to biliary damage. The term necrosis is 
used to describe the condition when irreversible damage occurs in cell beyond repair and 
cell death ensues. This is normally followed by a series of degenerative changes including 
hydrolysis of cellular components and protein denaturation (Timbrell 2003). Steatosis is 
defined as accumulation of fat, largely triglycerides, exceeding 5% of the liver weight 
(Sherlock & Dooley 2002). This is a common response to toxic compounds and is usually 
reversible. It is caused by failure of fat metabolism in the liver due to damage to the 
hepatocytes. The excess lipid may appear in the cell as small/large droplets thus producing 
characteristic yellowish liver. Cholestasis is defined as interference of bile flow or bile 
formation (Sherlock & Dooley 2002. ). This can occur anywhere in the sinusoids, 
hepatocytes and the ampullae of Vater. For instance, if the sinusoidal membrane lining of 
the hepatocytes is destroyed, blockages of the ductules can occur due to debris from 
necrotic cells thus triggering cholestasis. Cholestasis can also result from errors in bile 
synthesis. 
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1.6 Application of 1H NMR Spectroscopy to Metabolic Profiling 
1.6.1 Metabolic Profiling and the Metabonomics Approach 
Metabolic profiling provides a powerful new tool for gaining insight into functional 
biology. Xenobiotics cause perturbations of the concentration and fluxes of endogenous 
metabolites involved in the countless multifaceted catabolic and biosynthetic pathways 
existing in all living systems. The response of cells to toxic insult generally first entails an ID 
adjustment of the intra- and/or extra-cellular environment in order to maintain homeostatic 
control in their highly regulated environment. Metabolic regulations in response to 
pathophysiological and/or genetic stimuli can be expressed as a unique fingerprint of 
biochemical perturbations that is characteristic of the nature or site of toxic insult or disease 
processes. 
Metabolic profiling can be divided into two distinct classes according to the level of 
biological organisation. Metabolomics, is defined as the study of the metabolite profiles in 
single cell systems (Nicholson et al. 1999, Nicholson et al. 2002) whilst metabonomics is 
defined as 'the quantitative measurement of the dynamic multiparametric metabolic 
response of living systems to pathophysiological stimuli or genetic modification' 
(Nicholson et al. 1999). As a result, metabonomics represents a full system biology 
approach to understanding the dynamics as well as organ-specific biochemical responses in 
response to pathophysiological stimuli and genetic modification. 
A variety of spectroscopic methods can be used to acquire metabonomic data sets on 
complex biological samples. Nuclear Magnetic Resonance (NMR) spectroscopy has been 
instrumental in providing a snapshot of the level of numerous small molecules within a cell 
or a biofluid and how those levels change under different physiological, pharmacological 
and toxicological conditions. Additionally, NMR spectroscopy enables the study of 
molecular dynamics providing information such as molecular reorientation-correlation 
times and diffusion coefficients in solution and in intact tissues. It is complementary to 
gene expression (genomic) and proteomic studies. It is by far the most powerful method for 
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examining biofluids and essentially the only method capable of studying intact tissues 
providing comprehensive profile of metabolite signals without laborious sample 
preparation or derivatisation steps. Mass spectrometry can also be used to generate 
metabolic data, however, differences in the efficiency of ionisation can affect detectability 
and quantitation, and a prior separation stage such as HPLC is required as this can 
introduce additional variability. Nevertheless, mass spectrometry can be much more 
sensitive than NMR spectroscopy. Most metabonomic investigations have examined the 
biochemical effects of xenobiotics in animal models and the majority of these studies have 
employed high-resolution 'H-NMR spectroscopy to characterise and quantify various 
metabolites in biofluids such as urine and plasma whilst Magic Angle Spinning (MAS) 
NMR spectroscopy has been used to analyse cells and tissues (Holmes et al. 1994, 
Robertson et al. 2000, Waters et al. 2001 , Garrod et al. 2001 , Nicholson et al. 2002). These 
methods are usually coupled with powerful pattern recognition (PR) and expert system 
methods to allow classification of the samples on the basis of the different fingerprints 
arising from the highly complex and information-rich high-resolution NMR spectra. 
1.6.2 Principles ofNuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR) spectroscopy detects the way in which 
electromagnetic radiation interacts with the spin of atomic nuclei. The spin is characterised 
by a nuclear spin quantum number, 1, that can take integer and half integer values. Those 
nuclei with I=0 will have no spin and therefore are not observable by NMR. However, 
most elements i. e. 1H, 13 C, and 3 1P, have I>0 and are therefore NMR-observable. All 
charged spinning nuclei have an angular momentum, J, which give rise to a magnetic 
moment, ýt such that: 
ýL = yj 
where y is the magnetogyric ratio. The bigger the magnetogyric ratio the larger the 
magnetic moment of the nucleus. The magnetic moment is quantised and can only take 
certain values. When an external magnetic field, BO (measured in Tesla), is applied to 
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magnetic nuclei, the nuclei will precess at 21 +1 possible orientations. Therefore, for a 
spin-1/2 nucleus like 1H, this will generate two spin states in a magnetic field. The energy 
of these states can be characterised by the magnetic quantum number, in. The lower energy 
state corresponds to m, =+ 1/2. This occurs when the lower energy state, precesses parallel 
with the applied magnetic field, BO. The higher energy state corresponds to mp =- 1/2. This 
occurs when the energy state precesses against BO. This splitting of spin energy level into 
specific states is called the Zeeman effect. There is a tendency for the magnetic moments to 
align in the direction of BO because of the slightly lower energy state it is associated with, 
and the ratio of the populations (ij) of the two states is given by the Boltzmann rule: 
, n(y. /TIP e 
AE/kT 
where AE is the energy difference between the spin states, k is Boltzmann's constant and T 
is the absolute temperature in Kelvin. When the force Bo is applied to a nucleus, it causes 
the nuclei to precess at an angular frequency called the Larmor frequency. The angular 
frequency, (oo, increases proportionally with BO: (oo = yBo, or in frequency terms: vo = 
yBO/27r. Given the linear relationship between BO and AE, the natural precession frequency 
can be expressed in frequency terms by Planck's relationship: 
AE = hvo 
where h is the Planck's constant (6.626208 * 10-34 j S). Thus, as: 
AE= hyBo/2Tc 
All different types of nuclei have a unique resonant frequency because of their different 
values for y. When a second magnetic field, BI, is applied at a radio frequency, the 
frequency matching that of the Larmor frequency of the nucleus causes the excess spins to 
move from the lower energy state to the higher energy state by a process called resonance. 
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Figure 1.6 3D-Diagram of magnetization behaviour in magnetic field. 
If the axis system is considered to rotate at the Larmor frequency then the magnetisation 
has a net value along the Z (Bo) axis as shown in Figure 1.6. Application of radlofrequency 
energy can then be regarded as tipping M into the XY plane. This is usually done by a short 
intense pulse along the X-axis. Sufficient energy to tip M to along the Y-axis equalises the 
populations of the two states, and is termed a 90' pulse. The magnetisation that precesses in 
the XY plane induces an oscillating current in a receiver coil and is the NMR signal. This 
magnetisation will return to equilibrium when the radio frequency pulse is turned off and 
thus the signal will decay. This signal is called a Free Induction Decay (FID) (Figure 1.7). 
To convert this to a normal frequency domain spectrum, Fourier transformation is used, 
usually by employing the Cooley-Tukey algorithm. 
Figure 1.7 Free Induction Decay (FID). 
Not all nuclei of the same type (e. g. 1H) resonate at exactly the same frequency. The 
resonance frequency depends on the chemical environment, which leads to the phenomenon 
known as the chemical shift. Additionally, each peak can be split by an interaction called 
spin-spin coupling - an indirect interaction between magnetic nuclei mediated through the 
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chemical bonds. In addition peak areas are proportional to both the number of nuclei giving 
rise to the peak and to the concentration of the substance. 
1.6.3 NMR Spectroscopy of Biqfluids 
One of the most important developments in NMR spectroscopy in the last 20 years has 
been the application of high-resolution 1H NMR spectroscopy to the analysis of biofluids to 
investigate and understand numerous diseases and toxic processes. NMR spectroscopy 
enables the simultaneous detection of a wide range of low-molecular weight compounds 
within a biological matrix without sample preparation. Biofluids have diverse biological 
purposes and the composition of biofluids varies with their role and the functional integrity 
of the organ systems that are communicating with them and ultimately with the 
physiological status of the whole organism (Nicholson et al. 2002). A shift in the 
physiological status of a living organism in response to disease or xenobiotic exposure will 
result in subtle modifications in the biochemical composition of its intra- and extracellular 
fluids. These are often reflected in changes in the composition of other biofluids, such as 
urine and plasma as the organism tries to maintain homeostatic control. 
Metabolic profiles of biofluids such as plasma, urine and cerebrospinal fluid reflect both 
normal variation and the pathophysiological impact of toxicity or disease on single or 
multiple organ systems. Therefore, each biofluid will yield a characteristic 
'H-NMR 
spectroscopic fingerprint, which characteristically mirrors their altered endogenous 
metabolic profile in response to changes in physiological status, toxic insult or disease 
progression. Plasma and urine are, by far, the most useful and widely used biofluids 
because they can be obtained in a non- or minimally invasive manner and therefore, are 
ideal for disease diagnosis and clinical-trial monitoring. Analysis of these biofluids 
provides an abundance of information on the nature and severity of single or multiple organ 
dysfunctions thus reflecting the vast array of biochemical processes taking place in key 
organs and tissues within the body. 
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NMR spectroscopy of biofluids has clear advantage over conventional analytical techniques 
as a wide range of metabolites can be detected simultaneously without the need to pre- 
select metabolites of interest in order to detect and quantify them. Its non-destructive nature 
and the fact that no- or relatively minimal sample preparation is required makes NMR 
spectroscopy an ideal technique to probe many cellular biochemical status in the fields of 
toxicology (Holmes et al. 1998), drug metabolism (Bales et al. 1988) and clinical 
investigation (Foxall et aL 1995). The pattern of endogenous metabolites in biofluids 
depends strongly on the type of toxin an animal is exposed to or the animal's disease state. 
Each toxic compound or disease produces characteristic changes in the concentration and 
pattern of endogenous metabolites in biofluids that provide information on the sites and/or 
basic mechanism of toxic or disease processes. Such changes, if detectable, offers a much 
greater diagnostic value rather than relying on a change in a single chemical entity. This is 
because it is very difficult to ascertain that a change in a single compound is a marker for 
the disease or organ dysfunction. Numerous studies on NMR spectroscopy of biofluids 
have been well documented and some examples are surnmarised in Table 1.1. 
Table 1.1 Examples of NMR spectroscopy of biofluids. 
Biofluid Research Field References 
Bile Toxicology (Blackledge et al. 2002) 
Blood Inborn errors of metabolism (Constantinou et al. 2004) 
Cerebrospinal fluid Neuropathy (Ghauri et al. 1993) 
Plasma Toxicology (Anthony et al. 1993) 
Seminal fluid Baseline biochemical composition (Tomlins et al. 1998a) 
Urine Physiological variation (Bollard et al. 200 1) 
Urine Inborn errors of metabolism (Holmes et al. 1994) 
Urine Pharmaceuticals (Beckwith-Hall et al. 2002) 
Urine Toxicology (Holmes et al. 1998) 
Urine Drug metabolism (Bales et al. 1988) 
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1.6.4 1H NMR Spectroscopy of Blood Plasma 
Blood makes up about 6% of total body weight in humans. It consists of cellular elements 
suspended in a complex fluid matrix of proteins, mainly albumin, glycoproteins, 
lipoproteins and immunoglobulins, together with a vast number of inorganic and low 
molecular weight organic solvents (Lindon et al. 2000). Blood is the vehicle of 
transportation, transporting oxygen, carbon dioxide, metabolic products and hormones. It is 
this function that makes possible the specialisation of structure and function that is 
characteristic of all but the lowest organisms. It is by means of circulating blood that the 
constancy of the internal environment is maintained. Consequently, the concentration of 
many blood constituents may vary as a result of diverse influences such as diet and 
metabolic demand. Additionally, disease processes or abnormalities in the body will lead to 
the perturbation of the constancy of the internal environment, which are often reflected to 
various extents in altered blood composition. 
Various high-resolution 1H NMR studies have been applied on the biochemistry of blood 
and its numerous cellular components and plasma (Lindon et al. 2000). The 1H NMR 
spectra of blood plasma can provide a plethora of biochemical information on 
macromolecular structure and organisation, and on low molecular weight metabolites. The 
presence of proteins, lipids and lipoproteins in plasma give rise to highly overlapped and 
broad envelope of 1H signals in NMR spectra which over shadow the resonances from low 
molecular weight metabolites. However, the complexity of single pulse 1H NMR spectrum 
of blood plasma can be simplified by the use of spin-echo experiments that allow the 
signals from high molecular weight metabolites to be attenuated (Nicholson et aL 1995). 
The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence is an effective means of editing 
plasma 1H NMR spectra according to their transverse (T2) relaxation time, thus resulting in 
the elimination of broad signals from slowly tumbling high molecular weight species and 
the resultant spectra consist mainly of low molecular weight species, which cannot be 
resolved in the single pulse experiment. 
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1.6.5 1H NMR Spectroscopy of Urine 
The kidneys play an important role in the maintenance of body homeostasis, effectively 
regulating body biochemistry. This is done through the excretion of unwanted organic and 
inorganic compounds thus maintaining constancy in the internal environment at the 
expense of variation in urine composition. Therefore, varying urine composition reflects the 
large number of biochemical processes which take place in the body. This offers a great 
diagnostic potential in NMR urine analysis. Urine composition is highly variable and 
complex both between species and within species due to variation in lifestyle, gender and 
age (Bollard et al. 2005, Lindon et al. 2000). The kidneys also have an endocrine function 
that is associated with ionic and water balance. The variable nature of urine composition 
also reflects the functionality of the kidneys, and physiological and biochemical status of 
the organisms (Nicholson and Wilson, 1989). It is possible to detect vast numbers of 
organic species using NNM spectroscopy since a wide range of organic acids and bases, 
low molecular weight proteins, simple sugars and polysaccharides as well as inorganic 
species such as Na+, Ca2+, HC03- and phosphates are present together in urine (Lindon et 
al. 2000). 
The physiological processes in all animals are modulated by biological rhythms. These 
processes includes excretory processes, consequently, the urinary composition of an animal 
may vary according the time it is collected. Changes in urinary composition according to 
diurnal variations can be observed using NMR-based metabonomic method as observed by 
Bollard et aL (2001). Therefore it is imperative that closely matched controls are obtained 
when studying toxicological or disease processes. Urinary composition also changes 
according to diet both in man and animals. For example, the consumption of shellfish and 
fish is associated with high levels of betaine and trimethylamine in urine (Nicholson and 
Wilson 1989). Thus it is critical to distinguish these dietary signatures from disease-related 
processes in clinical or toxicological studies. 
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1.7 Introduction to Magic Angle Spinning NMR 
Tissue samples can provide complementary information to that obtained in biofluids. 
However, obtaining useful biochemical information from 1H NMR measurements of intact 
tissues in-vivo can be difficult as the spectral quality is severely compromised by the 
utilisation of low magnetic fields (Lindon et aL 2004). In addition, heterogeneity of the 
sample usually gives rise to magnetic susceptibility differences causing magnetic field 
inhomogeneity. This combined with restricted molecular motions of molecules in tissues 
leads to low sensitivity and resolution. Consequently, NMR spectral analysis of tissues has 
relied largely on tissue extraction methods. This requires relatively large amounts of tissue 
sample and multiple extraction methods to extract both the lipophilic and lipophobic 
phases. Although it is possible to extract water and lipid soluble compounds by using 
extraction techniques, the extract composition usually reflects the solubility of the 
metabolites as well as the tissue compositions. In addition, extraction methods do not take 
into account the composition of cell membrane constituents as aqueous soluble metabolites 
may be encapsulated in lipid compartments thereby inhibiting their extraction. Such bilayer 
structures are usually associated with chemical and more importantly xenobiotic transport 
around the cell. Moreover, extraction techniques are destructive in nature. In vivo 1H 
magnetic resonance spectroscopic (MRS) studies, on the other hand, uses low magnetic 
fields thus suffers from low sensitivity and spectral dispersion. 
Magic Angle Spinning (MAS) was initially developed to study rigid solids mainly in 13C 
NNM spectroscopy. 1 3C is a very dilute nucleus therefore produces low sensitivity. To 
obtain high-resOlution 13 C NMR spectra, three techniques were combined: 
1.1H to 13C spin cross polarisation to improve sensitivity 
2. High power broadband decoupling of 1H nuclei to remove heteronuclear dipolar 
coupling. 
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3. Magic Angle Spinning (MAS) to remove remaining residual dipolar coupling and 
13 C chemical shift anisotropy. 
However, the development of high resolution 'H magic-angle- spinning (MAS) NMR and 
its application in the field of metabonomics within the past few years has had a significant 
impact on the ability to analyse intact tissues (Garrod et aL 1999). An advantage of high 
resolution MAS NMR is that it avoids time-consuming sample extraction processes by 
analyzing the tissue directly and it is possible to observe metabolites lost in extraction 
processes through MAS NMR. 
1.7.1 Principles of Magic Angle Spinning NMR 
Molecules in liquid phases undergo fast isotropic motion and thus the chemical shift and 
spin coupling values, which are orientation dependent, are simple isotropic averages of 
second rank tensors (Andrew and Szczesniak 1995). This effectively removes line- 
broadening effects from the spectrum. In anisotropic environments, a new interaction 
termed direct dipole-dipole coupling (with an isotropic average value of zero) can be 
manifested. Biological samples, especially tissues, do not behave as true solids because the 
molecules experience some mobility in the cell compartments. Therefore they exhibit 
intermediate behaviour between a rigid solid and isotropic liquid and the interactions, 
which cause line broadening in solids, are partially averaged out. 
In MAS NMR spectroscopy, the tissue sample is placed in a zirconium rotor (Figure 1.8A) 
using a spacer. The use of a spacer enables analysis using smaller total sample size and thus 
easier adjustment of the shimming of the BO magnetic field to achieve homogeneity across 
the whole sample. This results in improved spectral quality. The rotor is placed into a 
magnet, tilted and rotated at an angle, 0 relative to the applied magnetic field, BO. This 
causes a modulation of the anisotropic interactions by a factor of 3 (COS2 P- 1)/2. If P is 
chosen to be 54-7 (i. e. when 3cos 2p_ I= 0) then the average value of the anisotropic 
parameters goes to zero. 54.7' is also known as the magic angle (Figure 1.8B). The 
advantage of using semi solids is that the 1H-1H dipolar couplings are partially averaged by 
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the resulting restricted molecular motion thus resulting in moderate line broadening. MAS 
experimental conditions can be applied to improve resolution and produce spectra with 
narrow lines. 
(A) 
Rotor Cap 
Teflon Grub Screw 
Zirconia Case 
Teflon Spacer 
Liver Tissue Sample 
H Teflon Spacer 
(B) 
Figure 1.8 Schematic diagram of. - (A) magic angle spinning rotor (adapted from 
Mehta 2004), and (B) Sample spinning at the magic angle (0 = 54.7'). 
In order for the MAS experiment to succeed, the spinning frequency must be greater than 
the value of the anisotropic broadening. Figure 1.9 shows the effects of spinning a sample 
at the magic angle on spectral resolution. However, the disadvantage of MAS-NMR is that 
it is time consuming where it is only possible to analyse about 10 samples per day as 
compared to solution state NMR, which can analyse more than 100 samples per day. 
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Figure 1.9 Effect of spinning at the magic angle on 111 NMR spectral resolution in 
intact rat liver tissue (Bollard et A 2000). 
1.7.2 Factors Affecting Line Broadening in MAS NMR 
1.7.2.1 Dipolar Coupling 
Dipolar coupling (D) is an anisotropic effect. Dipolar coupling between two nuclei is 
usually the major contributor to line broadening effect in solids and semi-solids. Dipolar 
coupling between two nuclei A and B is given by the equation: 
DAB I-- YA YB rAB -3 (3cos 2 OAB-1) 
Where, yAandYBare the magnetogyric moments of A and B, r is the internuclear distance 
and 0 is the angle between the internuclear vector and the magnetic field, B, Dipole 
coupling is orientation dependent such that if the internuclear vector is parallel or 
perpendicular to B. then the relative values will be +1 or -0.5 respectively. In solutions, the 
rapid isotropic motion averages the dipolar couplings to zero but the value of D at any one 
time will not be zero. These transient fluctuating interactions are an important source of 
spin relaxation giving rise to the Nuclear Overhauser Effect (NOE). In solids, the average 
of D is never zero. The D value between two hydrogens in a solid crystal can be as large as 
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20000 Hz. In a powder, the internuclear vector will experience a range of orientations from 
parallel to perpendicular to BO thus resulting in a Take doublet' broad line (Figure 1.10). 
o 
III 
-1 0 +1 
Figure 1.10 Take' doublet. 
Therefore, to generate a sharp line, the molecule must tumble fast enough to produce an 
average isotropic motion, which will give a dipolar coupling of zero. Biological tissues do 
not behave as true solids instead they exhibit interinediate behaviour between true solid and 
liquid because of the restricted molecular mobility due to tissue compartmentalisation. 
Therefore some components will experience considerable molecular motion, which can be 
either faster or slower than the other albeit slower in general as compare to liquid. This will 
generate an anisotropic effect due to residual dipolar couplings thus resulting in line 
broadening. The dipolar couplings in tissues are usually <I kHz. 
1.7.2.2 Magnetic Susceptibility 
Another major contributor to line broadening effects in semi-solids is anisotropy in 
magnetic susceptibility. Biological tissue i. e. liver samples are heterogeneous in nature, 
containing significant amounts of water, lipids, and other fluid components in different 
compartments. These samples suffer from anisotropy in magnetic susceptibility due to 
magnetic field inhomogeneity because components inside and outside a compartment will 
experience different magnetic fields leading to severe line broadening. Anisotropic 
magnetic susceptibility has a similar angular dependence to dipolar coupling. Therefore, 
magic angle spinning can be applied to circumvent the line broadening effect induced by 
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magnetic susceptibility anisotropy. Any differences in the isotropic value of the magnetic 
susceptibility due to different cellular environments for example will give rise to a chemical 
shift difference for a molecule, which is present in both compartments. 
1.7.2.3 Chemical Shift Anisotropy (CSA) 
Chemical shifts occur when the magnetic field is applied to the electron density 
surrounding a nucleus and thus shielding a nucleus. Chemical shifts in solids depend on the 
orientation of the molecule relative to the magnetic field, BO, applied. It is direction 
dependent. In a liquid the movements of the molecules are fast enough to produce a rapid 
isotropic motion, which therefore averages the chemical shift to a single value. In solids 
these chemical shifts are not averaged to one value because of the way the molecules are 
held in a tethered conformation. However, this is not a serious problem in 1H NMR 
spectroscopy because chemical shift anisotropies are small even before the motional 
averaging process. 
1.7.3 Application of MAS NMR Spectroscopy in Tissues Analysis 
Although MAS NMR method is time-consuming as compared to solution state NMR, it 
requires little or no sample preparation at all. In addition, the spectral information obtained 
has proven to be invaluable in the field of metabonomics. Recent advances in MAS 
instrumentation and probe technology, has made it possible to analyse very small biological 
tissue samples directly, ca 8 mg (Bollard et al. 2001), with little or no sample treatment 
required and an NLAS NMR spectrum, comprising well-resolved sharp peaks, can be 
acquired in less than 10 minutes. The application of NMR in tissue analysis has revealed 
that there are enormous differences between the diseased and toxin-affected tissues, and 
those of healthy organ (Moka et al. 1998, Waters et al. 2002). The application of MAS 
NMR to study tissue compartmentalisation by Griffin et al. (2000a) has yielded vital 
information on not only tissue compartmentalisation but on molecular dynamics as well 
which would have otherwise been very difficult to obtain. 
1H MAS NMR spectroscopy 
enables a holistic analysis of tissues, providing a link between biofluid and histopathology 
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and an insight into the actual mechanisms of toxicity at a molecular level (Lindon et aL 
2004) 
The various pulse sequences, spectral editing and 2-dimensional techniques used in normal 
fluid NMR can also be applied in MAS NMR and this make MAS NMR a very versatile 
method for tissue analysis. The principle of spectral editing is based largely on the spin 
properties of both macromolecules and small molecules, whereby the limited translational 
motion and longer rotational correlation times experienced by macromolecules entail a 
shorter T-, (transverse) relaxation time and smaller diffusion coefficient compared to those 
of smaller molecules (Johnson Jr. 1999, Wang et al. 2003). Spectral editing utilising T2 
relaxation time is termed T2-edited spectroscopy (Stejskal and Tanner 1965). One of the 
most common T2-edited spectroscopy methods used is the Carr-Purcell-Meiboom-Gill spin- 
echo pulse-sequence, which is very effective in removing broad signals from slowly 
tumbling macromolecules. Conversely, it is also possible to attenuate signals Erom smaller 
molecules with fast molecular diffusion coefficient to produce a spectrum of only 
macromolecules and slow-moving molecules and this is termed diffusion-edited 
spectroscopy. Molecular diffusion can cause NMR signal intensity changes when pulse 
field gradient are applied during the NMR experiment (Stejskal and Tanner 1965). 
Diffusion-edited spectroscopy has been successfully applied to study lipoproteins in blood 
plasma (Liu et al. 1996). Therefore it is noteworthy that by utilising both transverse 
relaxation and molecular diffusion coefficients the characterisation of biomolecules in 
complex biological matrix such as tissues can be improved. 
The NMR methods are extended by 2-dimensional spectroscopy. The use of J-Resolved 
NMR, where the spin-coupled multiplets are rotated at 90 ' to the chemical shift axis to 
reduce spectral overlap also causes exclusion of broad peaks, which are normally 
associated with macromolecules and more resolved signals can be obtained for the 
endogenous metabolites of interest. This technique is based on the spin-echo technique and 
works well because most small metabolite signals have long T2 relaxation times. The use of 
1H 
- 
1H NIAS Total Correlation Spectroscopy NMR (MAS TOCSY NMR), where 
information on protons, which are close together in chemical bond terms, can be obtained. 
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This is highly useful for biomarker identification (Moka et aL 1998). High resolution MAS 
NMR offers a way for the first time to simultaneously investigate all the different 
components of the cell. It provides very infori-native data for studying lipid profiles 
particularly for long-term effects of lipophilic xenobiotics (Griffin et aL 2000a). The 
application of the 1H - 
13 C Heteronuclear Multiple Quantum Coherence (HMQC) 
technique, where values of hydrogen and carbon chemical shifts in CHn groups of 
metabolites can be determined, provides information on small molecules, cytosolic 
components, and macromolecular and supramolecular bodies i. e. lipid moieties (Moka et 
al. 1998). The application of MAS NMR spectroscopy on various biological samples has 
been well documented. Some examples are listed in Table 1.2. 
Table 1.2 Examples of MAS NMR spectroscopy of tissues. 
Tissue Sample Type Field of Research References 
Adipocyte tissue Oncology (Millis et al. 1999) 
Brain tissue Oncology (Griffin et al. 2003a) 
Breast tissue Oncology (Cheng et al. 1998) 
Cardiac tissue Genetic disorders (Griffin et al. 200 1) 
Cardiac tissue Biochemical composition (Bollard et al. 2003) 
Endometrial cell Oncology (Griffin et al. 2003b) 
Liver tissue Biochemical composition (Bollard et al. 2000) 
Liver tissue Toxicology (Wang et al. 2003) 
Neuronal and glial cells Neurology (Griffin et al. 2002) 
Prostate tissue Oncology (Tomlins et al. 1998b) 
Renal tissue Biochemical composition (Waters et al., 2000) 
Renal tissue Oncology (Tate et al. 2000) 
Renal tissue Toxicology (Garrod et al. 200 1) 
Testicular tissue Biochemical composition (Griffin et al. 2000a) 
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1.8 Introduction to Multivariate Data Analysis 
Modem analytical methods such as NMR spectroscopy and chromatography generate large 
data sets where large numbers of variables are measured over large numbers of specimens. 
These multivariate data sets require specialised techniques, which can handle, interpret and 
predict the data sets in order to identify and display structure within the chemical data, and 
extract chemical information. Multivariate data analysis (MVDA) is the analysis of data 
with many observed variables as well as the study of systems with many important types of 
variation (Martens and Martens 200 1). MVDA belongs to a family of statistical techniques 
that are designed to handle complex multivariate data. 
1.8.1 Pattern Recognition 
Pattern recognition (PR) methods are often used to identify significant "patterns" within 
complex multiparametric data sets. It is a common phrase used to define data analysis 
methods that can be used to generate scientific hypotheses as well as testing the hypotheses 
by ways of reducing the many parameters mathematically (Nicholson et al. 1999). The aim 
of pattern recognition is to identify the intrinsic patterns or clustering behaviour in a set of 
measurements so as to categorise an object or predict the origin of an object; and to explain 
the relationship between the observations within each class in complex data sets. It is also 
used to reduce the dimensionality of complex data sets thus facilitating the visualisation of 
inherent patterns in a data set. 
NMR spectra of tissues and biofluids are highly complex, containing thousands of 
overlapping resonances within a small chemical shift range (10 ppm). This can make it 
difficult to extract meaningful biochemical information from the NMR spectra. Therefore, 
computer-based pattern recognition (PR) and expert systems have been used to enable 
interpretation of the complex multivariate NMR spectral data. Pattern recognition on NMR 
spectra enables classification of samples as being normal or abnormal, classifying target- 
organ toxicity and the site and mechanism of action within the organ, identifying potential 
biomarkers of toxicity and evaluating the time course of the effect i. e. the onset, evolution 
and regression of toxicity (Nicholson et aL 2002) 
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Pattern recognition methods can be either 'unsupervised' or 'supervised'. In the 
'unsupervised' approach, the inherent clustering behaviour of a set of samples is 
established without prior knowledge of classes. The most commonly used 'unsupervised' 
pattern recognition approaches are Principal Components Analysis (PCA) (Van Der Greef 
et al. 1983, Wold 1978,1987), Non-Linear Mapping (NLM) (Kakuso and Mizoguchi, 
1983, Van Der Greef et al. 1983) and Hierarchical Clustering Analysis (HCA) (Chtioui et 
al. 1996, Beckonert et al. 2003). 'Supervised' approaches, however, rely on prior 
knowledge of classes. This approach attempts to determine the characteristic or 
distinguishing features of pre-specified groups. The commonly used 'supervised' methods 
are Partial Least Squares regression (PLS) (Gerlach et al. 1979), Soft Independent 
Modelling of Classification Analogy (SIMCA) (Blomquist et al. 1979, Wold et al. 1981) 
and K-Nearest Neighbour (KNN) (Van Der Greef et al. 1983, Kakuso and Mizoguchi 1983, 
Beckonert et al. 2003). Preliminary analysis often involves the use of 'unsupervised' 
pattern recognition methods such as PCA to establish the site- and/or mechanisms-related 
metabolic responses. This is followed by more sophisticated 'supervised' algorithms, which 
can be applied to the data usMg the knowledge on sample class to optimise the 
differentiation between classes. This enables the extraction of information relating to 
biomarkers of toxicity or recovery, which will further the understanding of the mechanisms 
of toxicity. 
1.8.2 Data Reduction and Pre-processing ofNMR spectra 
Prior to pattern recognition, the highly complex high-resolution 1H NMR spectral region (6 
0.02 -69.0) can be digitised into integrated regions (typically 250 sequential spectral 
regions of 0.04 ppm width for urine and plasma samples, and 830 sequential spectral 
regions of 0.01 ppm for tissue samples). The 0.04 ppm bucket width was chosen for urine 
samples in order to account for variations in the pH-dependent chemical shift species i. e. 
citrate. Certain spectral regions carry no real diagnostic or conflicting biochemical 
information. Typically the spectral region between (8 4.5 and 8 6.0), where residual water 
and urea protons resonate, are usually removed to eliminate variations in water suppression 
and the urea signal due to partial cross saturation via proton solvent-exchange. Water peak 
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suppression is carried out due to the dynamic range problem with water in comparison with 
other metabolites. Small variations in water suppression can lead to classification problems. 
Partial cross saturation of urea and water will occur thus the urea signal can be affected by 
variation in water suppression. 
Variation in data not related to differences between treatment groups confounds any 
method of analysis. These variations cannot be removed even with careful experimentation 
and thus must be treated and minimised by normalization to make comparisons made on the 
data set as sensitive as possible by ensuring the variation remaining within the data set is 
related to the phenomenon of interest. Normalisation is very important when analyzing 
tissues and biofluids because the former suffers from variation in tissue weights and the 
latter suffers from concentration differences and differences in osmolarity. The reduced 
spectral data are normally normalized to constant total spectral area. Each spectral integral 
is standardized to the sum of the absolute value for all the spectral integrals. 
Scaling is an essential step of pre-processing in the analysis of spectral data in order to 
optimize information recovery. There are a variety of scaling methods that are used to scale 
spectral descriptors. The commonly used scaling techniques are mean centering, unit 
variance (auto scaling) and Pareto. In mean centering, the average value of each variable is 
calculated and subtracted from the data. This improves model interpretability when the 
variables are aligned together (Figure 1.11). Mean centering highlights the variations in 
high concentration signals in the spectra. It is used when the measurement units for 
variables are in the same scale of magnitude i. e. spectroscopic units. With unit variance 
scaling, each variables range is divided by its standard deviation to give all the variables an 
equal variance. Thus, by converting all variables to a comparable footing, no variable will 
dominate over another because of its numerical range. Through unit variance scaling, both 
variables with larger and lower ranges will have the same variance although the mean 
values remained different. Therefore, small variations in the levels of low concentration 
signal in the spectra will be detected. Unit variance scaling is effective when variables have 
different units of measurement and are not directly comparable. However, unit variance 
scaling has the tendency to make analyses more susceptible to the influence of artefacts. In 
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Pareto scaling, each variable is given a numerical variance that is equal to its initial 
standard deviation. Thus, Pareto scaling is intermediate between mean centering and unit 
variance (Eriksson et al. 200 1) 
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Figure 1.11 Schematic representation of mean centering & unit variance (adapted 
from Eriksson et A 2001). 
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The strategy for metabonomic analysis is shown in Figure 1.12. The spectra are obtained 
and processed (A), primary data reduction is carried out by the removal of all the redundant 
signals, normalisation of spectral data, application of appropriate scaling, and digitization 
of the one dimensional spectrum into a series of typically 250-1000 integrated regions (B). 
Primary data analysis is used to map the samples according to their biochemical 
composition, using methods such as PCA (C). Each class of samples is then modeled 
separately and class boundaries and confidence limits are calculated to construct a model 
for prediction of independent data (D). 
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Figure 1.12 Strategy for metabonomic analysis (adapted from Nicholson et A 2002). 
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NMR Spectra 
Primary Data Reduction 
1.8.3 Principal Components Analysis (PCA) 
PCA is regarded as the 'mother of all multivariate methods' (Martens and Martens 200 1). It 
is employed to represent highly complex multivariate data i. e. NMR spectra as a low- 
dimensional plane to obtain an overview of the data for trends and patterns that are 
dominating the data set as well as relationships between observations and variables, 
grouping observations, time trends and outliers (Eriksson et al., 200 1). As mentioned 
above, PCA is an unsupervised approach with no a priori assumptions being made about 
the sample classes. 
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Figure 1.13 Principal Component Analysis Sequential Diagram. 
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Statistically, PCA enables projection of data vectors in an n dimensional hyperplane (where 
n is typically 2 or 3), with as much of the variance explained as possible within the 
dimensions. It reduces the dimensionality of the initial data set (Figure 1.13A) according to 
its main variation in order to obtain an overview of the data. In an X-matrix (Figure 1.1313) 
with N-observations (e. g. NMR spectra) and K-variables i. e. the number of integral values 
for peaks per spectrum, a K-dimensions space is constructed (Figure 1.14A) with each 
variable representing a coordinate axis plotted in this K-dimensional space (Figure 1.14B). 
The effect of mean centering basically moves the origin of the co-ordinate system so that its 
origin now coincides with the average of the cluster of observations (Figure 1.14 C and D). 
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Figure 1.14 Principles of K-dimensional hyperspace and the effects of mean centering 
(adapted from Eriksson et A 2001). (A) A K-dimensional space. (B) The observations 
in the X-matrix represented by the swarm of points in the hyperspace. (C) The 
average point (9 dark grey) in the middle of the swarm of points. 
(D) The origin of the 
co-ordinates is moved to the centroid. 
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PCA finds planes in the K-dimensional space that best approximate the data in a least 
square sense. Each component is expressed as combinations of the response variables, and 
explains the dispersion structure in the data set; hence they are called Principal Components 
(PCs). The first PC is a linear combination of the original input variables with appropriate 
weighting coefficients and contains the maximum variance in the data set. The second PC 
is another linear combination of the variables that is orthogonal to the first PC and explains 
the next highest variance in the data set. Successive PCs are orthogonal and will therefore 
explain less of the data variance until the PCs only consist of the data noise. 
In order to get the new scores (t) (Figure 1.13C), each N-observation must be projected 
onto the plane and the axes are described by the relevant PC. Scores plot (Figure 1.13D), 
which is a 2- or 3- dimensional PC map, can be constructed to visualise information in the 
data set. The scores plot enables investigation of any inherent clustering behaviour of 
samples in the data set. Variables, which are correlated to each other and variables, which 
are influential in the PCs, can be investigated by the principal component loadings. The 
loadings (Figure 1.13 E and F) describe the orientation of the original variables in the PC 
plane therefore reveals the variables contributing to the scores plot. It provides information 
regarding the variables which are responsible for the pattern observed in the scores plot, 
and details the variable's correlations to each other. The loadings also describe the 
importance of the original variables to the respective PC. 
In PCA models, there exists a fundamental difference between how well a model fits the 
data and its ability to predict other samples. The quantitative measure of how well a model 
can fit the data is linked to the amount of variation within the data set that can be explained 
by the model. This is given by the parameter R. The problem with trying to fit a model 
well is that with sufficiently many components in the model, R2 can be made arbitrarily 
close to the optimal value of one, thus, the model is said to be over-fitted. However, this is 
not the case for the prediction ability Q2. Q2 is a measure of how accurately the X data can 
be predicted either by using the existing data set or by using an independent validation set 
of observation set. The addition of many latent variables may introduce components, which 
are uncorrelated with the patterns within the data set therefore reducing the predictive 
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ability of the model. Consequently, the number of PCs selected for a model is aimed at 
maximising both the Q2 and R2 values. 
1.8.4 Projection to Latent Structures by means ofPartial Least Squares (PLS) 
PLS is designed to relate two data matrices, X and Y, with each other by means of a linear 
multivariate model. It is a regression extension of PCA. It provides a means to model X 
and Y data matrices as well as to identify input and process variables (X) that are 
responsible for the change in the output variables Y with the aim of maximizing the 
correlation between X and Y. These models of X and Y spaces attempt to approximate the 
best variation in the point swarms of the X and Y spaces thus giving a geometric 
interpretations similar to that of PCA. However, PLS models of X and Y spaces share an 
inner relation such that the scores of X space can be related to the Y space thus maximizing 
the covariance between the scores. The first PLS component through the point swarms of 
the X and Y spaces provide a maximum correlation between each components whilst 
maintaining good approximation of each space. Successive components are orthogonal to 
preceding components. 
PLS-Discriminant Analysis (PLS-DA) emphasise more on class separation to ensure 
maximal separation between pre-defined classes is achieved. The method involves the 
rotation of the projection of latent variables. Latent variables are formed as the linear 
combination of all the original variables in the X matrix in such a way that most of the 
association with the Y variables can be explained together with the variation in X (Lee et 
aL 2003). Unlike PCA or PLS, the Y matrix of PLS-DA consists of a set of dummy 
variables, which are set up to describe the class membership of each observation in the X 
matrix. These dummy variables comprises a series of ones and zeros set in columns such 
that observations for a set class, B, will have a value of one and the others zero. The 
quantitative measure of the discriminatory power for each chemical descriptor in a PLS-DA 
model can be obtained from a Variable Importance Plot (VIP). The higher the numerical 
value for a variable in the VIP plot, the strongest its discriminatory ability in the X-matrix. 
However, it is important to note that discriminative techniques like PLS-DA, have a 
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tendency to over fit when variables out number samples. Therefore, it is very important to 
validate the models. 
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Chapter 2: Materials and Methodology Q?. / 
2.1 Introduction 
2.2.1 Outline of toxicity study design 
All animal studies were conducted in accordance to the requirements of the relevant 
national legislation and local guidelines. The studies were carried out at Pfizer, Centre de 
Recherche, Amboise, France. Male Sprague-Dawley rats (250 g, Charles River, St. 
Germainsur-l' Abresle, France) were acclimatised in individual metabolic cages with free 
access to water and standard rodent diet (diet A04C, Usine d'Alimentation Rationelle, 
Villemoisson-sur-Orge, France). Compounds and control treatments were administered on 
day 1 by intraperitoneal injection with the dosages and animal numbers shown in Table 2.1. 
All treatments were single dose with a constant volume of administration with each study. 
2.2.2 Sampling, pathology and clinical chemistry analyses 
Using C02, five animals of each treatment group were euthanased post-dosing at day 2 and 
the remainder at day 8. Prior to euthanasia, individual pre- and post-dose urine samples 
were collected into ice-cooled vessels containing 0.1 ml of a 100 mg/ml solution of sodium 
azide for 7h daily with an additional overnight urine collection on the day of dosing. 
Urinary volumes were measured by gravimetry. Individual blood samples were taken under 
isoflurane anaesthesia from the orbital sinus, immediately prior to euthanasia. These were 
collected into vials containing lithium heparin as anticoagulant and the plasma obtained by 
centrifugation. A summary of the sampling regime is show in Table 2.2 and Table 2.3. 
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Table 2.1: Summary of animal studies. 
Study Study 
Dose of toxin 
Animal 
Euthanased 
Number 
Compound 
Group administered 
(mg/kg) 
Number Day 2 Day 8 
Saline Control 0 1-10 6-10 1-5 
Allyl Fonnate Low Dose 25 101-110 106-110 101-105 
98053 in saline High Dose 75 201-210 206-210 201-205 
Chlorprornazine Low Dose 30 301-310 306-310 301-305 
in saline High Dose 60 401-410 406-410 401-405 
Saline Control 0 1-10 6-10 1-5 
99057 Thioacetarnide Low Dose 50 301-310 306-310 301-305 
in saline High Dose 200 401-410 406-410 401-405 
Table 2.2 Sampling regime for animal study 98053 
Study Day 
Pre-dose Post-dose 
-2 -1 1 1 2 3 4 5 6 7 8 
Urine Collection 
0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 
period (hrs) 
Late euthanased BL 
BU U U U U U U U U U 
9 group (Day 8) P U 
Early euthanased BL BU U U U 
group (Day 2) P 
blood, U= urine, L= liver, and P= pathology 
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Table 2.3 Sampling regime for animal study 99057. 
Study Day 
Pre-dose Post-dose 
-3 -2 -1 1 1 2 3 4 5 6 7 8 
Urine Collection 
0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 0-7 
period (hrs) 
Late euthanased BL 
BU U U U U U U U U U U 
09 group (Day 8) P 
Early euthanased BL 
BU U U U U 
group (Day 2) P 
B= blood, U= urine, L= liver, and P= pathology 
ZZ3 Necropsy andpathology 
Necropsy was carried out immediately after euthanasia. The liver was weighed and 
duplicate samples of the left liver lobe were immediately snap-frozen in liquid nitrogen and 
stored at -70'C for subsequent NMR analysis. Liver samples were embedded in paraffin 
wax, sectioned (4-6 tim) and stained with hernatoxylin and eosin for histopathological 
assessment. Selected liver samples were also stained with Oil Red 0 and according to the 
periodic acid-Schiff method. 
224 Clinical chemistty 
Clinical chemistry was carried on a Monarch 200 centrifugal analyser (Instrumentation 
Laboratory, Warrington, UK) in Study 98053 and on AU600 multiparametric analyser 
(Olympus, Hamburg, Germany) in Study 99057. The plasma parameters urea, glucose 
(GLUC), total bile acids (TBA), total cholesterol (CHOL), triglycerides (TRIG), albumin 
(ALB), total protein (PROT), bilirubin (BILI), alkaline phosphatase (ALP), aspartate 
aminotransferase (ASAT), alanine aminotransferase (ALAT), 5' nucleotidase (5NT), and y- 
glutamyltransferase (GGT) were measured. The albumin/globulin (A/G) ratio was 
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calculated as albumin/(total protein-albumin). For each parameter, analysis of variance was 
performed on rank-transformed data. When the analysis of variance was significant at the 
5% level, pair-wise comparisons were made for each treated group versus controls. 
Additionally, principal component analysis (PCA) was performed on the day 2 clinical 
chemistry data, unit variance (UV) scaling was being used to scale each variable prior to 
PCA in order to give equal weight to each variable. 
22.5 Samples analysed by NMR 
In the first toxicology study (Study 98053), every urine, plasma and liver samples was 
analysed by NMR. Based on the findings on the first study, selected samples were analysed 
in all subsequent studies (urine samples from Day - 1, Day +1 (0-7 hr), Day +2, Day +3 and 
Day +7; Day -3 and Day +2 plasma samples; Day -3 and Day +2 liver samples were 
selected for analysis). The majority of the urine and plasma NMR data were collected by T. 
A. Clayton as part of his PhD thesis (Clayton 2001) whilst the liver NMR data were 
collected and all NMR data analyses were carried out by 1. K. S. Yap. 
2.2.6 Liver sample preparation and 'H MAS NMR analysis 
The liver tissue samples were analysed by 1H MAS NMR spectroscopy at 400.13 MHz 
using a Bruker AV-400 spectrometer equipped with a high-resolution magic-angle-spinning 
(HR MAS) probe head with a field gradient coil at the magic angle. Each sample (approx. 
20 mg) was rinsed in saline/D20 and placed in a4 mm zirconium oxide rotor (Bruker 
Biospin, Rheinstetten, Germany), using a proprietary insert to make a spherical sample 
chamber. The samples were spun at 4000 Hz. To minimise sample degradation, the NMR 
spectra were acquired at an external temperature of 276 K measured by a Bruker VTU 3000 
temperature control unit. Typically, 512 transients were collected into 16K data points 
using a spectral width of 8 kHz and a standard 1D pulse sequence for solvent presaturation 
suppression (RD-90'-tl-90'-tm-90'-acquire data, where RD is a relaxation delay) with an 
irradiation at the water frequency during RD (2 s) and the mixing time, tm, of 100ms. The 
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chemical shifts were referenced to the H1 anomeric proton resonance of (x-glucose (8 
5.233). 
Additionally, water suppressed spin-echo CPMG spectra were acquired using the pulse 
sequence: RD-90'-(-c-l800-'r)n-acquire free induction decay, with a spin-spin relaxation 
delay, 2n-c, of 200 ms. This experiment reduces the spectral contribution from the 
resonances of large molecules such as lipids, proteins, and other less mobile membrane 
components, thus producing a clearer spectrum of resonances from low molecular weight 
components of the tissue. 
Small molecules have fast molecular diffusion coefficients and this was used in a further 
diffusion editing pulse sequence to enable observation of larger slow-moving molecules 
selectively. Diffusion edited 1H NMR spectra with water suppression were acquired using 
the bipolar-pair-longitudinal-eddy-current pulse sequence: RD-90'-Gj-T-l80'-G2-T-900-A- 
900-G3-T-180'-G4-T-900-Te-90'-acquire free induction decay (Wu et al. 1995), where G is 
the pulse field gradient, T is the time between bipolar gradients, A is the diffusion time and 
Teis an eddy current delay. A sine-shaped gradient strength of 19 G/cm with gradient pulse 
length of 5 ms was used, followed by a 300 ýts delay for eddy current decay. A diffusion 
time of 80 ms and delay Teof 5 ms were used. 
J-Resolved (JRES) NMR spectra provide information on chemical shift and coupling 
constant only presented in a 2-dimensional matrix. In this project, 2-dimensional JRES 111 
NMR spectra were acquired to provide confirmation on spectral assignments. 2K data 
points with 40 increments and 40 scans per increment were collected using spectral widths 
of 4.2 kHz in the F2 dimension and 50 Hz in the F1 dimension. 
It was found that the spin-echo spectra revealed a pattern of changes in the liver that was 
similar to that observed in the standard water- suppressed NMR spectra. Therefore, only the 
standard ID pulse sequence spectra will be use for this thesis. 
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227 Urine sample preparation and 'H NMR analysis 
Urine samples were prepared by mixing 200 ýtl phosphate buffer (81: 19 v/v mixture of 0.2 
M Na2HP04 and 0.2 M NaH2PO4; pH 7.4) with 400 ýd urine. The urine-buffer mixture was 
left to stand for 10 min at room temperature and then centrifuged at 13 000 rpm for 10 min 
and the clear supernatant (500 gl) was pipetted into a5 mm NMR tube together with 50 gl 
_2 of a TSP (3-trimethylsilyl-l-[2,2,3,3 , H41 propionate)/D20 solution giving a final TSP 
concentration of 0.1 mM in the prepared sample. The urine samples were analysed at 303 K 
by 1H NMR spectroscopy at 600.13 MHz using a Bruker AMX-600 spectrometer. 
Typically, 64 transients were collected into 64K data points using the standard 1D pulse 
sequence wit solvent presaturation suppression as given above and an irradiation at the 
water frequency during RD (3 s) and the mixing time, tm, of 100ms. 
2.2.8 Plasma sample preparation and 1H NMR analysis 
Plasma samples, were prepared by mixing 150 ml plasma with 350 ml saline (0.9% w/v 
NaCl in a mixture of 10% v/v D20 and 90% v/v H20). The plasma samples were analysed 
at 3 10 K by 1H NNM spectroscopy at 600.13 Nfflz using a Bruker AN4-X-600 spectrometer 
measured by a Bruker temperature control unit. Typically, 64 transients were collected into 
64K data points using the standard ID pulse sequence with solvent presaturation 
suppression given above. A spectral width of 10 kHz and an acquisition time per scan of 
3.28 s were used. The water suppression irradiation was applied during RD (3 s) and the 
mixing time, tm, of I OOms; and the chemical shift scale of the spectra was referenced to the 
HI anomeric proton resonance of a-glucose. 
In addition to the standard ID spectra for the blood plasma samples, standard Carr-Purcell- 
Meiboom-Gill (CPMG) spin-echo spectra were also acquired for 128 transients using the 
pulse sequence (RD-90'-(T-1800-T) n-acquire) with a spin-spin relaxation delay, 2n'C, of 
87.8 ms. The CPMG spectrum attenuates resonances from substances with short T2 
relaxation times, comprising high molecular weight compounds, motionally restricted 
species and those undergoing chemical exchange. Visual inspection of the spectra obtained 
from the blood plasma samples revealed that the CPMG spin-echo spectra were clearer in 
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highlighting the biochemical information within the plasma samples than the standard 1H 
NMR spectra. 
2. Z9 Data reduction andpre-processing of I HNMR spectral data 
Fourier transformed 1H NMR spectra were manually phased, baseline-corrected and 
referenced using standard XWTNNMR software (Bruker Biospin, Rheinstetten, Germany). 
For MAS NMR data, the spectral region of 6 0.2-9.0 was reduced to 828 regions each 0.01 
ppm wide and the signal within each region integrated using an in-house written routine 
(NIATLAB 6.5, Natick, MA, USA). The region of 6 4.5 - 5.0 was removed to eliminate any 
effects of imperfect water suppression. Each integral region was normalised prior to pattern 
recognition to give a total integration value of 1000 for each spectrum. For biofluid NMR 
data, the spectra over the range of 6 0.2 - 9.0 were segmented as above to 181 regions each 
0.04-ppm wide and the total signal intensity in each region was computed. The region 6 
4.0-6.0 was removed to eliminate variations in the suppressed water signal. Each integral 
region was normalized prior to pattern recognition to give a total integration value for each 
spectrum. These were then exported to SIMCA-P (version 10.5, Umetrics AB, Umea, 
Sweden) software where all subsequent data analysis was carried out. The data presented in 
this thesis were mean-centred prior to pattern recognition analysis. NMR spectral 
assignments were based on the literature (Beckwith-Hall et al. 2003; Bollard et al. 2000; 
Fan 1996; Garrod et al. 1999; Lindon et al. 1999; Nicholson et al. 1995) with confirmation 
by examination of the JRES spectra where necessary. 
PCA and PLS-DA analysis were perfonned on all standard ID MAS NMR spectra of Day 
2 liver samples. Additionally, PCA was also performed on all standard 1D MAS NMR 
spectra of Day 8 allyl formate and chlorpromazine liver samples. The data was mean- 
centered prior to modelling. In the scores plot, the data points are labelled and colour-coded 
so as to identify the treatment (e. g. C for control, LD for low dose and HD for high dose) 
and animal number. For the loadings plot, the data points are labelled according to the 
bucket or spectral segment that they represent. These buckets were always of 0.01 ppm so 
that each variable is a representation of the spectral chemical shift. 
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PCA and PLS-DA analysis were also performed on all CPMG spin-echo spectra of Day 2 
plasma samples. The data was mean-centered prior to modelling. In the scores plot, the data 
points are labelled and colour-coded so as to identify the treatment (e. g. C for control, LD 
for low dose and HD for high dose) and animal number. For the loadings plot, the data 
points are labelled according to the bucket or spectral segment that they represent and 
ending with the letter P (designating plasma). These buckets were always of 0.04 ppm. 
Prior to concatenating the data, each segmented spectral region of the reduced and 
normalised plasma ID spin-echo NMR data was labelled with its segment number and 
ending with the letter P (designating plasma) as above. These were then concatenated with 
the standard 1D MAS NMR tissue data and exported into SIMCA-P software in which 
pattern recognition analysis was carried out. For the subsequent unsupervised (PCA) and 
supervised methods (PLS, PLS-DA), mean centre scaling was used to extract variables 
from both tissue and plasma NMR data that contributed to the variation observed in the 
scores plot. In the scores plot, the data points are labelled and colour-coded so as to identify 
the treatment (e. g. C for control, LD for low dose and HD for high dose) and animal 
number. 
Urine NMR data was not concatenated with the tissue or plasma NMR data, because they 
were obtained from different animals and at different time points. PCA and mean trajectory 
analysis were performed on all the control and high dose standard 
1H NMR spectra of urine 
samples collected over five time points (predose, Day +1 (0-7h), Day +2, Day +3, and Day 
+7). The data were mean-centered prior to modelling. In the PCA scores plot, the data 
points are labelled and colour-coded so as to identify the treatment (e. g. C for control and 
HD for high dose) and animal number. For the loadings plot, the data points are labelled 
according to the bucket or spectral segment that they represent. These buckets were always 
of 0.04 ppm. 
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ZZIO Quantitation ofNMR data 
Quantitation in NMR spectroscopy involves the measurement of the areas of NMR signals 
in order to obtain numerical values that reflects the concentration of the corresponding 
molecules in the observed sample (Van Hecke and Van Huffel 2001). In the context of 
biomedical research, the concentrations of the individual molecules in a biological sample 
are of interest, and NMR spectroscopy is a unique non-invasive analytical technique 
providing both an interpretable biochemical signature of the compounds present in a 
mixture and also their concentrations. However, quantitation in MAS NMR is more 
complex than in biofluids and the observed spectral changes may not be fully representative 
of sample compartment. 
Over the years, substantial effort has been devoted in the search for accurate quantitative 
NLAS NMR methods. Metz et al. (1996) used cross polarisation-magic angle spinning 
NMR experiments using linear ramp cross polarisation amplitudes to improve NMR signals 
for quantitation of N-t-Boc-alanine. However, the method is only ideal for samples where 
the proton spin lattice relaxation time is longer than the cross polarisation time constant. 
Elliot et al. (1999) used principal component analysis to quantify NMR spectral data sets. 
They found that the use of PCA is limited to NMR signals that can be spectrally isolated. 
PCA was also found not to be able to quantify individual peaks that are overlapped 
(Stoyanova and Brown 2001). Cheng et al. (2001) evaluated the use of MAS NMR to 
measure the spermine level in human prostate tissue using tissue water signals obtained 
from spectra without water presaturation as an internal standard. They found that the 
spermine level measured by NMR correlated with the volume percentage of normal 
prostatic epithelial cells measured by histopathology. 
In the present studies, the normal approach was to normalise each spectrum to constant 
total area and to observe relative changes in pattern recognition investigation. However, the 
use of silicone rubber as an internal standard to quantify MAS spectral data has also been 
investigated in this project. Silicon rubber is used as an internal standard to measure the 
metabolite concentrations in both control and dosed liver samples. The mass of each liver 
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sample (ML) and silicon rubber (Ms) was obtained prior to NMR analysis. The silicone 
rubber is embedded into the liver sample and placed in a4 mm. zirconium oxide rotor filled 
with saline/D20, using a proprietary insert to make a spherical sample chamber. The 
samples were spun at 5000 Hz. High-resolution 1H NMR spectra were acquired on a Bruker 
DRX 600 Spectrometer (Bruker Biospin, Rheinstetten, Germany) operating at 600.13 MHz 
at an external temperature of 283K. Typically, 256 transients were collected into 32K data 
points using a spectral width of 7.2 kHz and a standard 1D pulse sequence for solvent 
presaturation suppression (as above) with RD (2 s) and the mixing time, tm, of 100ms was 
used. The integrals of all the peak of interest were obtained including the integrals of 
silicon peak. These were then divided by their respective masses i. e. integrals of peak of 
interest/mass of liver and integrals of silicon peak/mass of silicon. Therefore, the ratio 
(integrals of peak of interest/mass of liver)/( integrals of silicon peak/mass of silicon) will 
give a measure of liver metabolite concentration. 
In plasma quantitation, relative measure of plasma metabolite concentrations were obtained 
using the formula '(integrals of peak of interest/integrals of peak of a-glucose Hl) X 
(clinical chemistry glucose value)'. This essentially uses the clinical chemistry glucose 
values to scale the NMR spectra appropriately. This method assumes that the plasma ratio 
of a: P glucose anomers is constant at 36: 64 (Morrison and Boyd, 1992). 
Urine quantitation poses special problems because the experimenter has no control over 
when and what the rats urinate therefore what is excreted during a certain collection period 
may not be representative of what is passed to the bladder during that period. Moreover, 
some of the dosed compound i. e. chlorpromazine may caused reduce drinking which will 
produce small volume of highly concentrated urine. Thus there would 
be significant 
excretion error. Because of this, the changes in the excretion of endogenous urinary 
metabolites were measured relative to other endogenous urinary metabolite, 
in this case, 
creatinine. Creatinine is widely accepted as an internal standard 
for urinary quantitation. A 
correction was made for any pre-dose differences between control and treated groups. 
The 
levels of liver, plasma and urinary metabolites from the treated animals were compared 
with those from control animals sampled at the same time-point. 
71 
2.2.11 Reporting of quantitative results and univariate statistical analysis 
The average value for the treated groups were ratioed against the average value of the 
control groups to obtain the quantitative data such as the concentration of plasma 
components measured by clinical chemistry, NMR, and urinary concentration ratio. The 
following conventions were used to report the ratios obtained: 
T T: the average value for the treated groups was > 10 times the control average. 
T: the average value for the treated group was 1 -10 times the control average. 
1: the average value for the treated group was 1- 10 times less than the control average. 
11: the average value for the treated group was > 10 times less than the control average. 
Univariate statistical analyses were performed to the clinical chemistry and NMR data for 
each day and study separately. Analyses of variance (ANOVA) performed on rank 
transformed data were used to compare groups. When the analysis of variance was 
significant at the 5% level, pair-wise comparisons were made for each treated group versus 
controls. All tests were two-tailed tests performed at the 5% confidence level. 
The following conventions were used to report the ratios for treated/control: 
designates significant difference at 95% confidence level. 
designates significant difference at 99% confidence level. 
***: designates significant difference at 99.9% confidence level. 
NS designates no significant difference found at 95% confidence level. 
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Chapter 3: Integrated Allyl Formate Studies 
3.1 Background: Metabolism and hepatotoxicity of allyl formate 
Rees and Tarlow (1967) investigated the hepatotoxicity of allyl formate in rats. They 
suggested that the conversion of allyl formate to allyl alcohol and subsequently to toxic 
acrolein is the basis underlying the hepatotoxicity of allyl formate. From their study, they 
found necrosis in the periportal region of the liver lobule. This localised effect is believed 
to be due mainly to the localisation of the enzyme alcohol dehydrogenase (ADH), which is 
required for the conversion of allyl alcohol to acrolein. Rees and Tarlow also found 
acrolein to inhibit protein synthesis and to inhibit mitochondrial respiration and that 
acrolein and glutathione (GSH), at equimolar amounts, could react rapidly to near 
completion forming stable adducts without the presence of enzymes. 
HHH0 
Hydrolysis 
C=C-C- 
HH 
H 
ADH 
C=C-C-OH 
HI H 
H0 
C=C-C 
\H 
Allyl Formate Allyl Alcohol 
Figure 3.1 Conversion of allyl formate to toxic acrolein. 
Acrolein 
Kaye (1973) found evidence of mercapturic acid formation in rats administered with allyl 
alcohol or acrolein and Alarcon (1976) showed the presence of 3-hydroxypropyl 
mercapturic acid in urine from rats dosed with acrolein. Later, Sanduja et al. (1989) 
investigated the use of 3-hydroxypropylmercapturic acid (3-HPMA) as a biological marker 
of exposure to allylic and related compounds. They found that from 13 mg/kg of acrolein 
administered to rats, the amount of the mercapturic acid excreted in urine (0-24 hours after 
dosing) accounts for 79% of the dose. Chasseaud (1979) confirmed that ap-unsaturated 
compounds activated by electron-withdrawing substituents attached to the a-carbon will 
react with GSH through the addition of the nucleophile, GS-, to the P-carbon of the ap- 
double bond. Such reactions can proceed rapidly without the presence of enzyme although 
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they may also be catalysed by glutathione- S -trans ferases. Following experiments in isolated 
rat hepatocytes incubated with allyl alcohol, Ohno et al. (1985) suggested the formation of 
a 1: 1 ratio adduct between allyl alcohol-derived acrolein and glutathione with the adduct 
being further metabolised in a Phase 3 biotransformation. The addition of GSH to acrolein 
would be followed by the removal of the glutamyl group via 7-glutamyltranspeptidase, 
removal of the glycine group via the enzyme cysteinyl glycinase to form S-(2-fonnylethyl) 
cysteine, and acetylation of the amino group of cysteine by N-acetyl transferases coupled 
by acetyl CoA to form N-acetyl-S-(2-fonnylethyl) cysteine. N-acetyl-S-(2-formylethyl) 
cysteine would then be either reduced to form S-(3-hydroxypropyl) mercapturic acid (3- 
HPMA) or oxidised to form S-(2-carboxyethyl) mercapturic acid. This is surnmarised in 
Figure 3.2. 
Zitting and Heinonen (1980) found a reduction in the GSH level in isolated rat hepatocytes 
incubated with acrolein. Hepatocytes treated with 0.025-0.25 MM acrolein showed a 
decrease in the GSH level, which recovered as the cells recovered. However,, at 0.5 mm 
acrolein, the hepatocytes were depleted in GSH and were incapable of synthesising 
replacement GSH. At acrolein concentrations of 0.25-0.5 mM, lipid peroxidation impaired 
the membrane integrity of the hepatocytes. They also reported that acrolein is highly 
reactive and can react easily with sulphydryl groups in the biological system including 
glutathione-S-transferase. Thus, they concluded that extensive GSH decrease leads 
progressively to an increase in lipid peroxidation, cell membrane instability and finally cell 
lysis. 
Jaeschke et aL (1987) investigated the role of acrolein in allyl alcohol-induced lipid 
peroxidation and liver cell damage in mice. Their results showed that after administration 
of allyl alcohol (64mg/kg), complete loss of hepatic glutathione was observed within the 
first 15 minutes, which then led to massive lipid peroxidation. This is confirmed by the 
observed 40-45% loss of polyunsaturated fatty acids (arachidonic and docosahexaenoic 
acids) in liver lipids. They also found that both in vivo inhibition of alcohol dehydrogenase 
by pyrazole, or induction of aldehyde dehydrogenase prevented allyl alcohol-induced 
glutathione depletion and the subsequent lipid peroxidation and liver cell damage. 
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Furthermore, the inhibition of aldehyde dehydrogenase by cyanamide caused the normally 
sub-toxic dose of allyl alcohol (35mg/kg) to be highly toxic. Their results suggested that 
the direct oxidation of acrolein to acrylic acid is an important detoxification pathway in 
mouse liver especially when the glutathione levels are low. They also reported that 
enhanced hepatic glutathione levels in vivo protected the cells from damaging allyl alcohol 
effects and that the depletion of liver glutathione itself induced marginal lipid peroxidation 
and no liver cell damage. Therefore, they concluded that depletion of liver glutathione 
levels is an important factor in acrolein toxicity but is not sufficient to initiate lipid 
peroxidation in vitro itself. They also found that the presence of the ferric ion chelator, 
desferoxamine methane sulphonate, prevented allyl alcohol-induced lipid peroxidation and 
liver cell damage in vivo. This suggested the importance of iron in the mechanism of cell 
damage by allyl alcohol. Iron plays an important role lipid peroxidation. In the presence of 
certain transition metal ions e. g. iron ions, hydroxyl radicals can be formed through either 
the Haber-Weiss reaction or the Fenton reaction, and this can cause lipid peroxidation and 
cell injury. This suggested that allyl alcohol causes GSH depletion and also induced iron- 
mediated lipid peroxidation, which leads to liver cell damage. Mitchell and Petersen (1987) 
investigated the inhibition of rat liver enzyme aldehyde dehydrogenase (ALDH). They 
found that acrolein is a potent inhibitor of rat ALDH in particular the mitochondrial and 
cytosolic ALDH. Both irreversible and reversible non-competitive inhibition was observed 
after incubation of the mitochondrial and cytosolic fraction with 30 ýLM acrolein and a 
significant inhibition observed at acrolein concentration of ý! 50 ýtM. Inhibition of ALDH 
caused an increase in aldehydes thus leading to the potentiation of their toxicities. 
Miccadei et aL (1988a and 1988b) investigated the effects of the toxins allyl alcohol, 
dinitrofluorobenzene and diethyl maleate, and the abrupt depletion of glutathione in 
cultured hepatocytes. Besides the conjugation of electrophilic compounds with or without 
catalysis by glutathione-S-transferases, glutathione has various other functions such as 
translocation of amino acids across cell membranes, maintenance of sulphydryl groups, and 
the catabolism of peroxides via glutathione peroxidases. It also destroys free radicals. 
Partially reduced oxygen species are produced continuously by electron transport carriers in 
the mitochondria or through the action of cytoplasmic oxidases of aerobic cells. Depletion 
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of glutathione or inhibition of the reduced glutathione-oxidised glutathione (GSH-GSSG) 
redox cycle sensitises the cell to an imposed oxidative stress due to the accumulating 
oxygen species. Miccadei et al. (1988a and 1988b) investigated the effect of glutathione 
depletion in relation to endogenous stress and their results showed that acrolein produces an 
abrupt glutathione depletion, which is then followed by lipid peroxidation and cell death. 
They suggested that the oxidative cell injury is caused by the inability to detoxify 
endogenous hydrogen peroxide and that the resulting iron-dependent formation of potent 
oxidising agent accounts for the hepatotoxicity of allyl alcohol better than covalent binding 
of acrolein to cellular macromolecules. 
Ferrali et al. (1989), investigated allyl alcohol-induced haemolysis and its relation to iron 
release and lipid peroxidation. They reported that acrolein is a powerful electrophile, which 
will react spontaneously with nucleophiles such as sulphydryl groups, thus leading to a 
decrease in GSH and that acrolein is toxic not only to liver cells but also other cell types i. e. 
renal epithelial cells and pancreatic acinar cells. They found that haemolysis occurred in ca. 
50% of allyl-alcohol treated mice and proceeded to investigate whether lipid peroxidation 
occurs in the membranes of the erythrocytes. They reported a rapid decrease in hepatic SH 
groups upon administration of allyl alcohol. This is then followed by development of lipid 
peroxidation and liver necrosis. Haemolysis occurred due to a decrease in the erythrocyte 
GSH level, which led to lipid peroxidation and membrane structure instability. Acrolein 
induces the release of iron from iron complexes in erythrocytes and this free iron is able to 
undergo a redox reaction with molecular oxygen thereby generating oxygen-derived free 
radicals such as the hydroxyl radicals. Hydroxyl radicals are highly reactive and will react 
with lipids thus promoting lipid peroxidation. This in turn leads to an increase in free 
chelatable iron. 
Adams and Klaidman (1993) investigated acrolein-induced oxygen radical formation. The 
found that acrolein and the GSH adduct of acrolein, glutathionylpropionaldehyde (GS- 
propionaldehyde) can induce oxygen radical formation leading to lipid peroxidation thus 
suggesting an alternative mechanism for the cause of oxidative stress under conditions of 
depleted GSH. GS-propionaldehyde was found to be very reactive with ALDH and 
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xanthine oxidase to produce superoxide and acroleinyl radicals. It was found that acrolein 
was oxidised to superoxide and acroleinyl radicals through the action of xanthine oxidase 
whereas acrolein was oxidised to fonn superoxide radicals only through the action of 
ALDH. The study revealed that GS-propionaldehyde is a toxic metabolite of acrolein and is 
a more potent stimulator of oxygen radical formation than acrolein. 
3.1.1 Study Details 
Study number 98053 carried out at Pfizer, Centre de Recherche, Amboise, France. 
Study Study 
Dose of toxin 
Animal 
Euthanased 
Number 
Compound 
Group 
administered 
(mg/kg) 
Number Day 2 Day 8 
Saline Control 0 1-10 6-10 1-5 
98053 Allyl Fonnate Low Dose 25 101-110 106-110 101-105 
in saline High Dose 75 201-210 206-210 201-20 
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Figure 3.2 Metabolism of acrolein. Main pathway in red box (adapted from World 
Health Organisation). 
78 
3.2 Results 
3.2.1 Histopathology results 
The histopathological observations for allyl formate-closed rats are summarised below in 
Table 3.1. 
Table 3.1 Summary of the histopathological changes observed in allyl formate-dosed 
Sprague-Dawley rats. 
Day 
Dose of allyl 2 8 formate 
No significant differences No significant differences from controls. 
25 mglkg from controls. 
Periportal to diffuse lobular Multifocal chronic post-necrotic 
haernorrhagic coagulative inflammation characterised by variable 
necrosis. Necrosis was combinations of fibrosis, necrosis, 
minimal in animal 208; granulomas, mineralisation bile duct 
moderate in animals 207 proliferation, infiltration of macrophages 
75 mg/kg and 2 10; and marked in and the presence of variably vacuolated 
animals 206 and 209. No hepatocytes in the surrounding tissues. 
evidence of glycogen Changes were minimal in animal 204; mild 
depletion detected. in animals 202,203, and 205; and 
moderate in animal 201. 
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3.2.2 Clinical chemistry results 
The clinical chemistry data indicated minimal changes in the low dose animals on both Day 
2 and Day 8. Clear signs of liver toxicity were observed in the high dose animals on Day 2. 
The Day 8 clinical chemistry data of the high dose showed minimal effects indicating 
recovery. Details of the clinical chemistry findings are summarised in Table 3.2. 
Table 3.2 Summary of the plasma changes observed by clinical chemistry in allyl 
formate-dosed Sprague-Dawley rats. 
Day 
Dose of allyl 
2 
formate 
Triglycerides: 1 (33%, No group differences were found 
although y-glutamyltransferase 
25 mg/kg (GGT), bilirubin and triglycerides 
were elevated in animal 10 1. 
Variable liver necrosis and No group differences were found. 
cholestatic damage: TBA remained elevated in 
ASAT: TT animals 201 and 204. Animal 202 
ALAT: TT showed unusually low creatinine. 
TBA: 
GGT: 
75 mg/kg 
Triglycerides: 1 (54%, 
Albumin: 1 (19%, 
TP: 1 (14%, ***). 
3 out of 5 animals (animals 206,207 
& 209) showed an increase in 
bilirubin. 
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3.2-2-1. Principal Component Analysis of Day 2 Plasma Chemistry Data 
PCA scores and loadings plots for the first two components of the control/allyl formate Day 
2 clinical chemistry data are shown in Figure 3.3. In the scores plot, the data points are 
colour-coded and labelled so as to identify the treatment (e. g. black for control, red for low 
dose and blue for high dose) and animal number. 
The scores plot shown in Figure 33A shows separation between the low dose group and 
the controls along the second principal component. The corresponding loadings plot (Figure 
33B) shows that decreases in plasma triglycerides and total plasma cholesterol and 
increases in bile acids and the albumin/globulin ratio are major contributors to this 
separation. 
Figure 3.3C shows separation between the high dose group and the controls along the first 
principal component. An important feature observed in the corresponding loadings plot 
(Figure 3.3D) along the first principal component is the generalised increase in both 
aminotransferases, ALAT and ASAT, which are indicative of hepatocellular damage in the 
high dose animals. The loadings plot also shows that the high dose of allyl formate caused 
increases in 5-nucleotidase, y-glutamyl transferase, bilirubin and bile acids, which are 
markers of hepatobiliary damage (Handler et al. 1997). Amongst other things, the loadings 
plot also indicates decreases in plasma triglycerides, in the albumin/globulin ratio and in 
total plasma proteins as the contributors to the separation between the high dose animals 
and the control animals. The decrease in the albumin/globulin ratio in the high dose animals 
is in contrast to the low dose animals which showed an increase in the albumin/globulin 
ratio. 
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3.2.3 Analysis of the Tissue Spectra 
3.2.3.1 Examination of lH MAS NMR tissue spectra 
Figure 3.4 shows the dose-dependent effects of allyl formate hepatotoxicity as visualised 
using standard 1D 1H MAS NMR spectra of intact Day 2 rat liver. The corresponding NMR 
spectral assigmnents are listed in Table 3.3. 
Table 3.3 1H NMR resonance assignments for liver tissue. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Valine CH3 1.04 
2 Lactate CH3 1.33 
3 Acetate CH3 1.95 
4 Glutamine CH2 2.39 
5 Glucose/glycogen/cc-H amino acids Ring protons/a-CH 3.35-4.00 
6 Lactate CH 4.13 
7 P-Glucose CiH 4.64 
8 Glycogen CH 4.65 
9 cc-Glucose CjH 5.23 
10 Glycogen CH 5.38-5.45 
11 Alanine CH3 1.48 
12 Lipids CH=CH-CH2-CH2 2.07 
13 Glutamate CH 2.15 
14 Chollne/phosphocholine N+(CH3)3 3.22 
15 TMAO CH3 3.27 
Taurine 
CH2SO3_ 3.25 
16 Lipids CH3-(CH2)n 0.90 
17 Lipids CH3-(CH2)n 1.29 
18 Lipids CO-CH2-CH2 1.61 
19 Lipids CO-CH2-CH2 2.25 
20 Lipids =CH-CH2-CH= 2.78 
21 Lipids -CH=CH- 5.30-5.35 
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Figure 3. 4 Dose-dependent effects of allyl formate hepatotoxicity as visualised using 
standard 1D 'H MAS NMR spectr a of intact Day 2 rat liver. A. Control liver. Liver 
from an animal administered: (B) Low-dose allyl formate and (C) High-dose allyl 
formate. 
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Visual inspection of the standard 1D spectrum of Day 2 control rat liver (Figure 3.4A) 
shows that it contains broader signals from large molecule such as lipids and sharper 
signals from small molecules such as lactate, glucose, trimethylamine N-oxide (TMAO) 
and taurine. Administration of the low dose of allyl formate appears to have relatively little 
effect on the rat liver (Figure 3.4B) with increases in TMAO and some increase in lipids. 
However, the administration of the high dose of allyl formate appears to have severe effects 
on the rat liver (Figure 3.4C). The liver lipids content, in particular the CH2 and CH3 
moeties, increases drastically as compared to that of controls. In addition, depletion of liver 
glucose and glycogen levels are also observed in the high dose animals. Additionally, 
visual inspection of the high dose Day 2 MAS NMR spectra revealed that the extent of the 
lipid changes correlated with the extent of necrosis identified by histopathology, with 
animals 206 and 209 experiencing severe necrosis showing the biggest increase in the lipid 
moeties; and animals 207,208 and 210 experiencing mild to moderate necrosis showing 
small to intermediate increase in the lipid moeties. The Day 8 MAS NMR spectra indicated 
minimal effects. Details of the MAS NMR observations for allyl formate-dosed rats are 
summarised below in Table 3.4 and the changes reported were quantified according to the 
method described in Chapter 2. 
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Table 3.4 Summary of the liver tissue changes observed by MAS NMR in allyl 
formate-dosed Sprague-Dawley rats. 
Dose of Day 
aRyl 
2 8 
formate 
Changes were generally minimal. There were minimal 
TMAO: T (NS); All animals showed a slight differences from controls. 
Low dose 
relative increase in TMAO at 63.27 except 
(25 mg/kg) 
animal 106. 
Animal 110 also showed a relative decrease in 
glycogen signal at 63.80. 
A similar pattern appeared on all spectra The spectrum for animal 
obtained, with: 203 showed slightly 
Lipids: T* elevated lipids. In the 
High dose 
Glucose (between 6 3.40 and 6 4.00): other animals there was 
(75 mg/kg) 
Glycogen (63.80 and 65.42): occasionally a minor 
TMAO: relative increase in the 
signal at 63.27, compared 
to controls. 
86 
3.2.3.2 Principal Component Analysis of Day 2 Liver NMR Data 
Principal component analysis of the control/low dose Day 2 data set revealed some dose- 
related structure to the variation in the data. Some separation between the low dose animals 
and control animals can be observed in the scores plot on the second principal components 
(Figure 3.5A). In addition, control animal, C6, is situated away from the rest of the controls 
along the first principal component. The corresponding loadings plot (Figure 3.5B) 
identifies the NMR spectral regions that are responsible for separation seen in the scores 
plot in Figure 3.5A. An increase in liver TMAO was identified as the major contributor to 
the separation between the dosed and control animals. The loadings plot also revealed a 
lower lipids content in control animal, C6, which contributed to its separation. Spectral 
inspection confirmed that animal C6 had a lower liver lipids content as compared to the rest 
of the control animals. 
Figure 3.5C is a scores plot for the first two components of the control/high dose Day 2 
data set. There is very clear treatment-related variation in the data set, which is described 
mainly by the first principal component. The corresponding loadings plot (Figure 3.5D) 
indicates increases in the regions attributed to lipids, and decreases in the regions attributed 
to glucose, glycogen and TMAO as the major contributors for the separation between the 
high dose animals and control animals along the first principal component. The second 
principal component loadings plot also showed the extent of lipid increase which correlated 
with the histopathological findings with animals 206 and 209 showing marked necrosis 
furthest from the rest of the high dose animals which showed mild to moderate necrosis. 
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Figure 3.5 (A) PCA scores plot of the 1H NUS NMR spectra of allyl formate-dosed 
liver samples from Day 2 low-dose versus control groups, and (B) the corresponding 
loadings plot. (C) PCA scores plot of the 1H MAS NMR spectra of allyl formate-dosed 
liver samples from Day 2 high-dose versus control groups and (D) the corresponding 
loadings plot. 
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Figure 3.6 (A) Scores plot (PC1 vs. PC 3) from PCA of the standard 111 MAS NMR 
spectra from all the liver samples taken on Day 2 allyl formate study, and (B) the 
corresponding loadings plot. 
A scores plot of the first and third components from a PCA of all the Day 2 liver MAS 
NMR spectra for this study (Figure 3.6A) showed separation between the dosed groups and 
controls. The first component describes the variation between the high dose animals and 
control/low dose animals, whereas the third component describes the variation between the 
low dose animals and control animals. The corresponding loadings plot (Figure 3.6B) 
shows that allyl formate-induced increase in lipids, and decreases in glucose and glycogen 
are the major contributors to the separation along the first principal component, whereas an 
allyl formate-induced increase in TMAO is the major contributor to the separation along 
the third principal component. 
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3.2.3.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Liver NMR Data 
In order to improve the information recovered from the liver MAS NMR data, a PLS-DA 
model was constructed, where the samples were classified assigned to one of three mutually 
orthogonal classes with control being class 1, low dose being class 2 and high dose being b 
class 3. 
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Figure 3.7 PLS-DA cross validated scores plot of the standard 111 MAS NMR spectra 
of the Day 2 aflyl formate study. 
The resultant PLS-DA X-matrix cross validated scores plot of the first two components 
(Figure 3.7) shows distinct segregation of the three sample classes. The cluster of control 
animals is situated on the upper right quadrant of the plot. The low dose animals are 
separated from the control animals along PLS component two whereas the high dose 
animals are separated from the control/low dose animals along PLS component one. 
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Figure 3.8 PLS weights from the standard lH MAS NMR spectra of the Day 2 allyl 
formate study tissue samples (W[I] = PLS component 1, W[21 = PLS component 2). 
The corresponding X-block PLS loadings (Figure 3.8) are presented in line plots where the 
direction of the line along the intensity axis indicates the metabolites influencing the 
discrimination between control and dosed groups. The plot indicates that the first 
component, describing the variation between high dose and control/low dose animals, is 
due to elevated and altered liver lipid profiles and decreases in liver glucose and glycogen 
levels in the high dose animals. The second component, describing the variation between 
the low dose and control animals, is due to elevated liver TMAO level as well as some 
increase in the liver lipid in the low dose animals. The observations made from both PLS- 
DA scores and loadings plots confirmed the findings made by inspection of the 1H MAS 
NMR spectra (Table 3.4) and from the corresponding PCA. 
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3.2.3.4 Principal Component Analysis of Day 8 Liver NMR Data 
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Figure 3.9 PCA scores plot of the standard 1H MAS NMR spectra of Day 8 allyl 
formate study. (A) Low dose versus Control data set, and (B) High dose versus 
Control data set. 
The PCA scores of plot of the allyl formate Day 8 tissue samples (Figure 3.9 A and B) 
indicated no clear separation between the dosed and control groups. This indicates 
recovery by Day 8 compared to Day 2. 
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3.2.4 Analysis of the Plasma Spectra 
3.2.4.1 Examination of plasma CPMG spin-echo 111 NMR spectra 
The plasma NMR spectral assignments are listed in Table 3.5. 
Table 3.5 1H NMR resonance assignments for plasma. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Lipids (LDL) -CH2-CH3 0.84 
2 Lipids (VLDL) CH2-CH3 0.87 
3 Valine 
CH3 0.97 
CH3 1.02 
4 3-D-hydroxybutyrate CH3 1.20 
5 Lipids (VLDL) -(CH2)n 1.29 
6 Lactate CH3 1.33 
7 Alanine CH3 1.46 
8 Acetate CH3 1.91 
9 Acetoacetate CH3 2.22 
10 Glutamine CH2 2.41 
11 Citrate 
CH2 2.52 
CH2 2.69 
12 Choline N+ (CH3)3 3.21 
13 Glucose/Amino acids resonances Ring protons/a-CH 3.35-4.00 
14 Lactate CH 4.10 
15 a-Glucose CjH 5.23 
16 Isoleucine CH3 0.93 
17 Leucine CH3 0.95 
18 Isoleucine CH3 1.00 
19 Threonine CH3 1.31 
20 N-acetyl glycoprotems NHCO CH3 2.04 
21 Pyruvate CH2 2.36 
22 Creatine CH3 3.04 
23 TMAO CH3 3.26 
24 Creatine CH2 3.93 
25 Lipids -CH=CH- 5.30 
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Inspection of the Day 2 plasma CPMG spin-echo spectra revealed little change between the 
low dose and control animals. Figure 3.10 shows the effects of high dose allyl formate as 
visualised using CPMG spin-echo spectra of Day 2 plasma samples. The corresponding 
NMR spectral assignments are listed in Table 3.5. The most prominent change, observed in 
the high dose animals is a clear decrease in lipids especially the CH2 and CH3 moeties. 
Additionally, detailed inspection of the spectral data reveals more subtle biochemical 
variation between the spectral profiles of the high dose animals and control animals, with 
allyl formate-induced increases in creatine and tyrosine, and some changes in the glucose 
profiles. The Day 8 CPMG spin-echo spectra of the plasma samples indicate minimal 
effects. Details of the plasma NMR observations for allyl formate-dosed rats are 
summarised below in Table 3.6 and the changes reported being quantified according to the 
method described in Chapter 2. 
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Table 3.6 Summary of the plasma changes as observed in CPMG spin-echo NMR 
spectra of allyl formate-dosed rats. 
Dose of Day 
allyl 2 8 formate 
Visually, there were no clear differences from No observed differences 
controls. 
from controls 
25 
mg/kg VLDL/LDL: (NS). 
Total lipids: (27%, NS). 
Clear changes from controls were observed Approximately the same as 
by visual inspection. controls. 
Creatine: T ** 
Tyrosine: T **. Tyrosine was increased in 
75 animal, nos. 206,2075 209 and 210. No 
mg/kg 
increase was observed in animal 208. 
N-acetyl glycoprotein: 
VLDL/LDL: I **. 
Total lipids: ý (41%, NS). 
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3.2-4.2 Principal Component Analysis of Day 2 Plasma NMR Data 
An initial principal components analysis of the data set revealed some dose related structure 
to the variation in the data. Figure 3.11 shows the scores and loadings plots of the first two 
principal components of the PCA models between the allyl formate-treated animals and the 
controls. 
The PCA scores plot of the control/low dose data set (Figure 3.1 1A) indicates differences 
in the metabolic profiles of the allyl formate-treated and control animals. Although there is 
a certain degree of overlap between the two groups the model gives a starting point from 
which further analysis may be carried out. In this case, the first principal component 
describes the variation between the two groups of animals. The corresponding loadings plot 
(Figure 3.1 IB) reveals the changes in the lipid moeties (VLDL, CH2 and LDL, CH3) that 
are the major contributors to the separation along the first principal component. The scores 
plot also revealed that control animal C7 is separated from the rest of the control animals 
along the second principal component. The corresponding loadings plot indicated that 
decreases in plasma lactate and choline are the contributors to the separation. Inspection of 
the CPMG spin-echo NMR spectrum of animal C7 indicated lower levels of choline and 
lactate as detected by PCA; and broad water peak, which contributed to spectral artefact 
(3.96P) shown in the loadings plot. 
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Figure 3.11 (A) PCA scores plot of the CPMG spin-echo NMR spectra of allyl 
formate-dosed plasma samples from Day 2 low-dose versus control groups, and (B) 
the corresponding loadings plot. (C) PCA scores plot of the CPMG spin-echo NMR 
spectra of allyl formate-dosed plasma samples from Day 2 high-dose versus control 
groups and (D) the corresponding loadings plot. 
Figure 3.11 C is a scores plot for the first two components of the high dose Day 2 plasma 
data set. There is very clear separation between the high dose animals and control animals 
in the first principal component. The corresponding loadings plot (Figure 3.1 1D) indicates 
that decreases in the regions attributed to lipids are the major contributors to the separation 
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between the high dose animals and control animals. Additionally, variability within the 
high dose group can be seen in the score plot along the second principal component. The 
corresponding loadings plot indicated that differences in the levels of plasma LDL, creatine 
and lactate contributed to the variability within the high dose animals. 
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Figure 3.12 (A) PCA scores plot of the CPMG spin-echo NMR plasma spectra of the 
Day 2 allyl formate study, and (B) the corresponding loadings plot. 
A scores plot of the first two components from a PCA of the combined Day 2 plasma NMR 
data (Figure 3.12A) showed clear separation between the high dose animals and the control 
animals described by the first principal component. Partial separation also occurred 
between the low dose animals and control andnals along the first principal component. The 
corresponding loadings plot (Figure 3.12B) shows that allyl formate-induced decrease in 
lipids (VLDL) is the major contributor to the separation along the first principal 
component. Increases in plasma glucose as well as decreases in plasma lipids (LDL) 
contributed to the separation along the second principal component. 
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3.2.4.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Plasma NMR Data 
The Day 2 plasma NMR data were also analysed using the PLS-DA approach to further 
refine the information recovery. 
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Figure 3.13 PLS-DA cross validated scores plot of the CPMG spin-echo NMR spectra 
of the Day 2 allyl formate study plasma samples. 
The X matrix cross validated scores plot of the first two components (Figure 3.13) shows 
separation between each of the groups. The control group is situated on the lower right 
quadrant, with the low dose group (upper right quadrant) partially separated from the 
control group along the second PLS component. The high dose group is to the left of the 
plot separated from the control and low dose groups along the first PLS component. The 
score plot also revealed that control animal C7 is separated from the rest of the controls 
along the second PLS component. 
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Figure 3.14 PLS weights from the 1H CPMG spectra of the Day 2 allyl formate study 
plasma samples (W[Ij = PLS component 1, W[21 = PLS component 2). 
The corresponding X block PLS loadings plot (Figure 3.14) indicates that the first PLS 
component, describing the general variation between high dose and control/low dose 
animals, is due to a decrease plasma lipids and increases in plasma glycoprotem and 
creatine. The second PLS component, describing the variation between low dose and 
control animals, is due to increases in the plasma glucose and choline levels as well as 
some decrease in the plasma lipids. The loadings plot also indicated that reduced levels of 
plasma choline and glucose contributed to the separation of control animal C7 from the rest 
of the controls. 
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3.2.5 Analysis of the Urine Spectra 
3.2.5.1 Examination of lH NMR urine spectra 
Visual inspection of the low dose urine spectra revealed no substantial changes in 
endogenous urinary metabolites (data not shown). However, 3-hydroxypropylmercapturic 
acid (3-HPMA), an N-acetyl cysteine conjugate derived from allyl formate, was detected in 
the Day 1 (0-7 h post-dose) urine sample from each allyl formate-dosed rat and was also 
found in the Day 1 (7-24 h post-dose) urine samples obtained from the high dose animals. 
The effects of the high dose allyl formate treatment on endogenous urinary metabolites 
were assessed, as follows, using only the group euthanised at Day 8, which provided a 
sequence of daily urine samples covering the whole study. 
Figure 3.15 shows a series of standard 1H NMR urine spectra covering predose and various 
time points following the administration of high dose allyl formate. The high dose of allyl 
formate induced marked changes in the endogenous urinary metabolite profiles. The 
dominant changes included increases in creatine, taurine and phenylacetylglycine (PAG) 
and decreases in succinate, citrate, 2-oxoglutarate, TMAO and hippurate, which lasted up to 
Day 3 with maximal abnormality being observed in the Day 2 samples. In addition, the 
urine spectrum of animal 202 showed presence of short chain fatty acids i. e. propionate 
(61.08 and 52.18), butyrate (60.9 and 61.58) and lactate (81.32) on Day 2. The 1H NMR 
spectra indicated recovery to normality by Day 7 post-dosing. Details of the urine NMR 
observations for allyl formate-dosed rats are surnmarised below in Table 3.7 and the 
changes reported were quantified according to the method described in Chapter 2. 
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Figure 3.15 Series of standard 111 NMR spectra of urine at predose and various time 
points following the administration of AF (75 mg/kg). Key: Metabolite of AF (M*), 2- 
oxoglutarate (2-OG), phenylacetylglycine (PAG), dimethylglycine (DMG). 
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Table 3.7 Summary of the urinary changes observed by NMR in allyl formate-dosed 
rats. 
Dose of Allyl Formate 
25 mg/kg 75 mg/kg 
3-HPMA present in the day 1 3-HPMA present in both the day 1 (0-7 hrs) and day 1 
(0-1 hrs) samples. (7-24 hrs) samples. 
No substantial changes in the Marked changes in the endogenous metabolites were 
endogenous metabolites. detected on various days. On Day 2 the changes were 
assessed as follows: 
Creatine: T ** 
Taurine: T (NS) 
2-OG: I ** 
Citrate: I ** 
Phenylacetylglycine: T (NS) 
Hippurate: I (NS) 
TMAO: I ** 
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3.2-5.2 Principal Component Analysis of Urine NMR Data 
Figure 3.16 shows a series of PCA scores plots of the first two principal components for the 
high dose allyl formate-treated animals and the controls. The scores plot of the pre-dose 
urine samples showed partial separation between the two groups. Animals 203,204 and 
205 are separated from the rest of the animals along the first principal component and 
control animal 4 is separated from the rest of the controls along the second principal 
component. The series of PCA scores plot highlighted that the endogenous biochemical 
differences between the two groups increased post-dose reaching a maximum at Day 2. 
However, separation between high dose animals and control animals on Day l(O-7h) was 
mainly due to the presence of allyl fonnate metabolite, 3-HPMA. Additionally, the Day 
l(O-7h) scores plot also shows animal 203 separated from the rest of the high dose animals 
along the second principal component. The Day 2 PCA scores plot shows clear differences 
between the high dose and control animals. The scores plot also indicated big variation 
within the high dose animals, which could reflect individual susceptibility to the high dose 
of allyl formate. The PCA scores plot of Day 3 urine samples shows partial separation 
between the two groups. In addition high dose animals 202 and 203 appear to be less 
affected than animals 201 ý 204 and 205 on 
Day 2 and recover faster than the rest of the high 
dose animals, being situated within the control group on Day I Finally, the scores plot of 
Day 7 shows some separation indicating partial recovery. These observations confirm that 
there are biochemical changes between the groups upon administration of high dose allyl 
formate that is becoming more prominent with increasing time until a time maxima of Day 
2 before gradual recovery from the toxic insult on Day 3 onwards. 
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Figure 3.16 A series of PCA scores plots of the first two components to investigate 
time related metabolic differences associated with the effects of high dose allyl formate 
in the animals. 
106 
(A) Pre-dose 
0.40 
c, 4 0.20 
0 
0- 
0.00 
-0.20 
2.46 
3.02 
L 2.56 
. 68 AA339 
A 2.42 Akýft - . 
Ajý 
6 
. 66 
A ME 
A3.06 A 3.94 
A 3.42 
-0-10 0.00 0.10 0.20 0.30 
Pcl 
U. ou 
0.40 
(B) Day 1 (0-7h) 
3 42 
3. 5A 3.74 
AI Vs. 9 
8 
A 2.06 A 3.98 A 
4 
Al Jý'%2.68 
A 2.. 4 
4 
0.30, 
N 
800.20- a. 37 
0.10. 
0.00. 
-0.10. 
(C) Day 2 
0.50- 
0.40- 
0.30- 
cli 
al 0.20- 
0.10. 
0.00- 
-n in- 
A 3.06 
A 3.26 
Ak: 
2 
4 
L6A, 
3.0 2 
0.46 
9ý8 
-0.20 0.00 0.20 0.40 
Pcl 
. 68 56 
-0.20 0.00 0.20 0.40 0.60 
Pcl 
(D) Day 3 
0.60-. 
0.50f 
0.40:: 
0.30:: 
N 0.20:: 
U 0.10.: CL 
0-001A3,06 
-0.10- 
-0.20:: A 3.94 
-0.30:: 
-0.40 
3.26 
AL -. 68 
2.46 A 
1.56 
A 3,02 
-0.20 0.00 0.20 0.40 0.60 
Pcl 
0.60 
0.50 
0.40 
0.30 
0.20 
0.10 
0.00 
-0.10 
-0.20 
(E) Day 7 
A 3.26 
2.68 
A 2.56 
7 
A 
0.00 0.20 0.40 
Pcl 
26 
56 
Figure 3.17 A series of corresponding PCA loadings plots of the first two components 
to investigate time related metabolic differences associated with the effects of high 
dose allyl formate in the animals. 
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Figure 3.17 shows a series of PCA loadings plots of the first two principal components of 
the high dose allyl formate-treated animals and the controls. The loadings plot for the pre- 
dose data indicated that high dose animals 203,204 and 205 have lower urinary glucose 
and creatine as compare to the rest of the animals. Careful inspection of the urinary NMR 
data confirmed that high dose animals 203,204 and 205 have lower levels of urinary 
glucose and creatine. In addition, control animal 4 showed higher level of urinary 2- 
oxoglutarate as compared to the rest of the animals, which contributed to the separation 
along the second principal component. Overall the loadings plots show that the trends seen 
in the PCA scores plots (Figure 3.16) were attributed to relative changes in the urinary 
endogenous metabolites, with the exception of Day I (0-7h). The loadings plot for Day 1 
(0-7h) indicates changes in the endogenous metabolites i. e. decreases in urinary citrate, 
TMAO and 2-oxoglutarate as well as the appearance of N-acetyl cysteine conjugate of allyl 
formate, 3-hydroxypropylmercapturic acid (3-HPMA). High dose animal 203 was 
separated from the rest of the high dose animals due to higher urinary taurine level. The 
loadings plot for Day 2 shows that decreases in succinate, citrate, 2-oxoglutarate, TMAO 
and hippurate as well as increases in phenylacetylglycine (PAG), taurine and creatine are 
the major contributors to the separation along the first principal component. These changes 
can be seen clearly in the series of urinary NMR spectra (Figure 3.15). In addition, 
variation in the severity of changes of the endogenous metabolites contributed to the 
variation within the high dose animals along the second principal component. The loadings 
plot indicated that variation in the concentration of the endogenous metabolites such as 
creatine, citrate, TMAO and taurine contributed to the variation within the high dose 
animals. These changes could be due to inter-animal variability and susceptibility to allyl 
formate. The loadings plot for Day 3 indicated increases in urinary PAG, taurine and 
creatine as well as decreases in urinary citrate, TMAO, hippurate and 2-OG contributed to 
the separation along the first principal component. The loadings plot also shows that 
variation in urinary TMAO level contributed to the variation within the three most affected 
high dose animals (animals 201,204,205). The loadings plot for Day 7 shows the levels of 
endogenous metabolites returning to equilibrium. However, the loadings plot indicated that 
control animal C3 has a higher level of urinary TMAO and citrate as compare to the rest of 
the controls. 
108 
3.2.5.3 PCA Mean Trajectory of Urine NMR Data 
PCA mean trajectory was performed using the 1H NMR spectra of urine sample for all high 
dose animals over five time points as above to extract time-related metabolic changes in rat 
urine samples in response to xenobiotic insult. PCA mean trajectory was carry as described 
in chapter 2. 
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Figure 3.18 PCA mean metabolic trajectory plot mapping the average position of 
standard 1H NMR high dose allyl formate urine spectra over five time points. 
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A PCA mean trajectory plot (Figure 3.18) was constructed from the complete data-reduced 
IH NMR spectra, excluding the region of water and urea (6 4.0-6.0). The first two PCs 
described 93.2% of the total variance in X. The modelled metabolic evolution comprised 
three distinct phases. In phase one, corresponding to movement to the Day I (0-7h) time 
point, the trajectory of the urine sample coordinates moved away from the pre-dose (PD) 
position along the first component corresponding to the appearance of the mercapturic acid, 
3-HPMA as well as some decreases in urinary citrate, TMAO and 2-oxoglutarate. 
Thereafter in phase two, corresponding to movement to the Day 2 time point, the trajectory 
changes direction moving away from the origin along the second component corresponding 
to the disappearance of 3-HPMA from the urine with a concomitant decrease in 
endogenous metabolites 2-oxoglutarate, TMAO, citrate, succinate, hippurate and an 
increase in urinary PAG, creatine, and taurine levels with the changes reaching maximal 
level on Day 2. Finally in phase three, corresponding to movement to Day 3 and Day 7 time 
points, the trajectory returned towards the starting point along the first component 
corresponding to increases in 2-oxoglutarate, citrate, succinate hippurate and decreases in 
creatine, TMAO and taurine to control levels indicating recovery. 
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3.2 6 Pattern Recognition Analysis of Concatenated Liver and Plasma NMR Data 
3.2.6.1 Principal Component Analysis (PCA) 
For the first time, PCA was performed on concatenated liver and plasma NMR data and 
Figure 3.19 shows the resulting scores and loadings plots. The scores plot for the low dose 
and control animals (Figure 3.19A) shows partial separation between the two groups with 
all but one of the low dose animals separated from the controls. The first principal 
component describes the variation between low dose animals and control animals with 
animal C6 showing relatively low liver lipids levels located away from the rest of the 
controls. The loadings plot (Figure 3.19B) indicates that decreases in plasma lipids (61.28 
and 80.88) and an increase in liver TNIAO signal (6 3.27) are the contributors to this 
separation along the first principal component, with the change in the plasma lipids at 61.28 
being the dominant factor. 
A PCA scores plot of the high dose Day 2 liver and plasma data (Figure 3.19C) revealed 
clear separation between the high dose and control groups along principal component one. 
The corresponding loadings plot (Figure 3.19D) revealed that decreases in plasma lipids, 
liver glucose (63.30 -64.00) and glycogen (65.42 and 63.84) as well as increases in liver 
lipid signals (61.28 and 60.90), plasma N-acetylglycoprotein (62.04), creatine (53.04 and 
53.92), choline, glucose and amino acids regions are the contributors to the separation 
along the first principal component. Again, the change in the plasma lipids at 61.28 is the 
dominant factor contributing to this separation. The PCA model, however, failed to detect 
changes in tyrosine as observed in the plasma 1H NMR spectra. 
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Figure 3.19 Concatenated PCA models for the first two components of the Day 2 
standard ID NMR spectra of allyl formate-dosed liver and CPMG spin-echo plasma 
NMR spectra. (A) Low-dose vs. control data and the corresponding loadings plot (B). 
(C) High-dose vs. control data and the corresponding loadings plot (D). 
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3.2.6.2 PLS-Discriminant Analysis (PLS-DA) 
PLS-DA was also used to determine which variables in the liver and plasma NMR data 
predict the sample classes. 
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Figure 3.20 PLS-DA cross validated scores plot of standard 1H NMR spectra of allyl 
formate Day 2 liver tissue and CPMG spin-echo NMR of Day 2 plasma samples. 
By treating the NMR data as the X matrix and dosage groups as the Y matrix, the cross 
validated scores plot of the first two components (Figure 3.20) revealed clear separation 
between the controls and the dosed groups particularly between the low dose and control 
groups. The high dose animals are separated from the control and low dose animals along 
the first PLS component. The low dose animals are distinguished from the high dose and 
control animals along the second PLS component. The low dose animals are also partially 
separated from the high dose animals along the second PLS component. 
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Figure 3.21 First component PLS weight (W[II) from the PLS-DA model attributed to 
the standard 1D 1H MAS NNM spectra of Day 2 liver tissues. 
The corresponding X block first component PLS loadings attributed to the liver tissue data 
is shown in Figure 3.21. The plot shows the general effects of dosing on liver tissue along 
the first component. It indicates that animals dosed with high dose allyl formate exhibit 
elevated lipids and lower levels of carbohydrates and glycogen storage as well as TMAO. 
These changes contributed to the separation between the high dose animals and rest of the 
anitnals. 
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Figure 3.22 First component PLS weight (W[l]) from the PLS-DA model attributed to 
the CPMG spin-echo NMR data of Day 2 plasma samples. 
The corresponding X block first component PLS loadings attributed to the plasma data is 
shown in Figure 3.22. This plot shows changes in the plasma profile that contributed to the 
separation along the first component of the PLS-DA scores plot in Figure 3.20. The plot 
indicates a decrease in plasma lipids is the major contributor to the separation between the 
high dose animals and the rest of the animals. Additionally, increases in plasma N-acetyl 
glycoprotein and creatMe also contributed to the separation along the first component. 
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Figure 3.23 Second component PLS weight (W[21) from the PLS-DA model attributed 
to the 1H NUS NMR data of Day 2 liver tissues. 
The corresponding X block second component PLS loadings attributed to the liver tissue 
data are shown in Figure 3.23. The plot shows the general effects of dosing on liver tissue 
along the second component. It indicates that animals given the low dose of allyl formate 
exhibit some decrease in lipids and higher levels of TMAO, carbohydrates and glycogen 
relative to controls. The loadings plot also showed variation within the high dose animals 
that is mainly due to changes in liver TMAO level. 
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Figure 3.24 Second component PLS weight (W[21) from the PLS-DA model attributed 
to the CPMG spin-echo NMR data of Day 2 plasma samples. 
The corresponding X block second component PLS loadings attributed to the plasma data is 
shown in Figure 3.24. This plot shows changes in the plasma profile that contributed to the 
separation along the second component of the PLS-DA scores plot in Figure 3.20. The plot 
indicates that a decrease in plasma lipids and increase in plasma choline and glucose levels 
are the major contributors to the separation between the low dose animals and control 
animals. 
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3.2.6.3 Partial Least Square Projection to Latent Structures Approach (PLS) 
Having established that there were intrinsic differences between groups, the two NMR data 
matrices were analyzed against each other using PLS to try and improve classification 
between groups. This approach also enabled determination of plasma NMR features that 
correlated with the liver MAS NMR biomarkers. The NMR data were mean centre-scaled 
prior to modelling. 
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Figure 3.25 PLS cross validated scores plot of standard 1H NMR spectra of allyl 
formate Day 2 liver tissue and CPMG spin-echo NMR data of Day 2 plasma samples. 
By treating liver NMR data as the X matrix and plasma NMR data as the Y matrix, the 
cross validated scores plot (Figure 3.25) revealed clear separation between the high dose 
animals and the rest of the animals along the first PLS component. However, no separation 
occurs between the low dose and control groups. 
118 
0.20 
0.10 
0.00 
-0.10 
-0.20 
LO LO LO LO LO Lf) LO LO Lf) U-) LO LO Lf) LO LO U") Lf) LO 
194, m 1: 11 m 194- 0') CY) 00 (Y) 00 CY) 00 CY) 00 CY) 00 CY) 00 
clý NT N 0) r-- "t CN 0) rl- N 0) rý- It N CY) P- 
LO (Y) Cý m Cý N C%4i 04 C-ý C=; 
Chemical Shift (ppm) 
0.80 
0.70 
0.60 
0.50 
0.40 
ic 0.30 
0.20 
0.10 
0.00 
-0.10 
a- 
N 
0- 
(D 
r- 
0- 
r ,o . 
0- 
'It 
"qt 
0- 
00 
N 
Cl- 
N 
V. - 
a- 
(D 
CY) 
a- 00 
. 
a- 'ýT 
CD 
0- 00 
qT 
0- N 
C") 
0- (0 
- 
0- 
N 
0- "T 
00 
a- 00 
(0 
a- C4 
LO 
a- CD 
CIO 
a- N 
. 
a- "t 
C) 
a- 00 
00 
a- N 
r- 
a- CD 
LO 
Cý M C") Cli Cli Cli Cý 
'N C4 N Cý Cý C) 
Chemical Shift (ppm) 
Figure 3.26 First component PLS weight (W*[11) from the PLS model attributed to 
(A) 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples (-). 
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The corresponding PLS loadings plot (Figure 3.26) revealed that increases in liver lipids 
signals and decreases in liver carbohydrates and glycogen as well as increases in plasma 
creatine, N-acetyl glycoproteins and decreases in plasma lipids are the major contributors to 
the separation between the high dose animals and control animals along the first 
component. In addition, the loadings plot also indicated that increase in liver lipids is linked 
to a decrease in plasma lipids indicating possible reduction in lipid transport from the liver 
to the plasma. 
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3.3 Discussion 
3.3.1 Effects of Allyl Formate on rat liver 
At the high dose, allyl formate induced variable degrees of hepatocellular necrosis as 
revealed by the histopathological data The observed decreases in liver glycogen and 
glucose suggest increased energy demand within the liver and ATP-depletion by allyl 
alcohol has been confirmed in periportal regions of isolated perfused rat livers by Belinsky 
et al. (1986) and in isolated rat hepatocytes by Farghali et al. (1992). This increased 
demand for ATP is likely to arise through damage to the mitochondria, which are normally 
the major source of ATP, since allyl formate is also known to inhibit mitochondrial 
respiration (Rees and Tarlow 1967) and allyl alcohol can cause the collapse of 
mitochondrial membrane potentials in-vitro (Pang et al. 1997). With impairment of 
mitochondrial ATP-production, glycolysis would be expected to enable some ATP 
production as glucose is converted to lactate in the cytosol and glycogenolysis would 
increase the supply of glucose for this process. 
To be observable by 1H MAS NMR the lipid species must be in a mobile state and 
deposition of lipid droplets within the cell is the most likely candidate for the observed 
increases in lipid signals. Typically such lipid pools are found in cases of fatty liver and 
consist of a variety of compounds derived from fatty acids especially triglycerides. There 
are various reasons why liver triglycerides might increase with allyl formate-induced 
damage. 
1. Normally, fatty acid metabolism is under strict homeostatic control and is 
responsive to physiological demands, with fatty acids being synthesised when 
carbohydrates and ATP are readily available and degraded through the fatty acid 
cycle. The latter cycle involves reaction of ATP with fatty acid as an activation step 
to form fatty acid-ADP anhydride. This is followed by P-oxidation to form acetyl 
CoA, which will then enters the citric acid cycle and ultimately form ATP. The 
periportal region is a major site of fatty acid oxidation and severe and prolonged 
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impairment of P-oxidation in the mitochondria is known to cause steatosis and, in 
some severe cases, liver failure and death (Fromenty and Pessayre, 1995). Thus, 
mitochondrial impairment could lead to fatty liver through impairment of fatty acid 
oxidation. 
2. Secondly, the transport of triglycerides out of the liver requires apolipoprotein and 
could be decreased through impaired protein synthesis or through protein 
degradation. For example after dosing with ethionine or hydrazine, impaired 
apolipoprotein synthesis leads to reduced transport of triglycerides out of the liver 
(Waterfield et al. 1998; Waterfield et al. 1997). After dosing with allyl formate, 
impaired protein synthesis could arise simply through ATP-depletion but in vitro 
study has also shown that acrolein undergoes extensive carbonylation reactions with 
proteins (Burcham and Fontaine 2001) and that cysteine residues in proteins react 
readily with acrolein (Esterbauer et al. 1975). Thus, either ATP depletion or the 
presence of acrolein might lead to fatty liver by impairing the transport of 
triglycerides out of the liver. 
3. Additionally, Lin et al. (1996) demonstrated that an increase in the intracellular bile 
acids concentration also inhibits the secretion of VLDL-associated triglycerides 
from hepatocytes as well as the secretion of the apolipoprotein associated with 
transport of VLDL namely apoB-100. Allyl formate causes some biliary damage 
and the plasma clinical chemistry results in our current study indicated an increase 
in total bile acids (TBA). Thus, bile acids could have an inhibitory effect on 
triglyceride secretion leading to accumulation of triglycerides in the liver. 
The loss of glutathione is likely to be a key factor in the liver damage induced by allyl 
formate. GSH will be depleted by direct addition to acrolein and when GSH is depleted, 
acrolein will be free to attack other compounds and sites. However, our results do not 
appear to provide evidence for the lipid peroxidation reported by other worker (Adams and 
Klaidman 1993) and which has been suggested as a factor of allyl formate toxicity by 
Ferrali et al. (1989). The highly variable responses to allyl formate dosing are unexplained 
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but indicate inter-animal variation in the metabolism of allyl formate or in defensive 
capabilities. 
The MAS NMR also showed a decrease in liver TMAO level in the high dose allyl formate 
animals. Increased phospholipids could lead to a decrease in TMAO levels, but the NIAS 
NMR data did not show any such increase in liver phospholipids which would suggests the 
absence of phospholipidosis. The decrease in TMAO could then be related to a decrease in 
the level of the flavin monooxygenase (FMO) enzyme, which catalyse the oxidation of 
trimethylamine (TMA) to TMAO. The activity of FMO is highly dependent on NADPH 
(Ziegler 1990, Baker et al. 1963, Wu et al. 1986). At a pH of 7.4 and temperature of 41 'C, 
NADPH was found to have a short half-life of 6 1/2hrs (Wu et al. 1986) and acrolein has 
been shown to inhibit protein synthesis (Burcharn and Fontaine 2001, Esterbauer et al. 
1975). 
3.3.2 Effects of Allyl Formate on bloodplasma and urine 
The effects of allyl formate on blood plasma are characterised by increases in aspartate and 
alanine aminotransferases, which are indicative of hepatocellular damage and increases in 
5' nucleotidase, y-glutamyl transferase and bile acids, which are specific markers of 
hepatobiliary dysfunction. Allyl formate also caused increases in creatine and tyrosine and 
a reduction in lipids and the VLDL/LDL ratio. In the urine, increases in taurine and creatine 
were observed together with the presence of 3-hydroxymercapturic acid (3-HPNIA) 
(Clayton et al. 2003). Additionally, there were urinary decreases in citrate, 2-oxoglutarate, 
PAG and TNIAO. 
The reduction in the ratio of VLDL/LDL could be because of reduced lipid secretion from 
liver. The urinary taurine increases could arise from impaired hepatic protein synthesis with 
cysteine being diverted in consequence, from protein synthesis to taurine synthesis 
(Waterfield et aL 1991). The tyrosine increase in plasma also suggests protein degradation 
or impaired protein synthesis within the liver where, tyrosine is normally converted to p- 
hydroxyphenylpyruvate through the action of tyrosine-amino-transferase (TAT) which is an 
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unusually short-lived enzyme (tY2= 2 V2hours). Allyl formate-induced protein degradation 
or impaired protein synthesis could rapidly lead to TAT depletion and consequent increases 
in tyrosine in the liver and blood. 
The allyl formate-induced increases in urinary creatine may be related to increased cysteine 
biosynthesis from methionine as postulated by Clayton et al. (2003a). Cysteine is used to 
synthesise GSH, taurine and proteins. During this biosynthesis, S-adenosylmethionine 
donates a methyl group to the methyl acceptor, guanidinoacetic acid (GAA). The 
methylated-GAA is then converted to creatine, which enters the blood for use in peripheral 
tissues or excretion. The presence of 3-HPMA is supportive of the reaction of acrolein with 
glutathione (Sanduja et al. 1989). Decreases in urinary citrate, and 2-oxoglutarate are 
indicative of disruption in the tricarboxylic acid (TCA) cycle. 
3.3.3 Comparison of Information Obtainedfrom Different Sources 
The use of high resolution 1H MAS NMR spectroscopy to study intact liver tissues, which 
provides the essential link between the metabolite profiles obtained from biofluid NMR and 
the structural progression of the lesion observed by histopathological technique. The 
integrated approach wherein conventional toxicological data and multiple types of NMR 
data are analysed collectively, proved useful in describing allyl formate-induced toxicity in 
rats. Table 3.8 shows the summary of the effects of allyl formate in rats. Overall, the NMR 
findings are consistent with the clinical chemistry findings as well as the histopathology, 
which showed some allyl formate-induced effects in low dose animals and clear allyl 
formate-induced effects of variable severity in high dose animals with near total recovery 
by the end of the study. The Day 8 standard 1H NMR spectra showed minimal effect and 
this was reflected in the PCA plots. This suggests that recovery was largely complete by 
Day 8. This is consistent with the histopathology and clinical chemistry findings. The Day 
2 plasma NMR data showed clear increases in plasma tyrosine level in all high dose 
animals. The degree of change in plasma tyrosine level correlated with the variable severity 
of the hepatocellular necrosis observed in this group of animals as shown in Table 3.9. 
Thus plasma tyrosine could be a marker for liver necrosis as suggested by Kawamura- 
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Yasui et al. (1999) and Shaw and Lieber (1983), but might be partially related to ATP 
depletion and impaired protein synthesis. 
Additionally, the Day 2 plasma NMR data also showed increase in plasma creatine. 
Increase in plasma creatine level normally leads to increase in urinary creatine level, which 
is evident in the current study. However, the increased plasma creatine does not correlate 
with the extent of necrosis detected in histopathology as shown in Table 3.10. Clayton et aL 
(2003a & 2003b) suggested that creatine is synthesised as a by-product of cysteine 
synthesis with cysteine in turn being required for the synthesis of taurine, glutathione and 
proteins. Therefore, if the increase in creatine is a symptom of defensive processes then the 
amount of the increase would not be expected to show a simple relationship to the amount 
of damage caused. 
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Table 3.9 Plasma tyrosine in relation to the extent of liver necrosis. 
Animal 
Number 
Concentration of Day 2 plasma 
Tyrosine (multiple of average control 
level) 
Extent of Liver Necrosis 
Detected by Histopathology 
at Day 2 
206 2.4 x control average Marked 
209 2.4 x control average Marked 
207 1.9 x control average Moderate 
210 1.9 x control average Moderate 
208 1.3 x control average Minimal 
Table 3.10 Plasma creatine in relation to the extent of liver necrosis. 
Animal 
Number 
Concentration of Day 2 Plasma 
creatine (multiple of average control 
level) 
Extent of Liver Necrosis 
Detected by Histopathology at 
Day 2 
206 3.4 x control average Marked 
209 3.4 x control average Marked 
207 3.5 x control average Moderate 
210 1.7 x control average Moderate 
208 2.5 x control average Minimal 
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The Day 2 plasma NMR data also revealed variable decreases in plasma lipids but again, 
these changes did not correlate to the extent of necrosis observed by histopathology. 
Analysis of the LDL and VLDL moieties of the plasma NMR data showed decreases in 
both LDL and VLDL in the low dose animals. In the high dose animals, however, decrease 
in plasma VLDL is bigger in magnitude as compare to that of LDL (Table 3.11). 
Table 3.11 Changes in Day 2 plasma LDL and VLDL levels. 
Allyl formate 
dose group 
Decrease in Day 2 plasma LDL 
(NMR data, %) 
Decrease in Day 2 plasma VLDL 
(NMR data, %) 
LD 16.8 26.9 
HD 2.7 41.5 
The integrated metabonomic analysis of liver and plasma NMR data enabled simultaneous 
study and extraction of information embedded in these two biomatrices and the use of PLS 
analysis on liver and plasma data provided insights into the changes in the liver which 
correlated with the changes in the plasma. The data presented by the PLS plots (Figure 3.24 
and 3.25) showed an increase in liver triglycerides that correlated to a decrease in plasma 
lipids, which could indicate reduced lipid transport from the liver to the plasma. 
The urinary decreases in TCA cycle intermediates such as citrate and 2-oxoglutarate, 
suggest mitochondrial. dysfunction (Antti et al. 2002). The urine NMR data also showed 
increases in urinary creatine and taurine, which are indicative of hepatotoxicity (Waterfield 
et aL 1993a). At both dose levels, NMR spectroscopy of the urine data also revealed the 
presence of 3-hydroxypropyl mercapturic acid in the post-dose urine, which is consistent 
with the metabolism of allyl formate to toxic acrolein and the formation of a glutathione 
conjugate (Rees and Tarlow 1967, Kaye 1973, Alarcon 1976). 
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Goodwin et al. (1994) reported that phenylacetic acid and benzoic acid are metabolic 
precursors of PAG (phenylacetylglycine) and hippurate (benzoylglycine) respectively. Both 
these aromatic acids are normally detoxified via conjugation with glycine. Hence the 
observed reduction in urinary hippurate may be explained by insufficient glycine for the 
conjugation of benzoic acid, which has been channelled into PAG production instead. PAG 
has been proposed as a putative biomarker for phospholipidosis (Espina et al. 2001). 
Phenylacetyl-CoA, derived from phenylacetic acid, conjugates with glycine to give rise to 
observed PAG in urine. P-Oxidation of free phenyl-substituted fatty acids derived from 
excess lipids may also be one possible source of phenylacetic acid or it might be derived 
from metabolism of phenylalanine as proposed by Nicholls et al. (2000). 
The decrease in urinary TMAO level could be related to the decrease in liver TMAO level. 
There are three sources of methylamines: diet, bacterial synthesis and endogenous synthesis 
(Smith et al. 1994). Choline, a quartenary amine, is a precursor of phosphatidy1choline (a 
phospholipid), of betaine, of TMAO and of glycine (Figure 3.27). Changes in the level of 
TMAO could be directly related to the diet. The major route of biosynthesis of TMAO 
derives from the degradation of dietary choline which is metabolised to trimethylamine 
(TMA) by the enzymes of the gut microflora. Several strains of gut bacteria have been 
shown to decompose choline to TMA (Smith et al. 1994, Zhang et al. 1999). TMA is 
normally oxidised by the activity of the flavin monooxygenase system in the liver to 
TNIAO, which is then excreted in the urine (Smith et al. 1994, Gut and Conney 1993, 
Zhang et al. 1999). Allyl formate-induced disruption in protein synthesis and protein 
function may reduce the formation of TMAO from trimethylamine via flavin 
monooxygenase. However, increased biosynthesis of phospholipids could also reduce the 
formation of TMAO and at the high dose of allyl formate, increased in urinary 
phehylacetylglycine (PAG) was observed, which Nicholls et al. (2000) have suggested may 
be a marker of phospholipidosis. If an increase in urinary PAG is due to increased 
phospholipids synthesis, it could lead to a decrease in TMAO by diversion of the choline 
utilisation. However, the Day 2 MAS NMR data showed no increase in liver phospholipids 
indicating that phospholipidosis did not occur in the liver. TMAO change might also reflect 
a disturbance of the gut microflora. Disruption of gut microflora, which there is some 
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evidence for with presence of short chain fatty acids in the urine of some high dose rats, 
will lead to decrease TMA and TMAO formation. 
Diet 
Upper 
G. 1. 
Urine 
Lower 
G. 1. 
Figure 3.27 Metabolism and excretion of methylamines (adapted from Smith et aL 
1994). 
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3.3.4 Summary 
1H NMR spectroscopy of liver and biofluids coupled with multivariate data analysis and 
conventional clinical chemistry has enabled an integrated study of biochemical 
perturbations in liver tissue, blood plasma and urine following treatment with allyl formate 
of rats. These have been compared to the degree of liver damage observed by conventional 
histopathology. The main biochemical effects observed in the liver in this study appear to 
be energy depletion, inhibition of protein synthesis and disruption of fatty acid 
metabolism/transport. The depletion of hepatic ATP is likely to be due to acrolein-induced 
mitochondrial damage and the consequent disruption in protein synthesis could be the cause 
of the observed lipidosis. The urinary excretion of 3-HPMA indicated the likely 
involvement of conjugation with glutathione as a route for the detoxification and 
elimination of allyl formate. 
131 
Chapter 4: Integrated Chlorpromazine Studies 
4.1 Background: Metabolism and hepatotoxicity of chlorpromazine 
Chlorpromazine is a phenothiazine compound used as an antipsychotic drug. It was first 
introduced in the early 1950s (Yeung et al. 1993). Phenothiazines are dopamine-D2 
antagonists. They are also thought to act as CC2-adrenegic, muscarinic cholinergic and 
histamine HI blockers. Phenothiazines are designed to cross the blood-brain barrier and 
chlorpromazine is a cationic amphiphilic drug soluble in both hydrophobic and hydrophilic 
solvents. Like most amphiphilic cations, chlorpromazine is able to change the composition 
of glycerophospholipids in the plasma membrane by affecting enzymes involved in 
phospholipid metabolism (Underhaug, 2001). Chlorpromazine has been reported to inhibit 
choline phosphate cytidylyl transferase, a regulatory enzyme for the synthesis of 
phosphatidy1choline (Underhaug, 2001). Chlorpromazine is extensively metabolised to 
numerous Phase 1 and Phase 2 metabolites (Figure 4.1). Otton et al. (1982) found that 
aromatic hydroxylation at the 7-position is the major reaction in human microsomes. One 
study detected 75 chlorpromazine metabolites in blood, urine and faeces with 34 being 
matched to synthetic standards (Jorgensen, 1986). A battery of chlorpromazine metabolic 
pathways was identified involving N-oxidation, hydroxylation, N-demethylation, and S- 
oxidation (Boehme & Strobel, 1998). 
Dube et aL (1972) in their study of a single high dose (50 mg/kg) administration of 
chlorpromazine to adult male albino rats, found that chlorpromazine increased the activity 
of liver enzymes tyrosine-amino-transaminase (TAT), tryptophan pyrrolase and threonine 
dehydrase. They also found that administration of an inhibitor of RNA synthesis, 
Actinomycin D, inhibits the effect of chlorpromazine on the three liver enzymes. Knodell 
(1975) investigated the effect of chlorpromazine on bilirubin metabolism and biliary 
secretion in rats. Chlorpromazine was administered acutely and chronically and it was 
found that acute administration of chlorpromazine at 25 mg/kg increases bilirubin output 
and the level of plasma haemoglobin was elevated as well. Animals treated chronically also 
showed the same response. Knodell postulated that damage to hepatocytes or changes in the 
ability of the liver to conjugate bilirubin, might result in bilirubin accumulation. Increase in 
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plasma haernoglobin in acute treatment indicated an increase in bilirubin output, which is 
mainly due to haemolysis as chlorpromazine was able to change the osmotic pressure of 
erythrocytes. Chlorpromazine enhances hepatic heme synthesis by inducing haemolysis. 
The change in bilirubin conjugation is due to a chlorpromazine-induced defect in intrinsic 
hepatic function. It was further explained that the increase in unconjugated bilirubin and 
monoconjugated bilirubin, which are less soluble in bile than diconjugated bilirubin, may 
lead to the formation of biliary sludge or precipitation of bilirubin in the canaliculi. This 
would produce cholestatic lesion or initiate an inflammatory or immunological response 
leading to cholestasis. The increase in y-azopigment, characteristic of biliary obstruction in 
rat and human, is consistent with the cholestatic nature of hepatic dysfunction associated 
with chlorpromazine. 
Carey et al. (1976) studied the physicochemical interactions of chlorpromazine 
hydrochloride with biliary lipids in vitro. They reported that at pH values below the 
apparent pK of 7.4, chlorpromazine acts as a water-soluble cationic detergent. They found 
that chlorpromazine was able to form 1: 1 salt complexes with bile salts at bile salt 
concentrations above their critical micellar concentrations. They also found that by mixing 
phosphatidy1choline with bile salts, precipitation was inhibited. Therefore, they postulated 
that because bile-water flow is determined by canalicular bile-salt secretion, the formation 
of complexes and precipitation of bile salts by chlorpromazine and its metabolites might be 
related physicochernically to the chlorpromazine-induced reversible bile secretory failure. 
Tjioe et al. (1972) reported that chlorpromazine exerts various inhibitory effects on 
mitochondria. They also reported that 7,8-dihydroxychlorpromazine and 7,8- 
dioxochlorpromazine, metabolites of chlorpromazine, inhibit both calcium and oxygen 
uptake in isolated brain mitochondria. Abernathy et al. (1977) studied the effects of 
chlorpromazine and its metabolites on isolated hepatocytes. The study revealed that 
chlorpromazine at a concentration of 9* 10-5 M or greater caused leakage of aspartate 
aminotransferase from the hepatocytes. The results also showed that mono- and 
didesmethylated-chlorpromazine were 3 and 6 times more potent than chlorpromazine 
respectively; and hydroxylation at positions 7 or 8 gives rise to metabolites, which were 
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slightly less active than the parent drug. Sulphoxidation of chlorpromazine, however, 
produced inactive metabolites. Samuels and Carey (1978) investigated the effects of 
chlorpromazine hydrochloride and its metabolites on the Mg2+_ , and Na+, K+-ATPase 
activities of canalicular-enriched rat liver plasma membranes. They reported that 
chlorpromazine inhibits both bile salt-dependent and independent bile flow in primates in a 
predictable way, which led them to their study in rat liver plasma membranes. They found 
2+ that chlorpromazine hydrochloride inhibited the activities of both Mg and Na+, K- 
ATPase linearly. Of the metabolites of chlorpromazine, 7-hydroxychlorpromazine was 
found to be as potent as the parent drug and two sulfoxides of chlorpromazine were found 
to be the least potent, namely chlorpromazine sulfoxide and 7-hydroxychlorpromazine 
sulfoxide. They postulated that chlorpromazine-induced cholestasis might be due to a direct 
effect on the ATPase activities in the canalicular membranes; and that the degree of 
cholestasis might be influenced by the metabolic conversion of the drug to its more active 
metabolites i. e. free radicals or the less active metabolites i. e. sulfoxides of chlorpromazine 
and by the local environment of the canalicular membrane such as the pH and glutathione 
concentration. 
Traficante et al. (1979) investigated the in vitro sulfoxidation of chlorpromazine by human 
hepatic and extrahepatic tissues. They reported that chlorpromazine sulfoxide is inactive 
pharmacologically and a possible end product of the deactivation of chlorpromazine. They 
found that increase in sulfoxide formation in blood corresponded to a decrease in the parent 
compound and that the very fast rate is dependent on the volume of whole blood added. 
Tavaloni and Boyer in 1980, investigated the relationship between hepatic metabolism of 
chlorpromazine and the cholestatic effect in isolated perfused rat liver. They reported that 
the sulfoxide of chlorpromazine is much less toxic than the parent compound, which agrees 
with Traficante et al. (1979). They found that chlorpromazine caused a significant decrease 
in bile flow, hepatic perfusate flow and bile acid excretion. Addition of 7,8-dihydroxy 
chlorpromazine, caused a significant decrease in bile flow and bile acid excretion. 
However, addition of chlorpromazine sulfoxide failed to produce any effects. They 
suggested that the toxicity of chlorpromazine is modulated by its metabolism and the 
cholestatic effect might be enhanced by slower metabolic transformation of chlorpromazine 
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to the less toxic chlorpromazine sulfoxide. They also postulate that the toxicity of 
chlorpromazine might be enhanced if selective formation of multiple ring-hydroxylated 
metabolites such as 7,8-dihydroxy chlorpromazine occurred. 
4. LI Study Details 
Study number 98053 carried out at Pfizer, Centre de Recherche, Amboise, France. 
Study Study 
Dose of toxin 
Animal 
Euthanased 
Number 
Compound 
Group 
administered 
(mg/kg) 
Number Day 2 Day 8 
Saline Control 0 1-10 6-10 1-5 
98053 Chlorprornazine Low Dose 30 301-310 306-310 301-305 
in saline High Dose 60 401-410 406-410 401-405 
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Figure 4.1 Metabolism of chlorpromazine (adapted from Joegensen A., Progress in 
Drug Metabolism, 1986). 
136 
4.2 Results 
4.2.1 Histopathology results 
The histopathological observations for chlorpromazine-dosed rats are sununarised below in 
Table 4.1. 
Table 4.1 Summary of the histopathological changes observed in chlorpromazine- 
dosed Sprague-Dawley rats. 
Day 
Dose of 2 8 
chlorpromazine 
No significant differences from No significant differences from 
30 mg/kg controls. controls. 
Three out of five animals 
showed deposition of lipids in 
the centrilobular areas. Diffuse 
60 mg/kg hepatocellular cytoplasmic 
No significant changes observed. 
changes observed but no 
evidence of cholestatic 
changes. 
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4. Z2 Clinical chemistry results 
The clinical chemistry data indicated minimal changes in both dose groups on Day 2 and 
Day 8. Details of the clinical chemistry findings are summarised in Table 4.2. 
Table 4.2 Summary of the plasma changes observed by clinical chemistry in 
chlorpromazine-dosed Sprague-Dawley rats. 
Day 
Dose of 
2 8 
chlorpromazine 
Triglycerides: 1 (46% No group differences were found 
ASAT: T (61% although y-glutamyltransferase 
30 mg/kg ALAT: T (53% (GGT), bilirubin and triglycerides 
were elevated in animal 10 1. 
ASAT: T (64% No group differences were found. 
Triglycerides: 1 (64% TBA elevated in animals 201 and 
60 mg/kg 204. Animal 202 showed 
unusually low creatinine. 
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4.2.2.1. Principal Component Analysis of Day 2 Plasma Clinical Chemistry Data 
PCA scores and loadings plots for the first two components of the control/chlorpromazine 
Day 2 clinical chemistry data are shown in Figure 4.2. In the scores plot, the data points are 
colour-coded and labelled so as to identify the treatment (e. g. black for control, bright 
green for low dose and for high dose) and animal number. 
The scores plot of the low dose chlorpromazine data (Figure 4.2A) indicates separation 
between the low dose group and controls along the first principal component, and the 
corresponding loadings plot (Figure 4.2B) showed a decrease in triglycerides and increases 
in urea, ALAT and ASAT as the major contributors to the separation. 
However, PCA scores plot of the high dose chlorpromazine data (Figure 4.2C) indicates 
partial separation between the dosed group and controls. The separation involves 
combination of both the first and second principal component with the high dose animals 
separated from the controls at a diagonal. An important feature observed in the 
corresponding loadings plot (Figure 4.2D) along the first principal component is the 
generalised increase in both aminotransferases, ALAT and ASAT, which are indicative of 
hepatocellular damage. The loadings plot also shows increases in 5' nucleotidase, y- 
glutamyl transferase and bile acids, which are specific markers of hepatobiliary function 
(Handler et aL 1994); and decreases in glucose and triglycerides which contributed to the 
separation along the first principal component. The loadings plot also indicates increases in 
albumin, albumin/globulin ratio, urea and cholesterol as the contributors to the separation 
along the second principal component. 
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Figure 4.2 (A) Scores plot from PCA of control and low dose chlorpromazine Day 2 
clinical chemistry data, and (B) corresponding loadings plot. (C) Scores plot 
from 
PCA of control and high dose chlorpromazine Day 2 clinical chemistry data, and 
(D) 
corresponding loadings plot. 
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4. Z3 Analysis of the Tissue Spectra 
4.2.3.1 Examination of lH MAS NMR tissue spectra 
Figure 4.3 shows the dose-dependent effects of chlorpromazine hepatotoxicity as visualised 
using standard 1D 1H MAS NMR of intact Day 2 rat liver. The corresponding NMR 
spectral assignments are listed in Table 4.3. 
Table 4.3 1H NMR resonance assignments for liver tissue. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Valine CH3 1.04 
2 Lactate CH3 1.33 
3 Acetate CH3 1.95 
4 Glutarnme CH2 2.39 
5 Glucose/glycogen/a-H amino acids Ring protons/a-CH 3.35-4.00 
6 P-Glucose CiH 4.64 
7 (x-Glucose CIH 5.23 
8 Glycogen CH 5.38-5.45 
9 Alanine CH3 1.48 
10 Glutamate CH 2.15 
11 Choline/phosphocholine N+(CH3)3 3.22 
12 TNIAO CH3 3.27 
Taurine 
CH2SO3- 3.25 
13 Lipids CH3-(CH2)n 0.90 
14 Lipids CH3-(CH2)n 1.29 
15 Lipids CO-CH2-CH2 1.61 
16 Lipids CH=CH-CH2-CH2 2.07 
17 Lipids CO-CH2-CH2 2.25 
18 Lipids =CH-CH2-CH= 2.78 
19 Lipids -CH=CH- 5.30-5.35 
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Figure 4.3 Dose-dependent effects of chlorpromazine hepatotoxicity as visualised 
using standard 1D 1H MAS NMR spectroscopy of intact Day 2 rat liver. A. Control 
liver. Liver from an animal administered: (B) Low-dose chlorpromazine and (C) 
High-dose chlorpromazine. 
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Visual inspection of the Day 2 MAS NMR spectra indicates that administration of low dose 
chlorpromazine appears to have little effect on the rat liver (Figure 4.313) with small 
increases in lipids as well as some decrease in TMAO. However, the administration of high 
dose chlorpromazine appears to have considerable effect on the rat liver (Figure 4.3C). The 
liver trimethylamine N-oxide (TMAO) signal at 63.27 decreases drastically in all high dose 
animals, with animals 407 & 410 showing the biggest decrease, animals 408 & 409 
showing moderate decrease and animal 406 showing the least decrease. In addition, the 
CH2 and CH3 moieties of the liver lipids increase in high dose animals 406,408 and 409 as 
compared to that of the controls with animal 408 showing the biggest increase and animal 
409 showing the smallest increase. Depletion of liver glucose and glycogen levels are also 
observed in high dose animals 406,408 and 409. The changes observed are in contrast with 
the histopathology observations which revealed minimal changes. The Day 8 MAS NMR 
spectra indicated minimal effects indicating recovery. Details of the MAS NMR 
observations for chlorpromazine-dosed rats are summarised below in Table 4.4 and the 
changes reported were quantified according to the method described in Chapter 2. 
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Table 4.4 Summary of the liver tissue changes 
chlorpromazine-dosed Sprague-Dawley rats. 
observed by MAS NMR in 
Dose of Day 
chlorpromazine 2 8 
Changes were minimal, but: The spectra indicated 
Lipids: T (*) minimal changes 
Glucose region: I (NS); animals 306 & compared to controls. 
Low dose (30 307 showed relative decrease in the 
mg/kg) resonance at 65.233 (glucose). 
TMAO: I (*); 3/5 animals (306,308 & 
310) showed relative decreases in 
TMAO at 53.27. 
Choline: T (NS) 
Changes varied within the high dose The spectra indicated 
animals. minimal changes 
TMAO: compared to controls. 
High dose (60 
Lipids: T (NS) 
mg/kg) Glucose (between 6 3.40 and 6 4.00): 
(NS) 
Glycogen (63.80 and 65.42): 1 (NS) 
Choline: T (NS) 
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4.2.3.2 Principal Component Analysis of Day 2 Liver NMR Data 
Principal component analysis of the control/low dose Day 2 data set reveals some dose 
related structure to the variation in the data. The scores plot (Figure 4AA) shows that 
combination of the first and second principal component separates two low dose animals 
from the rest of the animals. The first principal component describes the variation between 
low dose animals and control animals, showing partial separation between the low dose 
animals and the control animals with low dose animals 306 and 307 separated from the rest 
of the animals. One control animal, C6, is situated away from the rest of the controls due to 
lower lipids content. The second principal component described some variation in the data 
set that was related to the treatment of the animals with chlorpromazine. The corresponding 
loadings plot (Figure 4AB) indicates that a decrease in TMAO is the main contributor to 
the separation along the first principal component. Increases in the regions attributed to 
lipids, and decrease in the region attributed to glucose and glycogen were also identified as 
the contributors for the separation between the dosed-animals and control animals along the 
first and second principal component. 
Figure 4AC shows the scores plot for the first two components of the control/high dose 
Day 2 tissue NMR data. The scores plot shows clear dose-related structure to the variation 
in the data with the controls and high dose group separated on a diagonal by a combination 
of the first and second principal component. The scores plot also reveals that the high dose 
animals are separated into two clusters. The first cluster which consists of animals 406 and 
408, were separated from the controls along the first principal component and the second 
cluster which consist of animals 407,409 and 410, were separated from the controls along 
the second principal component. The corresponding loadings plot (Figure 4AD) indicates 
that increases in the regions attributed to lipids and decreases in the region attributed to 
glucose and glycogen as the major contributors to the separation along the first principal 
component, whilst a decrease in liver TMAO level is the main contributor to the separation 
along the second principal component. The changes observed in the principal component 
plots agree with the changes seen in the MAS NMR spectra of Day 2 high dose animals. 
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Figure 4.4 (A) PCA scores plot of the 1H MAS NMR spectra of chlorpromazine-dosed 
liver samples from Day 2 low dose versus control groups, and (B) the corresponding 
loadings plot. (C) PCA scores plot of the 1H MAS NMR spectra of chlorpromazine- 
dosed liver samples from Day 2 high dose versus control groups and (D) the 
corresponding loadings plot. 
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Figure 4.5 (A) PCA scores plot for the first two principal components of the standard 
1H MAS NMR spectra of the Day 2 chlorpromazine study, and (B) the corresponding 
loadings plot. 
PCA scores plot of the first two components of the combined Day 2 MAS NMR data 
(Figure 4.5A) showed some dose-related progression from the low dose animals to the high 
dose animals. The first principal component describes the variation between the high dose 
animals 408 and 406 and the rest of the animals. The second principal component shows 
partial separation between the low dose and control animals as well as the separation of 
high dose animals 407,409 and 410 from the control group. The corresponding loadings 
plot (Figure 4.5B) shows that chlorpromazine-induced increases in lipids, and decreases in 
glucose and glycogen are the major contributors to the separation along the first principal 
component, whereas chlorpromazine-induced decrease in TMAO is the major contributor 
and an important factor to the separation along the second principal component. 
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4.2.3.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Liver NMR Data 
In an effort to improve class separation and information recovery from the tissue NMR data 
a PLS-DA model was constructed, where the samples were classified according to one of 
three mutually orthogonal classes with control being class 1, low dose being class 2 and 
being class 3. 
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Figure 4.6 PLS-DA cross validated scores plot of the standard 1H MAS NMR spectra 
of the Day 2 chlorpromazine study. 
The X-matrix cross validated scores of the first two components of the model shows some 
improvement in the separation between the low dose animals and the control animals as can 
be seen in Figure 4.6. A combination of the first and second PLS component partially 
separates the low dose animals (animals 306,307, & 308) from the controls. Again, the 
high dose animals are separated into two clusters with one cluster (animals 406 & 408) 
separated along the first PLS component and another cluster (animals 407,409 and 410) 
separated along the second PLS component. 
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The corresponding X-block PLS loadings plot (Figure 4.7) indicates that the first PLS 
component, describing the general variation between the high dose animals 406 and 408 
and the rest of the animals, is due to increases in liver lipids and decreases in liver glucose 
and glycogen levels. The second PLS component, describing the variation between the 
dosed animals and the control animals, is due to the drastic decrease in liver TMAO levels. 
These observations confirmed the findings made from the 1H MAS NMR spectra (Table 
4.4) and PCA analyses of the Day 2 tissue NMR data (Figure 4.4). 
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4.2.3.4 Principal Component Analysis of Day 8 Liver NMR Data 
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Figure 4.8 PCA scores plot of the standard 1H MAS NMR spectra of Day 8 
chlorpromazine study. (A) Low dose versus Control data set, and (B) High dose versus 
Control data set. 
The PCA scores of plot of the chlorpromazine Day 8 tissue samples (Figure 4.8 A and B) 
indicated no clear separation between the dosed and the control groups. This indicates 
recovery by Day 8 compared to Day 2. 
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4.2.4 Analysis of the Plasma Spectra 
4.2.4.1 Examination of plasma CPMG spin-echo 1H NMR spectra 
The plasma NMR spectral assignments are listed in Table 4.5. 
Table 4.5 1H NMR resonance assignments for plasma. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Lipids (LDL) -CH2-CH3 0.84 
2 Lipids (VLDL) CH2-CH3 0.87 
3 Valine 
CH3 0.97 
CH3 1.02 
4 3-D-hydroxybutyrate CH3 1.20 
CH2 2.31,2.38 
5 Lipids (VLDL) -(CH2)n 1.29 
6 Lactate CH3 1.33 
7 Alanine CH3 1.46 
8 Acetate CH3 1.91 
9 Acetoacetate CH3 2.22 
10 Glutarnme CH2 2.41 
11 Citrate 
CH2 2.52 
CH2 2.69 
12 Choline N+(CH3)3 3.21 
13 Glucose/Amino acids resonances Ring protons/a-CH 3.35-4.00 
14 Lactate CH 4.10 
15 a-Glucose CIH 5.23 
16 Isoleucine CH3 0.93 
17 Leucine CH3 0.95 
18 Isoleucine CH3 1.00 
19 Threonine CH3 1.31 
20 N-acetyl glycoproteins NHCO CH3 2.04 
21 Pyruvate CH2 2.36 
22 Creatine CH3 3.04 
23 TMAO CH3 3.26 
24 Creatine CH3 3.93 
25 Lipids -CH=CH- 5.30 
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Figure 4.9 Effects of chlorpromazine (60 mg/kg) as visualised using CPMG spin-echo 
1H NMR spectra of Day 2 rat plasma. A. Control plasma. B. High-dose 
chlorpromazine. 
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Visual inspection of the plasma CPMG spin echo spectra revealed little effects on the low 
dose animals with an increase in plasma creatine being a common factor (data not shown). 
Figure 4.9 shows the effects of high dose chlorpromazine as visualised using CPMG spin- 
echo spectra of Day 2 plasma samples. The corresponding NMR spectral assignments are 
listed in Table 4.5. It can be seen quite clearly that the signals derived from lipids especially 
the CH2 and CH3 moeties decreased in the high dose animals. Additionally, the majority of 
the high dose animals show an increase in plasma creatine level. However, within the high 
dose animals, a sub-group of animals (animals 406,408,409) were found to exhibit 
features of ketosis with increases in the levels of 3-D-hydroxybutyrate and acetoacetate. 
The presence of these ketone bodies in some of the high dose animals (Figure 4.10) is 
indicative of reduced food intake possibly induced by the sedative effect of 
chlorpromazine. The Day 8 CPMG spin echo spectra of the plasma samples indicate 
minimal effects. Details of the plasma NMR observations for chlorpromazine-dosed rats are 
summarised below in Table 4.6 and the changes reported being quantified according to the 
method described in Chapter 2. 
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Figure 4.10 Sedative effect of high dose chlorpromazine on rat plasma as visualised 
using CPMG spin-echo 1H NMR spectra of Day 2 rat plasma. A. Control plasma. B. 
High-dose chlorpromazine showing presence of 3-D-hydroxybutyrate and 
acetoacetate. 
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Table 4.6 Summary of the plasma changes observed by NMR in chlorpromazine- 
dosed rats. 
Dose of Day 
chlorpromazine 2 8 
Visually, there were some differences No differences observed. 
from controls. 
Creatine: T **. Increase in creatine was 
observed in all animals. 
Animal 306 showed some signs of 30mg/kg 
ketosis with some increase in 3-D- 
hydroxybutyrate and acetoacetate. 
There was some decrease in the VLDL 
(NS). 
Total lipids: 1 (NS). 
Clear changes from controls were Approximately the same 
observed by visual inspection. as controls. 
Creatine: T ** 
3-D-hydroxybutyrate and acetoacetate 
was increased in animals 406,408 and 
409 with the biggest increase in animal 
60 mg/kg 
409 and animal 408 showing the smallest 
increase. No increase was observed in 
animals 407 and 4 10. 
Decrease in plasma VLDL in all animals: 
Total lipids: 
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4.2.4.2 Principal Component Analysis of Day 2 Plasma NMR Data 
An initial principal components analysis of the data set revealed some dose-related 
structure to the variation in the data. Figure 4.11 shows the scores and loadings plots of the 
first two principal components of the PCA model between the chlorpromazine-treated 
animals and the controls. 
PCA scores plot of the control/low dose Day 2 data set (Figure 4.1 IA) indicates differences 
in the metabolic profiles of the chlorpromazine-treated and control animals. The first 
principal component describes the variation between the two groups of animals. The scores 
plot also indicates that the low dose group are separated into two clusters along principal 
component two. The corresponding loadings plot (Figure 4.1 1B) reveals that changes in the 
lipids, moeties (VLDL, CH-, and LDL, CH3) are the major contributors to the separation 
between the low dose animals and control animals along the first principal component. The 
second principal component reveals increases in plasma 3-D-hydroxybutyrate, lactate and 
choline levels, which contributed to the separation within the high dose animals. Animals 
309 and 310 appear to have lower levels of the aforementioned plasma metabolites. The 
plasma NMR data shows clearer separation as compared to that of the liver NMR data due 
to the presence of ketone bodies in the blood. 
The PCA scores plot of the control/high dose Day 2 plasma data set (Figure 4.1 IQ 
indicates clear separation between the high dose animals and the control animals. Again the 
high dose animals are separated into two clusters with animals 409 and 406 situated on the 
upper half of the scores plot and animals 408,407 and 410 situated on the lower half of the 
scores plot separated along the second principal component, The first principal component, 
describing the dose-related variation between the two groups, is due to changes in plasma 
lipid moeties (Figure 4.11 D). The loadings plot also reveals that increases in plasma 3 -D- 
hydroxybutyrate and acetoacetate, and decreases in plasma glucose are the major 
contributors to the separation within the high dose animals. These changes are attributed to 
the sedative effects of chlorpromazine which caused decreased activity and consequent lack 
of feeding. Acetoacetate, and 3-D-hydroxybutyrate are ketone bodies which are produced 
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when excessive amounts of fatty acids are being mobillsed and oxidised to produce energy 
i. e. during starvation. 
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Figure 4.11 (A) PCA scores plot of the 1H CPMG spectra of chlorpromazine-dosed 
plasma samples from Day 2 low dose versus control groups, and (B) the 
corresponding loadings plot. (C) PCA scores plot of the 1H CPMG spectra of 
chlorpromazine-dosed plasma samples from Day 2 high dose versus control groups 
and (D) the corresponding loadings plot. 
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Figure 4.12 (A) PCA scores plot of the 1H CPMG plasma spectra of the Day 2 
chlorpromazine study, and (B) the corresponding loadings plot. 
PCA scores plot of the combined Day 2 plasma NMR data (Figure 4.12A) showed clear 
separation between the dosed groups and controls as well as a progressive dose-related 
effect along the first principal component. Variation within the dosed groups especially 
within the high dose group can be seen clearly along the second principal component. The 
corresponding loadings plot (Figure 4.1213) shows that chlorpromazine-induced decrease in 
lipids is the major contributor to the separation along the first principal component. The 
dose-related decrease in plasma lipids also contributed to the observed progressive dose- 
related effects in the scores plot. In addition, the loadings plot also indicates increases in 
plasma 3-D-hydroxybutyrate and acetoacetate, and decrease in plasma glucose related to 
the sedative effect of chlorpromazine along the second principal component. 
1.2P 
A 0.8, JD1.24P 
ä2.2 4P 
Ä 0.88P 
4P 
1.32P 
ýp 
-0.20 0.00 0.20 0.40 0.60 0.80 
158 
4.2.4.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Plasma NMR Data 
The Day 2 plasma NMR data was analysed using PLS-DA approach to further refine the 
information recovery. 
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Figure 4.13 PLS-DA cross validated scores plot of the 1H CPMG spectra of the Day 2 
chlorpromazine study plasma samples. 
The X matrix cross validated scores plot of the first two components (Figure 4.13) shows 
clear separation between the dosed groups and the control group as well as a clear dose- 
response effect. The control animals are situated on the lower right quadrant, with the low 
dose animals are separated between the high dose animals and the control animals. The 
high dose animals are (to the left of the plot) separated from the control group along the 
first component. In addition, the high dose animals are separated into two clusters along the 
second PLS component with animals 407,408 and 410 on the upper half and animals 406 
and 409 on the lower half of the plot. 
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Figure 4.14 PLS weights from the lH CPMG spectra of the Day 2 chlorpromazine 
study plasma samples (W[I] = PLS component 1, W[2] = PLS component 2). 
The corresponding X block PLS loadings plot (Figure 4.14) indicates that the first 
component describing the general variation between high dose and control animals is due to 
decreased plasma lipids. The second component, describing the variation within the high 
dose animals, is due to decrease in the plasma glucose level as well as increases in the 
plasma 3-D-hydroxybutyrate and acetoacetate levels which are due to chlorpromazine- 
induced ketosis. The changes observed in the PLS-DA scores and loadings plots confirmed 
the findings made from the 1H NMR spectra (Figure 4.10) and PCA analyses of the Day 2 
plasma NMR data (Figure 4.11). 
160 
4.2.5 Analysis of the Urine Spectra 
4.2.5.1 Examination of lH NMR urine spectra 
Visual inspection of the low dose urine spectra show some changes in endogenous urinary 
metabolites (data not shown). Most of the low dose animals showed increases in taurine 
and creatine levels. Additionally, the animals also showed decreases in 2-oxoglutarate, and 
citrate. However, the extent of these changes varied between animals. All five animals 
appeared to have recovered by Day 7. 
Figure 4.15 shows a series of standard 1H NMR spectra of urine covering predose and 
various time points following the administration of high dose chlorpromazine. The high 
dose of chlorpromazine induced marked changes in the endogenous urinary metabolite 
profiles. The dominant changes included increases in urinary phenylacetylglycine, creatine 
and taurine, and decreases in TMAO, succinate, citrate, 2-oxoglutarate, and hippurate, 
which lasted up to Day 3 with maximal abnormality being observed in the Day 2 samples. 
The 1H NMR spectra indicated recovery to normality by Day 7 post-dosing. Details of the 
urine NMR observations for chlorpromazine-dosed rats are summarised below in Table 4.7, 
the changes reported being quantified according to the method described in Chapter 2. 
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Figure 4.15 Series of standard 111 NMR spectra of urine at predose and various time 
points following the administration of Chlorpromazine (60 mg/kg). Key: 2- 
oxoglutarate (2-OG), phenylacetylglycine (PAG), dimethylamine (DNU), 
dimethylglycine (DMG). 
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Table 4.7 Summary of the urinary changes observed by NMR in chlorpromazine- 
dosed rats. 
Dose of Chlorpromazine 
30 mg/kg 60 mg/kg 
Clear changes in the endogenous Marked changes in the endogenous metabolites 
metabolites were observed: were detected on various days. On Day 2 the 
Creatine: changes were assessed as follows: 
Taurine: TMAO: ý ** 
2-OG: I (NS) Creatine: T ** 
Citrate: I (NS) Taurine T (NS) 
2-OG: I ** 
Citrate: I ** 
Succinate: 
Hippurate: 
PAG: T ** 
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4.2.5.2 Principal Component Analysis of Urine NMR Data 
Figure 4.16 shows a series of PCA scores plots of the first two principal components of the 
high dose chlorpromazine-treated animals and the controls. The scores plot of the pre-dose 
urine samples showed partial separation between the two groups. Animals 403 and 405 are 
separated from the rest of the animals along the second principal component and animals 
401 is separated from the rest of the animals along the first principal component. The series 
of PCA scores plot highlighted that the endogenous biochemical differences between the 
two groups increased post-dose reaching a maximum at Day 2. Clear separation between 
the high dose animals and control animals can be observed on Day I (0-7h). The Day 2 
PCA scores plot shows clear differences between the high dose and control animals. 
Additionally, the Day 2 scores plot also shows animal 401 separated from the rest of the 
animals along the second principal component. The PCA scores plot of Day 3 urine 
samples shows clear separation between the two groups although variation within the high 
dose animals can be seen clearly. Finally, the scores plot of Day 7 shows some separation 
indicating partial recovery. These observations confirm that there are biochemical changes 
between the groups upon administration of high dose chlorpromazine that is becoming 
more prominent with increasing time until a time maxima of Day 2 before gradual recovery 
from the toxic insult on Day 3 onwards. 
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Figure 4.16 A series of PCA scores plots of the first two components to investigate 
time related metabolic differences associated with the effects of high dose 
chlorpromazine in the animals. 
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Figure 4.17 A series of corresponding PCA loadings plots of the first two components 
to investigate time related metabolic differences associated with the effects of high 
dose chlorpromazine in the animals. 
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Figure 4.17 shows a series of PCA loadings plots of the first two principal components of 
the high dose chlorpromazine-treated animals and the controls. The loadings plot for the 
pre-dose data indicated that high dose animals 403 and 405 have lower urinary glucose and 
creatine as compared to the rest of the animals. The loadings plot also shows that animal 
401 has higher levels of urinary TMAO and citrate. Careful inspection of the urinary NMR 
data confirmed that high dose animals 403 and 405 have lower levels of urinary glucose 
and creatine; and that animal 401 has high level of urinary TMAO and citrate. Overall the 
loadings plots show that the trends seen in the PCA scores plots (Figure 4.16) were 
attributed to relative changes in the urinary endogenous metabolites. The loadings plot for 
Day I(O-7h) indicates that decreases in urinary TMAO, citrate and 2-oxoglutarate are the 
biggest contributors to the separation along the first principal component. The loadings plot 
also identifies a decrease in urinary hippurate as the contributor to the separation between 
the high dose and control animals. However, on Day 2, increase in urinary creatine, and 
decreases in urinary citrate and 2-oxoglutarate are the biggest contributors to the separation 
between the two groups. In addition, the loadings plot shows increase in urinary 
phenyacetylglycine and decrease in urinary hippurate which contributed to the separation 
along the second principal component. The loadings plot also shows decrease in urinary 
TMAO level as the sole contributor to the separation between animal 401 and the rest of the 
animals. These changes can be seen clearly in the series of urinary NMR spectra (Figure 
4.15). The loadings plot for Day 3 indicated increases in urinary taurine and creatine as 
well as decreases in urinary citrate, TMAO, hippurate and 2-oxoglutarate contributed to the 
separation along the first principal component. The loadings plot also shows that variation 
in urinary TNLAO level contributed to the variation within the high dose animals with 
animals 402,403 and 405 showing higher level of TMAO as compared to animals 401 and 
404. The loadings plot for Day 7 shows some changes in the levels of endogenous 
metabolites with changes in urinary glucose and TMAO as the most prominent. 
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4.2.5.3 PCA Mean Trajectory of Urine NMR Data 
A PCA mean trajectory was calculated using the 1H NMR spectra of urine sample for all 
high dose animals over five time points as above to extract time-related metabolic changes 
in rat urine samples in response to the xenobiotic insult. The PCA mean trajectory was 
derived as described in chapter 2. 
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Figure 4.18 PCA mean metabolic trajectory plot mapping the average position of 
standard 111 NMR high dose chlorpromazine urine spectra over five time points. 
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A PCA mean trajectory plot (Figure 4.18) was constructed from the complete data-reduced 
1H NMR spectra, excluding the region of water and urea (8 4.0-6.0). The first two PCs 
described 94.9% of the total variance in X. The modelled metabolic evolution comprised 
four distinct phases. In phase one, corresponding to movement to the Day I (0-7h) time 
point, the trajectory of the urine sample coordinates moved away from the pre-dose (PD) 
position along the second principal component, corresponding to decreases in urinary 
TMAO, 2-oxoglutarate, hippurate and citrate as well as some increase in urinary taurine 
level, indicating onset of chlorpromazine-induced toxicity. In phase two, corresponding to 
movement to the Day 2 time point, the trajectory changes direction moving away from the 
origin along the first principal component corresponding to the concomitant increase in 
urinary creatine, taurine and phenylacetylglycine, and more severe decrease in urinary 
TMAO, 2-oxoglutarate, citrate succinate and hippurate with the changes reaching maximal 
level on Day 2. Thereafter in phase three, corresponding to movement to the Day 3 time 
point, the trajectory of the urine sample coordinates moved towards the pre-dose position 
along the second principal component, corresponding to increases in urinary taurine, 
TMAO and creatine as well as some decreases in urinary 2-oxoglutarate, citrate and 
hippurate. The changes observed in Day 3 are less severe as compare to the changes in Day 
2 indicating the beginning of recovery. In addition, the trajectory between Day 2 and Day 3 
time points are almost parallel albeit in opposite direction to the trajectory between Day 
I(O-7h) and Day 2 time points indicating a simple recovery response that corresponds with 
the level of liver toxicity. Finally in phase four, corresponding to movement to the Day 7 
time point, the trajectory moved towards the origin along the first principal component 
corresponding to the levels of urinary metabolites returning to 'normality' with increases in 
urinary TMAO, citrate, 2-oxoglutarate, hippurate and succinate, and decrease in urinary 
taurine. 
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4. Z 6 Pattern Recognition Analysis of Concatenated Liver and Plasma NMR Data 
4.2.6.1 Concatenated Principal Component Analysis (PCA) 
PCA was performed on concatenated liver and plasma NMR data and Figure 4.19 shows 
the resulting scores and loadings plots. The scores plot for the low dose and control animals 
(Figure 4.19A) showed separation between the two groups of animals. The first principal 
component describes the variation between the low dose animals and the control animals, 
whereas the variation within the dosed group is described by the second principal 
component with animals 3 09 and 3 10 separated from the rest of the low dose animals. The 
corresponding loadings plot (Figure 4.19B) indicates that decrease in plasma VLDL is the 
major contributor to the separation between the low dose animals and control animals along 
the first principal component. The loadings plot also shows that changes in plasma LDL, 
lactate and choline as well as liver TMAO are the contributors to the separation within the 
low dose animals along the second principal component. 
The PCA scores plot of the high dose liver and plasma data (Figure 4.19C) revealed clear 
separation between the high dose animals and the control animals. The first principal 
component describes the variation observed between the high dose animals and the control 
animals. Additionally, the scores plot also revealed differences within the high dose 
animals with animals 406 and 409 located on the upper half of the plots and the remaining 
three animals on the lower half of the scores plot separated along the second principal 
component. The corresponding loadings plot (Figure 4.19D) indicates that decreases in 
plasma lipids and lactate as well as decreases in liver TNIAO are the contributors to the 
variation along the first principal component, with the change in the plasma lipids at 81.28 
being the dominant factor. Additionally, the loadings plot also indicates that increases in 
plasma 3-D-hydroxybutyrate (61.20) and acetoacetate (62.24), and decreases in plasma 
glucose as well as changes in liver TMAO level are the major contributors to the separation 
along the second principal component, with animals 406 and 409 showing signs of ketosis 
separated from the rest of the high dose animals. 
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Figure 4.19 Concatenated PCA models for the first two components of the Day 2 
standard 1D NMR spectra of chlorpromazine-dosed liver and CPMG spin-echo 
plasma NMR spectra. (A) Low-dose vs. control data and the corresponding loadings 
plot (B). (C) High-dose vs. control data and the corresponding loadings plot (D). 
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4.2.6.2 PLS-Discriminant Analysis (PLS-DA) 
PLS-DA was also used to determine which variables in the liver and plasma NMR data 
predict the sample classes. 
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Figure 4.20 PLS-DA cross validated scores plot of standard 1H NMR spectra of 
chlorpromazine Day 2 liver tissue and plasma samples. 
Figure 4.20 shows the PLS-DA cross validated scores plot for the first two components of 
the chlorpromazine Day 2 liver tissue and plasma NMR data. The scores plot revealed clear 
separation between the controls and the dosed groups particularly between the low dose and 
control groups. The high dose animals are separated from the control animals along the first 
component. Similarly, the low dose animals are distinguished from the control animals 
along the first component situated between the control animals and high dose animals. 
Additionally, the scores plot also revealed separation within the high dose animals with 
animals 406 and 409 separated from the rest of the animals on the lower left quadrant of the 
scores plot along the second principal component. 
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Figure 4.21 Corresponding PLS loadings plot (W[1]) for the first component from the 
Day 2 (A) liver NMR data (-), and (B) plasma NMR data (-). 
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The corresponding X block first component PLS loadings attributed to the liver tissue and 
plasma NMR data are shown in Figure 4.21. The plot shows the general effects of dosing 
on liver tissue and plasma along the first component. It indicates that animals dosed with 
chlorpromazine exhibit elevated liver lipids and lower levels of liver carbohydrates and 
glycogen storage as well as TMAO (Figure 4.2 1 A), with changes in liver TMAO being the 
dorminant factor in the liver tissue. Additionally, Figure 4.21B indicates that 
administration of chlorpromazine caused decreases in plasma lipids and some increase in 
plasma N-acetyl glycoproteins along the first PLS component. The plot indicates a decrease 
in plasma lipids is the major contributor to the separation between the high dose animals 
and the rest of the animals. 
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Figure 4.22 Corresponding PLS loadings plot (W[2]) for the second component from 
the Day 2 (A) liver NMR data (-), and (B) plasma NMR data (-). 
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The corresponding X block second component PLS loadings attributed to the liver tissue 
and plasma NMR data are shown in Figure 4.22. The second component loadings plot 
shows the effects of chlorpromazine on liver tissues and plasma. The administration of low 
dose chlorpromazine does not induce lack of activity in the rats. However, administration 
of high dose chlorpromazine induces lack of activity in animals 406 and 409 as reflected in 
the plasma loadings with increases in plasma 3-D-hydroxybutyrate and acetoacetate as well 
as decreases in plasma glucose levels indicating reduce feeding. The loadings plot also 
shows that animals 407 and 410 have higher level of liver choline and lower level of liver 
lipids as compare to animals 406 and 409. 
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4.2.6.3 Partial Least Square Projection to Latent Structures Approach (PLS) 
Having established that there were intrinsic differences between groups, the data matrices 
were combined and analyzed using PLS that enabled determination of plasma NMR 
features that correlated with the liver MAS NMR biomarkers. The NMR data was mean 
centred prior to modelling. 
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Figure 4.23 PLS cross validated scores plot of Day 2 standard 1H NMR spectra of 
chlorpromazine liver tissue and CPMG spin-echo NMR data plasma samples. 
By treating liver NMR data as X matrix and plasma NMR data as Y matrix, the cross 
validated scores plot (Figure 4.23) revealed clear separation between the high dose samples 
and the controls along the second component. However, partial separation occurs between 
the low dose and control groups. Again, variation within the high dose animals can be seen 
in the scores plot along the first component. Unlike the PLS-DA scores plot in Figure 4.20, 
the scores plot here revealed that animals 406,408 and 409 are separated from animals 407 
and 410. 
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Figure 4.24 First component PLS weight (W*[I]) from the PLS model attributed to 
(A) 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples (-). 
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The corresponding PLS loadings plot for the first component revealed that increases in liver 
lipids and decreases in liver carbohydrates and glycogen (Figure 4.24A) as well as 
increases in plasma 3-D-hydroxybutyrate and acetoacetate, and decreases in plasma lipids 
(Figure 4.24B) are the major contributors to the separation of high dose animals 406,408 
and 409 from high dose animals 407 and 410. The loadings plot reveals the sedative effect 
of chlorpromazine as indicated by the raised plasma 3-D-hydroxybutyrate and acetoacetate 
levels in animals 406,408 and 409. 
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Figure 4.25 Second component PLS weight (W*[I]) from the PLS model attributed to 
(A) 111 NIAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples ". 
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The corresponding PLS loadings plot for the second component describes the dose related 
variation between the high dose animals and control animals. The loadings plot indicates 
that administration of chlorpromazine decreases liver TMAO level (Figure 4.25A) as well 
as plasma lipids profiles (Figure 4.25B) with the high dose animals showing the biggest 
changes. The loadings plot also indicates that the high dose animals react differently to the 
high dose of chlorpromazine with animals 407 and 410 experiencing decreases in liver 
TMAO and lipids as well as decreases in plasma lipids whereas animals 406,408 and 409 
suffers from chlorpromazine-induced ketosis as described previously. 
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4.3 Discussion 
4.3.1 Effects of Chlorpromazine on rat liver 
At the high dose, chlorpromazine induced mild changes in the liver as revealed by the 
histopathological data. However, the NMR findings indicate decrease in liver TMAO 
levels. Trimethylamine (TMA) is converted to its N-oxide derivative, trimethylamine-N- 
oxide (TMAO), in the liver through the action of flavin monooxygenase (FMO) with flavin 
adenine dinucleotide (FAD) as its cofactor (Baker and Chaykin, 1962; Ziegler, 1993; 
Maschke et al., 1997). The decrease in liver TMAO, as seen in the low dose and high dose 
animals, could indicate that chlorpromazine inhibits FMO activity and chlorpromazine has 
been shown to inhibit D-amino acid oxidase enzyme activity by competing and/or 
complexing with FAD (Yagi et al., 1956; Lasslo and Meyer, 1959). The chlorpromazine- 
FAD complex was also found to be not easily reversible (Lasslo and Meyer, 1959). Further 
investigation by Yagi et al. (1960) demonstrated that chlorpromazine formed complexes 
with FAD, riboflavin, riboflavin 5-monophosphate and flavin monophosphate. The study 
also indicated that chlorpromazine binds at the site of the adenosine monophosphate moiety 
of FAD. 
Decrease in liver glucose and glycogen indicated an increase in energy demand and 
chlorpromazine has been shown to reduce the efficiency of coupled phosphorylation in 
mitochondria (Dawkins et al., 1959a). Chlorpromazine has also been shown to inhibit 
electron transport between reduced diphosphopyridine nucleotide and cytochrome c 
reductase involving an intermediate (Dawkins et al., 1959b) and inhibit adenosine 
triphosphate (ATP)-adenosine diphosphate (ADP) reaction (Dawkins et al., 1960). Lbw 
(1959a) reported that flavin is involved in mitochondrial ATPase reaction. L6w, (1959b) 
suggested that the phosphorylated intermediate, which reacts with chlorpromazine, was a 
flavoprotein. Low (1959b) also found that chlorpromazine, inhibits the exchange of organic 
phosphate (Pi) with the terminal phosphate of ATP during ATP-Pi exchange in both liver 
and brain mitochondria. In addition, Medina et al. (1964) has shown that chlorpromazine 
inhibited the metabolic activity of mitochondria and the addition of a higher concentration 
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of chlorpromazine caused shrinking of mitochondria and disruption of its internal fine 
structure. The inhibition of ATP production in mitochondria by chlorpromazine and 
disruption of mitochondrial activity as well as mitochondrial structure may lead to 
decreased ATP production thus increasing energy demand for ATP. This may lead to 
glycogenolysis and gluconeogenesis, which would enable the production of ATP though 
less efficiently. The increase in liver lipids could be due to chlorpromazine-induced 
inhibition of ATP production in liver mitochondria, as well as the disruption of 
mitochondrial structure. Decreased ATP production could lead to reduced protein synthesis 
and thus a decrease in lipid transport out of the liver. The decrease in liver glucose could 
also reflect the effect of chlorpromazine on the activity and feeding of the animals. 
Chlorpromazine is a sedative and the current results indicated that at least two of the high 
dose animals showed signs of chlorpromazMe-induced ketosis characterised by severe 
decreases in liver glucose and glycogen. 
4.3.2 Effects of Chlorpromazine on bloodplasma and urine 
The effects of chlorpromazine on blood plasma are characterised by increases in aspartate 
aminotransferase, which are indicative of hepatocellular damaged and a decrease in plasma 
triglycerides. Generally the highly variable results in the plasma samples reflects the effect 
of the chlorpromazine-induced changes in the animals, with some high dose animals (407 
and 410) showing some signs of chlorpromazine toxicity characterised by decrease in 
plasma lipids and an increase in plasma creatine, and some animals (406,408 and 409) 
suffering ketosis attributed to the sedative effects of chlorpromazine. Again, the reduction 
in the plasma VLDL could be due to reduced lipid secretion from liver. The increases in 
plasma 3-D-hydroxybutyrate and acetoacetate and decrease in plasma glucose as identified 
by 1H NMR spectroscopy in animals 406,408 and 409 reflects chlorpromazine-induced 
ketosis due to lack of activity and feeding. Acetoacetate and 3-D-hydroxybutyrate are 
ketone bodies, produced when excessive amounts of fatty acids are being mobilised and 
oxidised to produce energy i. e. during starvation (Figure 4.26). The presence of these 
ketone bodies are useful markers of reduced food intake although the clinical chemistry 
data showed that the Day 2 blood glucose levels were not substantially depleted by dosing 
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with high dose of chlorpromazine. It, therefore, appears that ketosis occurred in animals 
406,408 and 409 whilst animals 407 and 410 showed no signs of ketosis through analysis 
of the CPMG spin-echo plasma NMR spectra. 
In the urine, a clear decrease in urine TMAO was observed. TMAO and related 
methylamine compounds are involved in methane metabolism. A number of these 
compounds are dietary derived, synthesised from precursors in the diet by the gut 
microflora. Trimethylamine is normally oxidised by the activity of the flavin 
monooxygenase (FMO) system to the odourless, TMAO, in the liver which is excreted in 
the urine. A decreased TMAO level as observed in urine NMR spectra reflects the 
inhibitory effects of chlorpromazine towards FMO. This observation further supports the 
similar observation made in liver tissue NMR spectra. Hippurate, synthesised in the kidney 
and liver from glycine and benzoic acid, is secreted by the renal tubular cells and 
continually excreted in the urine. A significant decrease of this metabolite in urine may be 
indicative of a metabolic alteration or increased phenylacetylglycine (PAG) synthesis. 
2-Oxoglutatrate, citrate and succinate are all compounds related to energy metabolism 
within the organism particularly in the tricarboxylic acid (TCA) cycle. Decreases of these 
TCA intermediates in urine samples could indicate changes in energy metabolism in 
response to chlorpromazine. Reduced urinary excretion of TCA cycle intermediates is a 
common non-specific effect of toxic injury (Waters et al. 2005, Antti et al. 2002). 
Additionally, increases in taurine and creatine were also observed in the urine. These are 
well-known urinary biomarkers of liver injury (Waterfield et al. 1993b, Timbrell et al. 
1995b, Timbrell 1998). The increase in urinary taurine also suggested impaired protein 
synthesis or a link to increased cysteine synthesis. The chlorpromazine-induced increases in 
urinary creatine may be related to cysteine biosynthesis from methionine as postulated by 
Clayton et al. (2003a). 
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Figure 4.26 Synthesis and degradation of ketone bodies (adapted from 
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4.3.3 Comparison of Information Obtainedftom Different Sources 
Table 4.8 shows the summary of the effects of chlorpromazine in rats. In general, the NMR 
findings indicated clear chlorpromazine-induced effects in the low dose and high dose 
animals. These findings disagree with the histopathology and clinical chemistry findings 
which show little effects in the treated animals. However, the high dose animals were 
separated into two distinct groups; with one group consisting of animals 406,408 and 409 
showing clear signs of chlorpromazine-induced ketosis indicating reduced activity and 
feeding brought on by the sedative effect of chlorpromazine, and another group showing 
clear signs of chlorpromazine-induced toxicity. The Day 8 standard 1H NMR spectra 
showed minimal effects and this was reflected in the PCA plots. This suggests that recovery 
was largely complete by Day 8. This is consistent with the histopathology and clinical 
chemistry findings. The integrated approach proves to be more useful in analysing the 
conventional toxicological data and NMR data collectively to describe chlorpromazine- 
induced metabolic flux in the rats. In this case, NMR spectroscopy proved to be more 
sensitive in identitiing chlorpromazine-induced toxicity at the high dose, since 
histopathology failed to show any clear signs of liver toxicity or cholestasis and clinical 
chemistry data showed mild changes which include increases in aspartate aminotransferase 
(ASAT) activity and decrease in triglycerides. Blood glucose is relatively invariant due to 
tight homeostatic control, and therefore is relatively unhelpful for elucidating nutritional 
status because one of the functions of liver is to keep constant blood glucose level by 
glycogenolysis, gluconeogenesis etc. However, 1H NMR spectroscopy of blood plasma 
clearly provided a much more useful insight into chlorpromazine-induced effects than was 
available from the clinical chemistry data as it was able to detect ketosis-induced changes 
in plasma glucose as well as presence of ketone bodies such as 3-D-hydroxybutyrate and 
acetoacetate. 
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MAS NMR spectroscopy of the liver showed that chlorpromazine (30 & 60 mg/kg) induced 
a clear decrease in the liver TMAO level. Increased biosynthesis of phospholipids could 
reduce the formation of TMAO and at the high dose of chlorpromazine, increase in urinary 
phehylacetylglycine (PAG) was observed, which Nicholls et al. (2000) have suggested may 
be a marker of phospholipidosis. If an increase in urinary PAG is due to increased 
phospholipids synthesis, it could lead to a decrease in TMAO by diversion of the choline 
utilisation. However, the Day 2 MAS NMR data showed no increase in liver phospholipids 
indicating that phospholipidosis did not occur in the liver. Trimethylamine undergoes N- 
oxidation to trimethylamine N-oxide in the liver through the action of flavin 
monooxygenase (FMO) enzymes (Ziegler 1990, Ziegler 1993) and excreted in the urine 
(Smith et al. 1994). Like many monooxygenases, FMO requires NADPH and oxygen as 
co-substrates in the oxidation of trimethylamine to trimethylamine N-oxide. The catalytic 
cycle of TMA N-oxidation by FMO enzyme is shown in Figure 4.27. Step 1 and 2 involves 
the reduction and oxidation of FMO to form the highly reactive 4a-hydroperoxyflavin form 
(Ziegler 1993). Due to the high reactivity of the 4a-hydroperoxyflavin form of FMO, any 
soft nucleophile including trimethylamine that makes contact with this potent 
monooxygenating agent will be oxidised as shown in step 3. Step 4,5,1 and 2 simply 
regenerates the enzyme-bound oxygenating agent from NADPH and oxygen. 
Chlorpromazine is a known inhibitor of FMO (Yagi et aL 1956, Lasslo and Meyer 1959, 
Ayesh and Smith 1990). Therefore, inhibition of FMO by chlorpromazine will lead to a 
decrease in formation of TMAO in the liver as well as reduce excretion of this metabolite in 
the urine. 
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Figure 4.27 Catalytic cycle for N-oxidation of TMA by flavin monooxygenase (FMO) 
enzymes to TNMO (adapted from Ziegler 1993). 
MAS NMR spectroscopy of the liver also showed that chlorpromazine (60 mg/kg) induced 
hepatic lipidosis and depletion of liver glucose and glycogen in all the animals. However, 
these changes were much clearer in three of the high dose animals as compared to the 
remaining two. These changes are indicative of increased energy demand in the liver and 
possible mitochondrial dysfunction since chlorpromazine has been shown to reduce the 
efficiency of coupled phosphorylation in mitochondria (Dawkins et aL, 1959a) and 
chlorpromazine inhibits the metabolic activity of mitochondria and caused shrinking of 
mitochondria and disruption of its internal fine structure (Medina et al. 1964). Loss of ATP 
and mitochondrial disruption will reduce lipid transport out of the liver. This could explain 
the changes observed in high dose animals 407 and 410 where both suffered decreases in 
liver glycogen and glucose as well as an increase in liver lipids. However, three of the high 
dose animals (406,408 and 409) showed severe decrease in liver glucose and glycogen and 
the corresponding plasma NMR data indicated increases in ketone bodies 3-D- 
hydroxybutyrate and acetoacetate. Raised levels of plasma 3-D-hydroxybutyrate and 
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acetoacetate indicated a shift in energy metabolism toward ketone body formation and 
utilisation. These changes are indicative of reduced food intake due to chlorpromazine- 
induced sedation in the animals. The differences in effects of chlorpromazine within the 
high dose animals could explain the inability for the univariate statistical ANOVA method 
to produce significant results shown in Table 4.4. 
The Day 2 plasma NMR data showed clear increases in the plasma tyrosine level in all high 
dose animals except animal 406. Animal 410 showed the biggest increase in plasma 
tyrosine as compared to the rest of the high dose animals as shown in Table 4.9. It is also 
the animal that showed the biggest change in liver TMAO and plasma lipids. However, 
since chlorpromazine is not a liver necrotic agent, no correlation in the level of plasma 
tyrosine with severity of chlorpromazine-induced toxicity is expected. 
Table 4.9 Plasma tyrosine changes. 
Animal 
Number 
Concentration of Day 2 plasma Tyrosine (multiple of average control 
level) 
406 0.9 x control average 
408 1.1 x control average 
409 1.2 x control average 
407 1.3 x control average 
410 1.7 x control average 
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Table 4.10 Changes in Day 2 plasma cholesterol, LDL and VLDL levels. 
Chlorpromazine Increase in Day 2 Increase in Day 2 Decrease in Day 2 
Dose Group Plasma Cholesterol Plasma LDL (NMR Plasma VLDL 
(clinical chemistry data, %) (NNM data, %) 
data, %) 
LD 0.3 5.8 32.7 
HD 6.9 10.7 55.3 
Additionally, the Day 2 plasma NMR data also showed increase in plasma creatine in two 
of the high dose animals. Increase in plasma creatine level normally leads to increase in 
urinary creatine level, which is evident in the current study. The Day 2 plasma revealed an 
increase in plasma LDL and a decrease plasma VLDL in both low dose and high dose 
animals (Table 4.10). The increase in plasma LDL level measured by NMR correlated with 
the increase in plasma cholesterol measured by plasma clinical chemistry. This is expected 
as plasma LDL is cholesterol-rich (Mason 1998). Although chlorpromazine is a cholestatic 
agent, the result shown indicates that it is not a reliable one. The use of PLS analysis on 
concatenated liver and plasma data (Figure 4.23 and 4.24) showed an increase in liver 
triglycerides that correlated to a decrease in plasma VLDL, which could indicate reduced 
lipid transport from the liver to the plasma. In addition, Figure 4.24 also showed increases 
in plasma LDL which agree with the plasma clinical chemistry finding. 
The urine NMR data showed decreases in citrate, 2-oxoglutarate and hippurate. Reduced 
urinary excretion of TCA cycle intermediates would suggest mitochondrial dysfunction 
(Antii et al. 2002) and increased energy metabolism (Waters et al. 2005). In addition, the 
urine NMR data also revealed clear decrease in urinary TMAO level. Changes in the level 
of TMAO can be directly related to the diet. The major route of biosynthesis of TMAO 
derives from the degradation of dietary choline which is metabolised to trimethylamine by 
the enzymes of the gut microflora. As discussed earlier, TMA is converted to TMAO 
in the 
liver through the action of flavin monooxygenase enzyme (FMO). TMAO is then excreted 
in the urine. Chlorpromazine is a known FMO inhibitor thus a decrease in TNIAO is 
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expected. Therefore, the severe decrease in liver TMAO, observed in this study, will lead to 
a decrease in urinary TMAO level. The decrease in urinary hippurate level could be related 
to increase in urinary phenylacetylyglycine as discussed in chapter 3. 
4.3.4 Summary 
The use of NMR spectroscopy of liver and biofluids coupled with multivariate analysis and 
conventional clinical chemistry enabled differentiation of the disparate effects the 
chlorprornazine had on rats following administration. The treatment with chlorpromazine 
seems to have two distinct effects in the rat. In the first case, chlorpromazine induced 
severe decrease in liver TMAO levels. This was followed by concomitant decrease in 
urinary TMAO levels. The treatment also caused depletion in liver glucose and glycogen 
followed by reduced urinary excretion of TCA cycle intermediates, citrate and 2- 
oxoglutarate indicating toxic injury. This in turn caused disruption in lipid metabolism with 
accumulation of triglycerides in the liver and reduced transport of lipids from the liver to 
the blood. In the second case,, chlorpromazine caused reduced activity and feeding in three 
out of five rats characterised by the appearance of ketone bodies, 3-D-hydroxybutyrate and 
acetoacetate in the blood plasma. This is also evident in the corresponding liver NMR 
spectra with severe decreases in liver glycogen and glucose indicating glycogenolysis. In 
conclusion, the use of high resolution NMR spectroscopy to study intact liver tissue and 
biofluids i. e. blood plasma and urine, prove to be more sensitive in detecting 
chlorpromazine-induced biochemical perturbation in the rats as compared to conventional 
histopathological. and clinical chemistry methods. 
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Chapter 5: Integrated Thioacetamide Studies 
5.1 Background: Metabolism and hepatotoxicity of thioacetamide 
According to the US Department of Health and Human Services' National Toxicological 
Program, Thioacetamide (TAA) is used as a replacement for hydrogen sulfide in qualitative 
analyses. It has also been used as an organic solvent in the leather, textile, and paper 
industries, as an accelerator in the vulcanization of buna rubber, and as a stabilizer of motor 
fuel. Grant and Rees (1958) investigated the correlations of histological and biochemical 
changes in thioacetamide-treated rats and found that administration of thioacetamide to rats 
caused changes in the parenchymatous cells of the liver, bile duct proliferation and 
development of tumours. Their results also showed a progressive decrease in mitochondrial 
nitrogen content and phospholipid. Additionally, the nuclear fraction of the treated animals 
had an increase in nitrogen and RNA content. Their results also showed a decrease in 
mitochondrial content and the phenomenon of 'ageing' mitochondria. RNA synthesis was 
also reduced but the incorporation of glycine into nuclear protein was increased. These 
fi. ndings led them to conclude that the decrease in mitochondrial respiration is due to the 
action of an inhibitor. 
Thioacetamide is known to cause central lobular necrosis (Klaassen 2001, Haschek et al. 
2002). This localised effect is believed to be due mainly to the higher concentration of 
cytochrome P-450 and other enzymes associated with drug metabolism in the central 
lobular region, which ultimately resulted in higher concentration of toxicant in this region. 
Rees et al. (1966) investigated the metabolism of trititated thioacetamide in the rat. The rats 
were fed with thioacetamide_3 H at a level known to cause liver turnours. They found that 
less than 1% of the tritiated thioacetamide was excreted unchanged in the urine. 
Radioactivity was found in all the organs examined as well as in the chemical constituents 
of all the cell fractions. Over 95% of the thioacetamide was converted to acetate in 24 
hours. Incubation of liver slices with thioacetamide indicated that metabolism occurred via 
acetamide formation. Liver slices were found to be more active than kidney slices in 
converting thioacetamide to acetamide. They postulated that thioacetamide was first 
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converted to acetamide, and that the acetamide was further hydrolysed to acetate. They also 
suggested that this metabolic step is a pre-requisite for thioacetamide to exert its toxic and 
carcinogenic effects. 
Porter and Neal (1978) investigated the metabolism of thioacetamide and thioacetamide-S- 
oxide. They found that thioacetamide is oxidised to thioacetamide- S -oxide by rat liver 
microsomes and the NADPH-driven mixed-function oxidase system. Thioacetamide-S- 
oxide is further metabolised to acetamide and unidentified polar products through the action 
of rat liver microsomes. They also found that the introduction of the mixed-function 
oxidase inducer, Phenobarbital, ) increased the metabolism of thioacetamide and 
thioacetarnide- S -oxide. Their data also suggested that thioacetamide- S -oxide is an 
obligatory intermediate in the conversion of thioacetamide to acetamide, polar products and 
microsome-bound products. Porter et aL (1979) studied the pharmacokinetics of 
thioacetamide and thioacetamide-S-oxide in the rat. They found that thioacetamide-S-oxide 
is a more potent hepatotoxin as compared to thioacetamide. They suggested that 
metabolism of thioacetamide to thioacetamide- S -oxide through the action of mixed- 
function oxidase and the subsequent conversion of thioacetamide-S-oxide to reactive 
intermediates is the basis underlying the toxicity of thioacetamide (Figure 5.1). They also 
postulated that the reactive intermediate can bind to either the liver macromolecules or be 
further metabolised to acetamide and polar products. 
Hunter et aL (1977) examined the role of the mixed-function oxidase enzyme system in 
thioacetamide-induced hepatic necrosis. They found that treatment of liver with an inducer 
of the mixed-function oxidase enzyme, phenobarbital, potentiated the hepatic necrosis 
produced by both thioacetamide and thioacetamide- S -oxide. Thioacetamide-S-oxide was 
found to be a more potent hepatotoxin than thioacetamide. They postulated that 
hepatotoxicity of thioacetamide is mediated by the metabolism of thioacetamide to 
thioacetamide-S-oxide, which is then metabolised to an ultimate toxic metabolite. Timbrell 
(2000) stated that thioacetarnide undergoes S-oxidation to yield thioacetamide-S-oxide. 
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Figure 5.1 Metabolism of thioacetamide. 
Dyroff and Neal (1981) examined the in vivo covalent binding of thioacetamide to rat liver 
protein and found that N-E-acetyllysine, with the acetyl groups derived from thioacetamide, 
was the major modified amino acid that binds to cytosolic proteins. This led them to 
investigate the mechanism of thioacetamide-S -oxide metabolism in rat liver microsomes 
(1982). They found that apart from N-c-acetyllysine, acetamide was another product of 
thioacetamide- S -oxide metabolism. They suggested that both acetamide and N-E- 
acetyllysine were derived from a common intermediate during thioacetamide-S -oxide 
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metabolism. The predominant microsomal enzyme involved in the metabolism of 
thioacetamide- S -oxide is flavin-containing monooxygenase. They also found that N-F, - 
acetyllysine was the predominant amino acid adduct formed at pH 7.4 during the oxidation 
of thioacetamide-S-oxide by hydrogen peroxide in the presence of bovine serum albumin. 
De Ferreyra et al. (1980) investigated the effect of different chemicals on thioacetamide- 
induced liver necrosis. They found evidence suggesting that liver microsomal flavin- 
containing monooxygenase controls the critical activation of thioacetamide to the ultimate 
necrogenic agent and that cytochrome P-450 does not play a major role in this 
bioactivation. 
Kleinfield and Haam (1959) studied the effect of thioacetamide on rat liver regeneration 
and found that thioacetamide induced an increase in nuclear ribonucleoproteins. A study by 
Steele and Busch (1966) on thioacetamide-treated rats found that thioacetamide is a hepatic 
carcinogen, which increases nucleolar RNA biosynthesis and blocked the fon-nation of 
ribosomal RNA. The liver nuclei of the thioacetamide-treated rats were characterised and 
the result showed that prolonged administration of thioacetamide caused an increase in high 
molecular weight RNA. It also induced an increase in the biosynthesis and accumulation of 
guanine/cytosine-rich RNA. The results correlated with the enlargement of nucleoli, 
increased levels of nuclear RNA and decreased levels of cytoplasmic ribosomal RNA. 
Kizer et aL (1966) investigated the relationship between increased adenylic acid deaminase 
activity and changes in nuclear RNA metabolism in thioacetamide-treated rat liver. They 
found that thioacetamide induced an increase in AMP deaminase activity and the reaction 
was not affected by the simultaneous administration of actinomycin or 5-fluorouracil, both 
inhibitors of RNA biosynthesis. They also found that rat liver AMP deaminase was 
activated by ATP. Their study also revealed a thioacetamide-induced increase in both 
nuclei and nucleoli diameter. Fausto (1970) studied the metabolism of nuclear RNA and 
amine synthesis in the liver of rats administered with thioacetamide. This study found that 
thioacetamide induced a sharp increase in ornithine decarboxylase activity. The rise in the 
activity this enzyme coincides with the labelling of ribosomal RNA and is usually 
associated with liver regeneration. Additionally, he also found that repeated injections of 
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thioacetamide caused the accumulation of RNA in the nucleus and increases in spermidine 
and spermine levels. 
Barker and Smuckler (1972) studied the effects of thioacetamide on hepatic mixed- 
functions oxidases and found that microsomal cytochrome b5 decreased 16 hours after the 
administration of thioacetamide. In addition, cytochrome P-450 declined to 32% of control 
after four days. The functional state of this enzyme after thioacetamide administration was 
tested and it was found that the enzyme function was depressed. The activities of aryl 
hydrocarbon hydroxylase, N-demethylase, N-oxidase, lipid peroxidase and NADPH 2- 
neotetrazoliurn reductase were also depressed. Chakrabartty and Schneider (1978) found 
that thioacetamide induced an increase in liver messenger RNA as well as albumin 
synthesis in thioacetamide-treated rats. This is followed by another investigation by 
Chakrabartty et al. (1982) to study the basis for the increase in albumin synthesis in rat 
liver following thioacetamide administration. They found that thioacetamide-induced 
increase in translational activity of messenger RNA was responsible for the increased rate 
of total protein and albumin synthesis. Clawson et al. (1980) investigated the effects of 
thioacetamide on nuclear envelope nucleoside triphosphatase activity and transport of RNA 
from rat liver nuclei. They found that thioacetamide enhanced the transport of RNA, which 
was related to hydrolysis of high-energy nucleoside triphosphate esters. They postulated 
that an enhanced NTPase activity is an early indication of carcinogen exposure. Clawson et 
al. (1981) studied the nuclear envelope alterations accompanying thioacetamide-induced 
enlargement of nucleus in thioacetamide-treated rats and found that the increase in nuclear 
swelling coincides with alterations in sedimentation properties of isolated nuclei. 
Franke et aL (1985) studied the effects of single dose thioacetamide (100 mg/kg) on intra- 
and extrahepatic VLDL output. They showed that there were functional differences 
between hepatocytes of the periportal and centrilobular region of the liver in terms of 
VLDL accumulation. Their data indicated that thioacetamide lowers the hepatic VLDL- 
triglycerides output by 50% in comparison to controls. However, the unchanged level of 
serum triglycerides after dosing with thioacetamide indicated that clearance of triglycerides 
from serum is diminished to the same extent as the hepatic output. They postulated that 
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thioacetamide inhibited the intracellular formation of VLDL. Cascales et al. (1986) 
reported that short-term administration of thioacetamide caused an increase in accumulation 
of triacylglycerols in the rat liver. They postulated that this could be due to a combination 
of increased synthesis due to fatty acid mobilization and a decrease in the secretion of 
VLDL. They also found that thioacetamide caused an increase in ornithine decarboxylase 
activity and a decrease in tyrosine aminotransferase activity. Increased ornithine 
decarboxylase activity is associated with the stimulation of cell growth and tumour 
formation. Nozu et al. (1992) studied the effects of thioacetamide on hepatic mitochondrial 
fatty acid metabolism. Their results indicated an increased diversion of cytosolic long chain 
acyl-coenzyme A into the mitochondria for P-oxidation rather than their esterification and 
use in lipogenesis. This is a reflection of the whole-body catabolic state in response to toxic 
insult for maintaining energy homeostasis. Shukla et al. (1992) demonstrated that 
thioacetamide (100 and 200 mg/kg) reduced the volume of bile secreted by rats 
accompanied by reductions in the secretion of bile acids and bile salts. 
Mesa et al. (1996) investigated the protective role of S-adenosyl-L-methionine against 
changes in the rat liver gene expression induced by thioacetamide. Their result indicated 
that thioacetamide induced changes in the expression of genes related to P-actin and 
albumin. The introduction of S-adenosyl-L-methionine to the rats prevented the 
thioacetamide-induced changes. They proposed a glutathione-dependent mechanism for S- 
adenosyl-L-methionine protection against thioacetamide hepatotoxicity in the rat. The role 
of glutathione in protecting against thioacetamide appears to be in combating oxidative 
stress and mechanisms by which it destroys free radicals and peroxides are well known, 
rather than in conjugation. Bruck et al. (1999) reported that hydroxyl radical scavengers i. e. 
dimethylsulphoxide and dimethyurea protected rats against thioacetamide-induced liver 
injury. Spira and Raw (2000) investigated the effect of thioacetamide on the expression and 
activity of glutathione-S-transferase (GST). They proposed that the covalent binding of 
thioacetamide or its derivatives to the GST subunits does not affect the activity of the 
enzyme. However,, the inhibition of GST activity is due to the deleterious effect of 
thioacetamide on GST transcription. Sun et al. (2000) evaluated the thioacetamide-induced 
oxidative stress on the levels of antioxidant in the rats. They found that thioacetamide 
(500 
198 
mg/kg) increased the activity of caspase-3-like protease, an enzyme involve in the 
activation of apoptosis. Their data also showed an increase in the level of liver lipid 
hydroperoxides and decreases in the levels of vitamin C and vitamin E. They proposed that 
decrease of antioxidants and formation of lipid hydroperoxides after thioacetamide 
administration support the view that extensive radical reactions accur in the liver during the 
necrotic process. 
5. LI Study Details 
Study number 99057 carried out at Pfizer, Centre de Recherche, Amboise, France. 
Study Study 
Dose of toxin 
Animal 
Euthanased 
Number 
Compound 
Group 
administered 
(mg/kg) 
Number Day 2 Day 8 
Saline Control 0 1-10 6-10 1-5 
99057 Thioacetamide Low Dose 50 301-310 306-310 301-305 
in saline High Dose 200 401-410 406-410 401-405 
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5.2 Results 
5.2.1 Histopathology Results 
The histopathological observations for thioacetamide-dosed rats are summarised below in 
Table 5.1. 
Table 5.1 Summary of the histopathological changes observed in thioacetamide-dosed 
Sprague-Dawley rats. 
Day 
Dose of 
2 8 
thioacetamide 
Mild hepatocellular No significant differences from controls. 
centrilobular necrosis 
50 mg/kg 
was observed in all 
animals. 
Moderate hepatocellular 
centrilobular necrosis 
200 mg/kg No significant differences from controls. 
was observed in all 
animals. 
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5.22 Clinical Chemistry Results 
Clear signs of toxicity were observed in both the low dose and high dose Day 2 animals. 
The clinical chemistry data indicates minimal changes in the Day 8 animals. Details of the 
clinical chemistry findings are summarised in Table 5.2. 
Table 5.2 Summary of the plasma changes observed by clinical chemistry in 
thioacetamide-dosed Sprague-Dawley rats. 
Day 
Dose of 
8 
thioacetamide 
Glucose: No group 
Cholesterol: differences were 
Bilirubin: found. 
ASAT: T 
50 mg/kg 
ALAT: 
5NT: T 
GGT: T 
Bile Acids: T 
Variable liver necrosis and cholestatic damage: No group 
Glucose: I (**) differences were 
Cholesterol: I (*) found except for 
Triglycerides: I (**) slightly elevated bile 
Albumin/Globulin: acids (2 fold). 
200 mg/kg Bilirubin: 
ASAT: T 
ALAT: T 
5NT: 
GGT: 
Bile acids: TT 
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5.2.2.1. Principal Component Analysis of Clinical Chemistry Data 
PCA scores and loadings plots for the first two components of the control/thioacetamide 
Day 2 UV-scaled clinical chemistry data are shown in Figure 5.2. In the scores plot, the 
data points are colour-coded and labelled so as to identify the treatment (e. g. black for 
control, mauve for low dose and green for high dose) and animal number. 
The scores plot of the control/low dose thioacetamide data (Figure 5.2A) indicates clear 
separation between the dosed and control groups along the first principal component. The 
corresponding loadings plot (Figure 5.2B) along the first principal component showed 
decreases in glucose, urea and cholesterol, and increases in bilirubin, bile acids, 5' 
nucleotidase, y-glutamyl transferase, ALAT and ASAT as the major contributors to the 
separation between the low dose animals and the control animals. 
Figure 5.2C shows clear separation between the high dose group and controls along the first 
principal component. The changes observed were almost identical with the changes 
observed in the low dose animals. One of the main features observed in the corresponding 
loadings plot (Figure 5.2D) along the first principal component are the generalised increase 
in both aminotransferases,, ALAT and ASAT, which is indicative of hepatocellular damage 
in the high dose animals. The loadings plot also showed increases in 5' nucleotidase, y- 
glutarnyl transferase and bile acids, which are markers of hepatobiliary damage (Handler et 
aL 1994). In addition, the loadings plot also indicates decreases in triglycerides, cholesterol 
and glucose levels as contributors to the separation between the high dose animals and the 
control animals. The decrease in plasma triglycerides level in the high dose animals is in 
contrast to the low dose animals which showed no change in plasma triglycerides level. 
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Figure 5.2 (A) PCA scores plot of low dose thioacetamide Day 2 clinical chemistry 
data, and (B) corresponding loadings plot. (C) PCA scores plot of high dose 
thioacetamide Day 2 clinical chemistry data, and (D) corresponding loadings plot. 
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5. Z3 Analysis of the Tissue Spectra 
5.2.3.1 Examination of lH MAS NMR tissue spectra 
Figure 5.3 shows the dose-dependent effects of thioacetamide hepatotoxicity as visualised 
using standard 1D 1H MAS NMR spectra of intact Day 2 rat liver. The corresponding NMR 
spectral assigments are listed in Table 5.3. 
Table 5.3 1H NMR resonance assignments for liver tissue. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Valine CH3 1.04 
2 Lactate CH3 1.33 
3 Glutarnate CH 2.15 
4 Choline/phosphocholine N+(CH3)3 3.22 
5 TMAO CH3 3.24-3.27 
Taurine CH2SO3- 3.24-3.27 
6 O-Glucose CIH 4.64 
Glycogen CH 4.65 
7 (x-Glucose CIH 5.23 
8 Leucine/Isoleucine CH3 0.93-0.95 
9 Lipids CH3-(CH2)n 1.29 
10 Alanine CH3 1.48 
11 Lipids CH=CH-CH2-CH2 2.07 
12 Glutarnme CH2 2.39 
13 Glucose/glycogen/(x-H amino acids Ring protons/a-CH 3.35-4.00 
14 Glycogen CH 5.38-5.45 
15 Lipids CH3-(CH2)n 0.90 
16 3-D-hydroxybutyrate CH3 1.20 
17 Lipids CO-CH2-CH2 1.61 
18 Acetate CH3 1.95 
19 Lipids CO-CH2-CH2 2.25 
20 Lipids =CH-CH2-CH= 2.78 
21 Lactate CH 4.13 
22 Lipids -CH=CH- 5.30-5.35 
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Figure 5.3 Dose-dependent effects of thioacetamide hepatotoxicity as visualised using 
standard 1D 1H NUS NMR spectroscopy of intact Day 2 rat liver. A. Control liver. 
Liver from an animal administered: (B) Low-dose thioacetamide and (C) High-dose 
thioacetamide. 
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Visual inspection of the standard ID NMR spectra of the Day 2 tissue samples showed that 
control animal 9 had a higher lipids content that the others. Administration of the low dose 
of thioacetamide appears to induce some dose related differences between the low dose 
animals and the control animals (Figure 5.3B). The changes are generally mild with some 
increases in lipids and choline, and decreases in glycogen and glucose levels. However, the 
administration of the high dose of thioacetamide resulted in clear effects on the rat liver 
(Figure 5.3C). The effects are severe with clear decreases in liver glucose and glycogen 
levels. Also noticeable is an increase in the levels of liver lipids, particularly at 8 0.90 
((CH2)n-CH3), 6 1.29 ((CH2)n)ý 6 1.61 (CH2-CH2-CO), 6 2.07 (CH2-CH2-CH=CH), 6 2.25 
(CH2-CH2-CO), 
) 6 2.78 (=CH-CH2-CH=) and 6 5.30 (-CH=CH-) moeties as compared to 
the control animals. Additionally,, a clear decrease in the TMAO level is also observed in 
the high dose animals. Only the Day 2 liver samples were analysed for this study. Details of 
the NIAS NMR observations for thioacetamide-dosed rats are summarised below in Table 
5.4 and the changes reported were quantified according to the method described in Chapter 
2. 
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Table 5.4 Summary of the liver tissue 
thioacetamide-dosed Sprague-Dawley rats. 
changes observed by MAS NMR in 
Day 
Dose of thioacetamide 
2 
Relative to controls, the changes observed in the low dose 
spectra were generally mild. 
Lipids: T* 
Low dose (50 mg/kg) 
Choline: T* 
Glucose: I (NS) 
Glycogen: I (NS) 
Lipids: T* 
Animals 409 & 410 showed the smallest overall changes, 
animal 406 showed an intermediate change, and animals 407 
& 408 showed the biggest change in terms of the lipid 
High dose (200 mg/kg) changes. 
Choline: 
TMAO: 
Glucose: 
Glycogen: 
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5.2.3.2 Principal Component Analysis of Day 2 Liver NMR Data 
Principal component analysis of the control/low dose Day 2 data set revealed some dose- 
related structure to the variation in the data. Some separation between the low dose animals 
and control animals can be observed in the scores plot on the first principal component 
(Figure 5.4A). In addition, control animal 9 shows an aberrant position and is situated away 
from the rest of the controls along the first principal component. The second principal 
component, however, described very little variation in the data set that was related to the 
treatment of the animals with thioacetamide. The corresponding loadings plot (Figure 5.4B) 
identifies the NMR spectral regions that are responsible for separation seen in the scores 
plot in Figure 5.4A. Increases in the regions attributed to lipids, and decrease in the region 
attributed to liver glucose were identified as the major contributors for the separation 
between the dosed and control animals. Additionally, the loadings plot also revealed higher 
lipids content in control animal 9, which contributed to its separation from the rest of the 
controls. 
Figure 5AC is a scores plot for the first two components of the control/high dose Day 2 
data set. There is very clear treatment-related variation in the data set, which is described 
mainly by the first principal component. The separation occurred in opposite direction as 
compared to the control/low dose scores plot due to scaling effect. The corresponding 
loadings plot (Figure 3.5D) indicates increases in the regions attributed to lipids and 
choline, and decreases in the regions attributed to glucose, glycogen and TMAO as the 
major contributors for the separation between the high dose animals and control animals 
along the first principal component. 
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Figure 5.4 (A) PCA scores plot of the 1H MAS NMR spectra of thioacetamide-dosed 
liver samples from Day 2 low-dose versus control groups, and (B) the corresponding 
loadings plot. (C) PCA scores plot of the 1H MAS NMR spectra of thioacetamide- 
dosed liver samples from Day 2 high-dose versus control groups and (D) the 
corresponding loadings plot. 
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Figure 5.5 (A) PCA scores plot for the first two principal components of the standard 
1H MAS NMR spectra of the Day 2 thioacetamide study, and (B) the corresponding 
loadings plot. 
A scores plot of the first and second components from a PCA of all the Day 2 liver MAS 
NMR spectra for this study (Figure 5.5A) showed separation between the dosed groups and 
controls. The first principal component describes the dose-dependent effect with the low 
dose group of animals appearing at intermediate position along the first principal 
component between the control and high dose groups. The second principal component 
decribes the variation within the dosed animals. The corresponding loadings plot (Figure 
5.5B) shows that thioacetamide-induced increases in lipids and choline and decreases in 
glucose and glycogen are the major contributors to the separation along the first principal 
component, whereas thioacetarnide-induced increase in choline and some increase in lipids 
are the major contributors to the variation along the second principal component. 
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5.2.3.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Liver NMR Data 
In order to maximise the separation between the dose classes based on the liver MAS NMR 
data, a PLS-DA model was constructed, where the samples were classified assigned to one 
of three mutually orthogonal classes with control being class 1, being class 2 and 
high dose being class 3. 
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Figure 5.6 PLS-DA cross validated scores plot of the standard 111 MAS NMR spectra 
of the Day 2 thioacetamide study. 
The resultant PLS-DA X-matrix cross validated scores plot of the first two components 
(Figure 5.6) shows distinct segregation of the three sample classes. The cluster of control is 
located on the lower right quadrant of the scores plot. In addition, control animal 9 is 
somewhat separated from the cluster of control animals. The low dose animals are 
separated from the control animals along the second PLS component, whereas the high 
dose animals are separated from the control animals along the first PLS component. The 
plots indicated variable effects in the high dose animals which agrees with visual inspection 
of the liver NMR spectra. 
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Figure 5.7 PLS weights from the standard 1H MAS NMR spectra of the Day 2 
thioacetamide study tissue samples (W[11 = PLS component 1, W[2] = PLS component 
2). 
The corresponding X-block PLS loadings plot (Figure 5.7) indicates that the first 
component describing the general variation between high dose and control animals is due to 
elevated and altered liver lipids profiles, some increase in liver choline and decreases in 
liver glucose, glycogen and TMAO levels. The second component, describing the variation 
between low dose and control animals, is due to elevated liver choline level as well as some 
increase in the liver lipids profiles. The observations made from both PLS-DA scores and 
loadings plots confirmed the findings made by inspection of the 1H MAS NMR spectra 
(Table 5.4) and from the PCA analyses of the Day 2 tissue NMR data (Figure 5.4). 
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5.24 Analysis of the Plasma Spectra 
5.2.4.1 Examination of 1H NMR plasma spectra 
The plasma NMR spectral assignments are listed in Table 5.5. 
Table 5.5 1H NMR resonance assignments for plasma. 
Peak No. Molecule Assignment 1H chemical shift (ppm) 
I Lipids (LDL) -CH2-CH3 0.84 
2 Lipids (VLDL) CH2-CH3 0.87 
3 Valine 
CH3 0.97 
CH3 1.02 
4 3-D-hydroxybutyrate CH3 1.20 
5 Lipids (VLDL) -(CH2)n 1.29 
6 Lactate CH3 1.33 
7 Alanine CH3 1.46 
8 Acetate CH3 1.91 
9 Acetoacetate CH3 2.22 
10 Glutarnine CH2 2.41 
11 Citrate 
CH2 2.52 
CH2 2.69 
12 Choline N+(CH3)3 3.21 
13 Glucose/Ammo acids resonances Ring protons/a-CH 3.35-4.00 
14 Lactate CH 4.10 
15 (x-Glucose CIH 5.23 
16 Isoleucine CH3 0.93 
17 Leucine CH3 0.95 
18 Isoleucine CH3 1.00 
19 Threonine CH3 1.31 
20 N-acetyl glycoproteins NHCO CH3 2.04 
21 Pyruvate CH2 2.36 
22 Creatine CH3 3.04 
23 TMAO CH3 3.26 
24 Creatine CH3 3.93 
25 Lipids -CH=CH- 5.30 
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Figure 5.8 Effects of thioacetamide (200 mg/kg) as visualised using CPMG spin-echo 
1H NMR spectra of Day 2 rat plasma. A. Control plasma. B. ffigh-dose thioacetamide. 
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Inspection of the plasma CPMG spin echo spectra of the thioacetamide-dosed Day 2 
plasma samples revealed little effects on the low dose animals as compared to the control 
animals. Figure 5.8 shows the dose-dependent effects of high dose thioacetamide 
heptatotoxicity as visualized using CPMG spin echo spectra of Day 2 plasma samples and 
the corresponding NMR spectral assignments are listed in Table 5.5. The main visual 
changes that can be observed in the high dose animals is a clear decrease in lipids 
especially the CH2 (VLDL) and CH3 (VLDL/LDL) moieties. The changes in the plasma 
lipids profiles correlated well with the changes observed in the liver lipids profiles (Table 
5.4). In addition, detailed spectral inspection reveals more subtle biochemical variation 
between the spectral profiles of the high dose animals and control animals represented by 
increases in creatine, pyruvate and acetate. Details of the plasma NMR observations for 
thioacetamide-dosed rats are surnmarised below in Table 5.6 and the changes reported 
being quantified according to the method described in Chapter 2. 
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Table 5.6 Summary of the plasma changes observed by NMR in thioacetamide-dosed 
rats. 
Dose of Day 
thioacetamide 2 
The changes observed were generally mild relative to controls: 
Creatine: T (NS). 
50 mg/kg Lipids: 24.6% 1 (NS). 
Acetate: T (NS). 
Pyruvate: T (NS). 
Clear changes were observed relative to controls 
Creatine: T (NS). 
Lipids: 53.4 %I **. 
(Animals 407 & 408 marked, animal 406 intermediate, animals 409 & 
4 10 minimal) 
Clear changes in lipoproteins (NS) 
200 mg/kg (Clearest change: animals 406 & 408, clear change: animals 407 & 
409, least clear change: 410) 
Acetate: T (NS). 
Pyruvate: T (NS) 
(Animals 407 & 408 marked, animals 406 & 410 moderate, animal 
409 mild). 
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5.2.4.2 Principal Component Analysis of Day 2 Plasma NMR Data 
Figure 5.9 shows the scores and loadings plots of the first two principal components of the 
PCA model based on the spectral intensities in the CPMG NMR spectra between the drug- 
treated animals and the controls. The PCA scores plot of the low dose Day 2 plasma data 
set (Figure 5.9A) revealed no dose related variation between the low dose animals and the 
control animals. 
The PCA scores plot of the control/high dose data set (Figure 5.9C) indicates clear 
differences in the metabolic profiles of thioacetamide-treated and control animals. The first 
principal component describes the variation between the two groups of animals. The 
corresponding loadings plot (Figure 5.91)) reveals that changes in the lipid moieties 
(VLDL, CH2 and LDL, CH3) are the major contributors to the separation between the high 
dose animals and control animals along the first principal component. In addition, the 
loadings plot also reveals variation in plasma lactate that leads to the variation within the 
high dose animals along the second principal component. 
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Figure 5.9 (A) PCA scores plot of the CPMG spin-echo NMR plasma spectra of 
thioacetamide-dosed plasma samples from Day 2 low-dose versus control groups, and 
(B) the corresponding loadings plot. (C) PCA scores plot of the 1H CPMG spectra of 
thioacetamide-dosed plasma samples from Day 2 high-dose versus control groups and 
(D) the corresponding loadings plot. 
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Figure 5.10 (A) PCA scores plot of the CPMG spin-echo NMR plasma spectra of the 
Day 2 thioacetamide study, and (B) the corresponding loadings plot. 
A scores plot of the first two components from a PCA of the combined Day 2 plasma NMR 
data (Figure 5.1 OA) showed clear separation between the high dose animals and the control 
animals but little separation between the control and low dose groups. The first component 
describes the variation between the high dose and control animals. The corresponding 
loadings plot (Figure 5.1 OB) shows that a thioacetamide-induced decrease in lipids is the 
major contributor to the separation along the first principal component, whereas changes in 
lactate, cholme, 3-D hydroxybutyrate and LDL are contributors to the variation within the 
dosed groups. 
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5.2.4.3 PLS - Discriminant Analysis (PLS-DA) of Day 2 Plasma NMR Data 
The Day 2 plasma NMR data were also analysed using the PLS-DA approach to further 
refine the information recovery. 
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Figure 5.11 PLS-DA cross validated scores plot of the CPMG spin-echo NMR plasma 
spectra of the Day 2 thioacetamide study plasma samples. 
The X matrix PLS-DA cross validated scores plot of the first two components (Figure 5.11) 
shows separation between the dosed groups and control group. The PLS-DA has now 
forced some separation between the control and low dose groups. The control group is 
situated on the lower right quadrant, with the low dose group (upper right quadrant) 
partially separated from the control group along PLS component two. The high dose group 
is (to the left of the plot) separated from the control group along PLS component one. 
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Figure 5.12 PLS weights from the CPMG spin-echo NMR plasma spectra of the Day 2 
thioacetamide study plasma samples (W[Ij = PLS component 1, W[21 = PLS 
component 2). 
The corresponding X block PLS loadings plot (Figure 5.12) indicates that the first PLS 
component, describing the general variation between high dose and control/low dose 
animals, is due to a decrease in plasma lipids. The second PLS component, describing the 
variation between low dose and control animals, is due to changes in the plasma choline 
level as well as some decrease in the plasma lipids. 
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5. Z5 Analysis of the Urine Spectra 
5.2.5.1 Examination of lH NMR urine spectra 
Initial visual inspection of the low dose urine spectra showed no substantial changes in 
endogenous urinary metabolites (data not shown) as compared to the control group. 
However, the presence of thioacetamide metabolites was detected in Day 1 (0-7 h post- 
dose) urine samples from both the low dose and high dose animals. The effects of the high 
dose thioacetamide treatments on endogenous urinary metabolites were assessed, as 
follows, using only the group euthanased at Day 8 post-dose, which provided a sequence of 
daily urine samples covering the whole study. 
Figure 5.13 shows a series of standard 1H NMR spectra of urine at predose and various 
time points following the administration of high dose thioacetamide. The high dose of 
thioacetamide induced marked changes in the endogenous urinary metabolite profiles. The 
dominant changes included increases in creatine, taurine and guanidinoacetic acid, and 
decreases in citrate, 2-oxoglutarate, TMAO and hippurate, which lasted up to Day 3 with 
maximal abnormality being observed in the samples obtained from Day 2 post-dose 
samples. In addition, the presence of glucose, lactate and alanine in the urine samples of 
animals 402,403 and 404 was detected on Day 2 and Day 3, possibly indicating renal 
dysfunction. The 1H NMR spectra indicated recovery to normality by Day 7 post-dosing. 
Details of the urine NMR observations for thioacetamide-dosed rats are summarised below 
in Table 5.7. 
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Figure 5.13 Series of standard lH NMR spectra of urine at predose and various time 
points following the administration of thioacetamide (200 mg/kg). Key: Metabolite of 
thioacetamide (M*), 2-oxoglutarate (2-OG), dimethylglycine (DMG). 
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Table 5.7 Summary of the urinary changes observed by NMR in thioacetamide-dosed 
rats. 
Dose of Thioacetamide 
50 mg/kg 200 mg/kg 
Thioacetamide metabolites (3 Thioacetamide metabolites (6 2.89,8 2.43 and 6 
singlet peaks at 8 2.89,6 2.43 and 2.19) were clearly observed in the Day 1 (0-7 
8 2.19) were clearly observed in hours) urine samples at a stronger intensity 
the Day 1 (0-7 hours) urine relative to the low dose group. In addition, 
samples. thioacetamide itself was detected in the Day 1 (0- 
7 hours) urine samples with animals 401 & 405 
showing more thioacetamide than animals 402- 
404. 
Creatine: T Marked changes in the endogenous metabolites 
Taurine: T (NS). were detected on various days. On Day 2 the 
Lactate: T (NS). changes were assessed as follows: 
Hippurate: I in 4/5 animals (NS). 
2-Oxoglutarate (2-OG): I (NS). 
Citrate: I (NS). 
Creatine: T **. 
Taurine: T (NS). 
Guanidinoacetic acid (GAA): T in 3/5 animals 
(NS). 
Lactate: T (NS). 
Glucose: T (NS). 
Alanine: T (NS). 
TMAO: ý (NS). 
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5.2.5.2 Principal Component Analysis of Urine NMR Data 
Figure 5.14 shows a series of PCA scores plots of the first two principal components of the 
high dose thioacetamide-treated animals and the controls. Overall the series of PCA scores 
plot highlighted that the biochemical differences between the two groups increases as the 
time point at which the sample was taken increases until it reaches a maximum on Day 2, 
thereafter recovery sets in. The scores plot of the pre-dose urine samples shows some 
separation between the two groups. Animal 402 is separated from the rest of the animals 
along the second principal component. Clear separation between the high dose and control 
animals can be seen on Day I(O-7h). However, separation between high dose animals and 
control animals on Day I(O-7h) was mainly due to the presence of the thioacetamide 
metabolite, thioacetamide S-oxide (6 2.19). The Day 2 PCA scores plot shows clear 
differences between the high dose and control animals. The scores plot indicated that the 
high dose animals are separated from the control animals along the second principal 
component with the exception on animal 402 which is separated from the control/high dose 
animals along the first principal component. The PCA scores plot of Day 3 urine samples 
shows clear separation between the two groups along the first principal component 
although it appears that one of the high dose animals (animal 405) had recovered by Day 3. 
The scores plot also shows that animal 401 is separated from the control/high dose animal 
along the second principal component. Finally, the scores plot of Day 7 shows some 
separation indicating partial recovery. These observations confirm that there are 
biochemical changes between the groups upon administration of high dose thioacetamide 
that is becoming more prominent with increasing time until a time maxima of Day 2 before 
gradual recovery from the toxic insult on Day 3 onwards. This graphical approach is a good 
way to visualise time-dependent biochemical effects and also allows understanding of inter- 
animal variation. 
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Figure 5.14 A series of PCA scores plots of the first two components to investigate 
time related metabolic differences associated with the effects of high dose 
thioacetamide in the animals. 
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Figure 5.15 A series of corresponding PCA loadings plots of the first two components 
to investigate time related metabolic differences associated with the effects of high 
dose thioacetamide in the animals. 
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Figure 5.15 shows a series of PCA loadings plots of the first two principal components of 
the high dose thioacetamide-treated animals and the controls. The loadings plot for the pre- 
dose data indicated that high dose animal 402 has higher urinary 2-oxoglutarate and lower 
urinary TMAO levels which contributed to the separation from the rest of the animals. 
Overall the loadings plots show that the trends seen in the PCA scores plots (Figure 5.14) 
were attributed to relative changes in the urinary endogenous metabolites, with the 
exception of Day 1 (0-7h). The Day 1 (0-7h) loadings plot indicates mainly the presence of 
thioacetamide metabolites (6 2.18 and 6 2.42), which are the major contributors to the 
separation between the high dose animals and the control animals along the first principal 
component. Additionally, variation in urinary endogenous metabolites contributed to the 
variation within the control animals along the second principal component. The loadings 
plot for Day 2 shows increase in urinary creatine and decreases in urinary TMAO, 
di. methylamine and hippurate as the major contributor to the separation between the high 
dose animals and the control animals except high dose animal 402. The loadings plot 
indicates that increases in urinary taurine, glucose and lactate as well as decreases in 
urinary hipurate, citrate and 2-oxoglutarate contributed to the separation of high dose 
animal 402 from the control/high dose animals along the first principal component. These 
changes can be seen clearly in the series of urinary NMR spectra (Figure 5.13). The 
loadings plot for the Day 3 shows increases in urinary taurine, glucose, lactate and alanine 
and a decrease in urinary citrate contributed to the separation between the high dose and 
control animals along the first principal component. In addition, the loadings plot also 
shows increase in urinary 2-oxoglutarate and decreases in urinary TMAO and hippurate, 
which contributed to the separation of animal 401 from the rest of the animals along the 
second principal component. The presence of urinary glucose could indicate renal 
dysfunction in the high dose animals. The loadings plot for Day 7 shows some changes in 
the urinary endogenous metabolites mainly from 2-oxoglutarate, TMAO and succinate 
indicating partial recovery by Day 7. 
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5.2.5.3 PCA Mean Trajectory of Urine NMR Data 
The mean principal component position was computed for each dose group at each time 
point and this PCA mean trajectory was performed using the 1H NMR spectra of urine 
sample for all high dose animals over five time points as above to extract time-related 
metabolic changes in rat urine samples in response to xenobiotic insult. PCA mean 
trajectory was carried as described in chapter 2. 
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Figure 5.16 PCA mean metabolic trajectory plot mapping the average position of 
standard 1H NMR high dose thioacetamide urine spectra over five time points. 
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The PCA mean trajectory plot (Figure 5.16) was constructed from the complete data- 
reduced 1H NMR spectra, excluding the region of water and urea (6 4.0-6.0). The first two 
PCs described 94.3% of the total variance in X. The modelled metabolic evolution 
comprised four distinct phases. In phase one, corresponding to movement to the Day 1(0- 
7h) time point, the trajectory of the urine sample coordinates moved away from the pre- 
dose (PD) position along the first principal component, corresponding to the appearance of 
the metabolites of thioacetamide (6 2.18 and 6 2.42) in the urine. In phase two, 
corresponding to movement to the Day 2 time point, the trajectory changes direction 
moving away from Day 1(0-7h) time point along the first component corresponding to the 
disappearance of the metabolites of thioacetamide and the concomitant decreases in urinary 
endogenous metabolites citrate, succinate, 2-oxoglutarate, TMAO and hippurate as well as 
increases in taurine and creatine. In phase three, the trajectory changes direction moving 
away from origin along the second principal component, corresponding to the appearance 
of urinary glucose, alanine and lactate, indicating a second type of toxicity, namely renal 
dysfunction on Day 3 as well as decreases in urinary endogenous metabolites citrate, 
succinate, 2-oxoglutarate, TMAO and hippurate, and increases in taurine, lactate, alanine 
and creatine. Maximal changes in urinary endogenous metabolites were observed in Day 3 
samples which is in contrast with PCA of the urine NMR spectra (Figure 5.14). Finally, in 
phase four, the trajectory move towards the origin along the second principal component 
corresponding to the levels of urinary metabolites returning to 'normality' indicating total 
recovery by Day 7. These changes were in good agreement with the changes observed in 
the urinary 1H NMR spectra. 
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5. Z 6 Pattern Recognition Analysis of Concatenated Liver and Plasma NMR Data 
5.2.6.1 Concatenated Principal Component Analysis (PCA) 
The PCA of concatenated liver and plasma NMR data did not improve the separation 
between the low dose animals and the control animals (Figure 5.17A) as compared to the 
PCA of tissue samples alone (Figure 5.4A). Only three out of the five low dose animals 
were separated from the control animals along the second principal component. In addition, 
control animal 9 was separated from the rest of the control animals along the first principal 
component. The corresponding loadings plot (Figure 5.17B) indicated that increase in liver 
lipids as well as changes in plasma lipids are the major contributors to the separation 
between the two groups. The loadings plot also revealed changes in plasma choline, 
glucose and amino acids regions that contributed to the separation between the low dose 
animals and the control animals. Control animal 9, which showed high liver lipids, was 
separated from the rest of the control animals. 
The PCA scores plot of the high dose Day 2 liver and plasma data (Figure 5.17C) revealed 
separation between the high dose animals and the control animals. The first principal 
component as well as the second principal component describes the variation observed 
between the high dose animals and the control animals. Additionally, the scores plot also 
revealed differences within the high dose animals with animals 406 and 409 located on the 
lower half of the plots and the remaining three animals on the lower half of the scores plot 
separated along the second principal component. The corresponding loadings plot (Figure 
5.17D) indicates that decrease in plasma lipids is the major contributors to the variation 
along the first principal component. On the other hand, changes in liver lipids and decreases 
in liver glucose as well as changes in plasma lipid, choline and glucose regions are the 
major contributors to the variation within the dosed groups along the second principal 
component. 
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Figure 5.17 Concatenated PCA models for the first two components of the standard 
ID NMR spectra of thioacetamide-dosed Day 2 liver and CPMG spin-echo plasma 
NMR spectra. (A) Low-dose vs. control data set and the corresponding loadings plot 
(B). (C) High-dose vs. control data set and the corresponding loadings plot (D). 
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5.2.6.2 Concatenated PLS-Discriminant Analysis (PLS-DA) 
PLS-DA was used to determine which variables in the concatenated NMR data predict the 
sample classes as well as to refine information recovery from the data. 
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Figure 5.18 PLS-DA cross validated scores plot of standard 1H NMR spectra of 
thioacetamide Day 2 liver tissue and CPMG spin-echo NMR of Day 2 plasma samples. 
Figure 5.18 shows the PLS-DA cross validated scores plot for the first two components of 
the thioacetamide Day 2 liver tissue and plasma NMR data. The scores plot now revealed 
clear separation between the control and dosed groups. Animals 9 and 10 are separated by a 
combination of the first and second PLS component. The first PLS component describes 
the variation between the high dose animals and the control animals whereas the second 
PLS component describes the variation between the low dose animals and the control 
animals. 
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Figure 5.19 First component PLS weight (W[I]) from the PLS-DA model attributed to 
(A) 1H NIAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples (-). 
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The corresponding first component PLS loadings attributed to the liver tissue and plasma 
NMR data are shown in Figure 5.19A and B respectively. The plot shows the general 
effects of dose related variations on liver tissues and plasma along the first component. The 
loadings plot revealed thioacetamide-induced severe decreases in plasma lipids and liver 
glucose and glycogen as well as an increase in liver lipids are the major contributor to the 
separation between the high dose animals and the control animals. In addition, the first PLS 
component loadings plot also indicates some increase in plasma glycoprotein and glucose 
as well as increase in liver choline and decrease in liver TMAO contributing to the 
separation between the two groups. 
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Figure 5.20 Second component PLS weight (W[21) from the PLS-DA model attributed 
to (A) 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples (-). 
0- 
N 
m 
Cl- 
(0 
N 
0- 
(0 
. 
0- 
xt 
e 
Cl- 
OD 
C, 4 
D- 
C%4 
x- 
0- 
(D 
M 
0- 
CD 
. 
0- 
'-t 
C. 0 
c2- 
OD 
Kt 
0- 
CN 
M 
Cl- 
(0 
- 
c- 
N 
0- 
ýt 
OD 
ü- 
CO 
(D 
a- 
N 
Ln 
a- 
(0 
n 
a- 
N 
. 
ü- 
e 
CD 
Cl- 
OD 
OD 
Cl- 
CN 
rl_ 
D- 
(D 
Lt) 
m m cli M m N N N N CD CD CD 
236 
The corresponding second component PLS loadings attributed to the liver tissue and 
plasma NMR data are shown in Figure 5.20A and B. Generally, the effects observed in the 
low dose animals were identical to that observed in the high dose animals only milder. 
However, in contrast to the high dose animals, the loadings plot indicated greater increase 
in liver choline in the low dose animals. The second component loadings plot indicated that 
the administration of the low dose of thioacetamide induced increases in liver lipids and 
choline levels as well as decreases in liver glucose and glycogen levels as the major 
contributors to the separation between the low dose animals and the control animals. In 
addition, the second PLS component also revealed decreases in plasma lipids and choline 
levels as well as increases in plasma lactate and TMAO that contributed to the separation 
between the low dose and control groups. 
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5.2.6.3 Partial Least Square Projection to Latent Structures Approach (PLS) 
Having established that there were intrinsic differences between groups, the data matrices 
were combined and analyzed using PLS to further improve classification between groups. 
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Figure 5.21 PLS cross validated scores plot of standard 1H NMR spectra of 
thioacetamide Day 2 liver tissue and CPMG spin-echo NMR data of Day 2 plasma 
samples. 
By treating liver NMR data as the X matrix and plasma NMR data as the Y matrix, the 
cross validated scores plot (Figure 5.21) revealed clear separation between the dosed 
animals and the control animals along the first component. The scores plot also revealed the 
progression from low dose to high dose which is related to the severity of thloacetamide- 
induced metabolic changes in both the liver and the plasma. In addition, variation within 
the high dose animals, which correlated to the varying degree of severity in the changes of 
both liver and plasma lipids profiles, can be seen in the scores plot along the first 
component. 
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Figure 5.22 First component PLS weight (W*[I]) from the PLS model attributed to 
(A) 1H NIAS NMR data of Day 2 liver tissues (-), and (B) CPMG spin-echo NMR 
data of Day 2 plasma samples (-). 
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The corresponding PLS loadings plot for the first component revealed that increases in liver 
lipids and decreases in liver carbohydrates and glycogen (Figure 5.22A) as well as decrease 
in plasma lipids (Figure 5.22B) are the major contributors to the separation between the 
dosed and control animals. In addition, the loadings plot also revealed some increase in 
liver and plasma choline as well as changes in plasma glucose levels which contributed to 
the separation. The degree of severity induced by thioacetamide is the only factor that 
contributed to the separation between the high dose animals and the low dose animals. 
Again, the loadings plot revealed a correlation between the changes in liver and plasma 
lipids profiles which contributed to the separation within the high dose animals. 
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5.3 Discussion 
5.3.1 Effects of Thioacetamide on rat liver 
At the high dose, thioacetamide induced moderate hepatic centrilobular necrosis as revealed 
by the histopathological data. Severe depletion of liver glucose and glycogen, as detected 
by the MAS NMR of liver tissues, suggests increased energy demands within the liver. The 
latter fmding suggests increased rate of hepatic glycogenolysis, which is consistent with the 
depletion of hepatic ATP following mitochondrial impairment (Trennery and Waring 
1983). Since structure and function of mitochondria are closely linked, changes in the 
structure of mitochondria will affect the overall mitochondrial functions and therefore ATP 
production. Thioacetamide has been shown to change the permeability of cell membrane 
(Anghileri et al. 1977), induce loss of respiratory control in the mitochondria and reduced 
mitochondria cytochrome levels (Moller and Dargel, 1984), and induce functional 
disturbances in the mitochondria as well as structural alterations of the inner mitochondrial 
membrane (Moller and Dargel, 1985). With impairment of mitochondrial ATP-production, 
glycolysis would enable some ATP production as glucose is converted to lactate in the 
cytosol and glycogenolysis would increase the supply of glucose for this process. 
As discussed previously, the observed increase in liver lipid could arise either through 
impaired transport from the liver or through impaired protein synthesis within the liver. 
Teck et al. (2004) found that administration of thioacetamide down-regulates the enzymes 
involved in hepatic fatty acid P-oxidation thus leading to impaired ATP production and 
fatty acid accumulation. Moller and Dargel (1984) also found evidence of decreased fatty 
acid oxidation in thioacetamide-treated rat liver. Severe and prolonged impairment of P- 
oxidation in the mitochondria is known to cause steatosis and, in some severe cases, liver 
failure and death (Fromenty and Pessayre 1995). In addition, the transport of triglycerides 
out of the liver is likely to be decreased if protein synthesis is impaired. Impaired protein 
synthesis could arise simply through thioacetamide-induced ATP-depletion, and study has 
shown that thioacetamide stops glycine incorporation into liver protein (Reynolds 1972). 
This result also showed that thioacetamide-induced structural changes to the endoplasmic 
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reticulum. and such damage would be expected to lead to the disruption of protein synthesis 
of the whole organelle. The endoplasmic reticulum is also involved in the homeostatic 
control of cellular calcium sequestration. Therefore, damage to the endoplasmic reticulum 
will lead to the disruption of calcium ion homeostasis and hence to apoptosis. 
Additionally, Lin et al. (1996) demonstrated that an increase in the intracellular bile acids 
concentration inhibits the secretion of VLDL-associated triglycerides from hepatocytes as 
well as the secretion of apolipoprotein associated with transport of VLDL namely apoB- 
100. Thioacetamide causes some biliary damage and the plasma clinical chemistry results 
in the current study indicated an increase in total bile acids (TBA). This could have an 
inhibitory effect on triglyceride secretion leading to accumulation of triglycerides in the 
liver. 
5.3.2 Effects of Thioacetamide on bloodplasma and urine 
The effects of thioacetamide on blood plasma are characterised by increases in creatine, 
lactate, acetate and pyruvate, and by a reduction in lipids and in the VLDL/LDL ratio. The 
reduction in the ratio of VLDL/LDL could be because of reduced lipid secretion from the 
liver. In the urine, increases in taurine and creatine were observed together with the 
presence of thioacetarnide metabolites. Decreases in urinary citrate, 2-oxoglutarate and 
succinate are indicative of disruption in the tricarboxylic acid (TCA) cycle. 
The urinary taurine increase would be consistent with impaired protein synthesis. but could 
also be the result of increased cysteine synthesis. The thioacetamide-induced increases in 
urinary creatine may be related to cysteine biosynthesis from methionine as postulated by 
Clayton et al. (2003a). Cysteine is used to synthesise GSH, taurine and proteins. During 
this biosynthesis, S-adenosylmethionine donates a methyl group to the methyl acceptor, 
guanidinoacetic acid (GAA). The methylated-GAA is then converted to creatine. 
Combining the findings in this study with the literature findings on thioacetamide 
metabolism and toxicity suggests that thioacetamide may stimulate glutathione synthesis in 
response to thioacetamide-induced oxidative stress. Sun et al. (2000) have shown that 
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thioacetamide reduces vitamin C and vitamin E levels in treated rat livers. Bruck et al. 
(2001) found that free radical scavengers prevented the development of thioacetamide- 
induced liver cirrhosis supporting the concept of oxidative stress involvement in 
thioacetamide toxicity. In addition, Avni et al. (2004) found increased level of 
malondialdehyde, an end product of lipid peroxidation, in thioacetamide-treated rat liver, 
suggesting oxidative stress. However, in this study, malondialdehyde was not detected by 
NMR. The presence of thioacetamide-derived reactive polar compounds or free radicals 
that might react directly with glutathione could lead to glutathione depletion and hence to 
glutathione synthesis and increased oxidative stress and lipid peroxidation can also 
stimulate glutathione synthesis This could explain the increased synthesis of cysteine as 
evident by increased urinary creatine as both glutathione and taurine play an important role 
in cellular protection against free radicals and oxidative stress. 
The presence of glucose, acetate and lactate in the urine are indicative of renal dysfunction. 
Thioacetamide is known to cause glomerular atrophy in the cortical tubules (Virtanen and 
Lassila 1986) and treatment of a monkey kidney cell line with thioacetamide was shown to 
cause nucleolar and mitotic alterations (Mironescu et al. 1969). 
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5.3.3 Comparison of Information Obtainedftom Different Sources 
The integrated approach proves to be useful in analysing the conventional toxicological 
data and NMR data of different sample types collectively to describe thioacetamide- 
induced toxicity in the rats. Table 5.8 shows the summary of the effects of thiuoacetamdie 
in rats. Overall, the NMR findings are consistent with the clinical chemistry findings as 
well as the histopathology, which showed clear thioacetamide-induced effects in high dose 
animals. However, histopathology findings indicated no dose related effects in the Day 2 
low dose animals which are in contrast to the clinical chemistry and NMR spectral data 
observations. 
The MAS NMR showed a decrease in the liver TMAO level in the high dose thioacetamide 
animals. Increased phospholipids could lead to a decrease in TMAO levels, however, the 
MAS NMR data did not show any increase in liver phospholipids that would have 
suggested phospholipidosis although liver choline level had increased. In liver, the drop in 
liver TMAO levels suggests a thioacetamide-induced block in this N-oxidation pathway or 
a reduction in the supply of trimethylamine (TMA) reacting in the liver. The lipid 
intermediary metabolites, choline and TMAO, were present in the blood plasma before 
excretion into the urine. The decrease in TMAO could then be related to decrease NADPH- 
dependent flavin monooxygenase enzyme, which catalyses the oxidation of TMA to 
TNIAO since thioacetamide has been shown to inhibit protein synthesis (Reynolds 1972, 
Platt and Cockrill 1967). The decrease in liver TMAO could also explain the increase in 
liver and plasma choline since choline is the precursor of TMAO. Schriewer and Lohmann 
(1976) found that thioacetamide impaired phospholipid metabolism in both the liver and 
mitochondria, thus the elevated liver choline could also indicate disruption in phospholipid 
metabolism (Figure 5.23). 
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Figure 5.23 Choline and its involvement in the metabolism of methylamines and 
phospholipids (adapted from Smith et A 1994, Podo 1999). Key: MNU = 
monomethylamine, DMA = dimethylamine, TMA = trimethylamine, TMAO = 
trimethylamine N-oxide, FMO = flavin monooxygenase system. 
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A number of metabolites involved in energy generation were perturbed as a result of 
thioacetamide treatment. Depleted liver glucose and glycogen on Day 2 was accompanied 
by elevated lactate in plasma suggesting extensive glycogenolysis and glycolysis (Cascales 
et al. 1992). These changes are indicative of increase energy demand in the liver and 
possible mitochondria dysfunction. In addition, the increase levels of plasma lactate and 
alanine indicates gluconeogenesis suggesting increased energy demand. Reduced urinary 
excretion of TCA cycle intermediates, citrate, succinate, and 2-oxoglutarate might also be a 
consequence of energy metabolism disruption but might also result from changes in the gut 
microflora. Glycosuria on Day 2 and Day 3 without any detected perturbation of plasma 
glucose suggests kidney damage as opposed to saturation or inhibition of kidney glucose 
reabsorption. 
Increase in plasma creatine level normally leads to increase in urinary creatine level, as 
seen in the current study. The Day 2 plasma NMR data also revealed decreases in plasma 
lipids. However, these changes did not correlate to the extent of necrosis observed by 
histopathology. Analysis of the LDL and VLDL peaks seen in the plasma NMR data 
showed decreases in both LDL and VLDL in the low dose animals. In the high dose 
animals, however, the decrease in plasma VLDL was bigger in magnitude as compare to 
that of LDL (Table 5.9). 
Table 5.9 Changes in Day 2 plasma LDL and VLDL levels 
Thioacetamide 
Dose Group 
Percentage Decrease in Day 2 
Plasma LDL (NMR data, %) 
Percentage Decrease in Day 2 
Plasma VLDL (NMR data, %) 
LD 14.3 21.7 
HD 26.6 60.6 
1H NMR spectroscopic analysis of Day I(O-7h) urine samples detected the primary 
metabolite of thioacetamide, thioacetamide-S-oxide. The available evidence suggests that 
the development of hepatic necrosis after the administration of thioacetamide occurs 
following metabolism of thioacetamide through the action of flavin-containing 
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monooxygenase (FMO) in the liver to thioacetamide- S -oxide. Since both thioacetamide and 
TMA require FMO in their oxidation reaction, the conversion of thioacetamide to its S- 
oxide would be expected to compete with the conversion of TMA to TMAO for FMO as 
evident by the reduced level of liver TMAO. 
Thioacetamide- S -oxide is then converted to an intermediate capable of reacting with tissue 
macromolecules in a cytochrome P450 monooxygenase-catalysed reaction. Finally, the 
formation of irreversibly bound products of thioacetamide- S -oxide metabolism may initiate 
changes in hepatic cellular function resulting in cell death (Rees et aL 1966, Hunter et al. 
1977, Porter and Neal 1978, Porter et aL 1979, Dyroff and Neal 1982). 
5.3.4 Summary 
1H MAS NMR spectroscopy coupled with 1H NMR spectroscopy of biofluids and 
multivariate data analysis as well as conventional histopathological and clinical chemistry 
data has enabled the detailed study of biochemical perturbations in liver tissue, blood 
plasma and urine following treatment with thioacetamide. NMR-based metabonomic 
approach appears to be more sensitive in picking up subtle thioacetamide-induced changes 
particularly in the low dose as compare to conventional histopathological method. The 
treatment with thioacetamide had several effects in the rats in that it disrupted energy 
metabolism characterised by depletion in liver glycogen and glucose followed by reduced 
urinary TCA cycle intermediates, citrate and 2-oxoglutarate. The treatment also caused 
disruption in lipid metabolism. The accumulation of triglycerides is a common cellular 
response to toxic compounds, which is normally reversible. This can occur by increased 
synthesis or uptake of lipid, decreased lipid metabolism, or inhibition of lipid transport 
from the cell. In the case of thioacetamide, the latter of these is the most likely case as the 
observed hepatic lipidosis was concomitant with hypolipidaemia as in the case of allyl 
formate toxicity. The urinary excretion of thioacetamide- S -oxide indicated the likely 
involvement of flavin-containing monooxygenase system as a route for the elimination and 
inadvertently, the hepatotoxicity of thioacetamide through the formation of reactive 
intermediates. In conclusion, this study has utilised high resolution 1H MAS NMR 
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spectroscopy to study intact liver tissues, which provides the essential link between the 
metabolite profiles obtained from biofluid NMR and the structural progression of the lesion 
observed by histopathological technique. 
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Chapter 6: Global Pattern Recognition Analysis 
6.1 Introduction 
The differing effects of allyl formate, chlorpromazine and thioacetamide were compared by 
pattern recognition analysis of combined data. The clinical chemistry data and 1H NMR 
spectra were analysed separately and in certain combinations using principal component 
analysis (PCA) and partial least square (PLS) analysis. Possible correlation between liver 
and plasma NMR data was examined. It should be noted again that the Day 2 tissue and 
plasma samples and the Day 2 urme samples were provided by different sets of animals and 
were therefore not directly comparable. The data sets analysed as well as the sample 
labelling and codes are summarised in Table 6.1. Prior to concatenating the plasma and 
liver NMR data, each segmented spectral region of the reduced and normalised plasma data 
was labelled with its segment number and ending with the letter P (designating plasma). All 
data were mean centered, unless stated otherwise, prior to pattern recognition analysis. All 
subsequent data analysis was performed using SIMCA-P (version 10.5, Umetrics AB, 
Umea, Sweden) software. 
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Table 6.1 NMR data Analysed and Sample Labelling and Code. 
Compound Day 2 NMR 
Spectral Type 
Study Group Sample Label 
Liver - Standard Control C6-CIO 
ID Low Dose (25 mg/kg) ALD 1 06-ALD I 10 
Allyl Formate 
Plasma - CPMG High Dose (75 mg/kg) AHD206-AHD210 
Urine - Standard 
Control CI-C5 
ID 
Low Dose (25 mg/kg) ALDIOI-ALD105 
High Dose (75 mg/kg) AHD201-AHD205 
Liver - Standard Control C6-ClO 
1D Low Dose (30 mg/kg) CPLD306-CPLD310 
Chlorpromazine 
Plasma - CPMG Highdose (60 mg/kg) CPHD406-CPHD410 
Urine - Standard 
Control CI-C5 
ID 
Low Dose (30 mg/kg) CPLD301-CPLD305 
High Dose (60 mg/kg) CPHD401-CPHD405 
Liver - Standard 
Control TC6-TClO 
1D Low Dose (50 mg/kg) TLD306-TLD310 
Thioacetamide 
Plasma - CPMG High Dose (200 mg/kg) THD406-THD410 
U i - Standard 
Control TCl-TC5 
r ne 
1D 
Low Dose (50 mg/kg) TLD301-TLD305 
High Dose (200 mg/kg) THD401-THD405 
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6.2 Global Pattern Recognition of Day 2 Plasma Clinical Chemistry Data 
PCA analysis was performed on the Day 2 plasma clinical chemistry data with individual 
variables being unit variance-scaled prior to modelling. In the scores plot, the data points 
are labelled so as to identify the treatment (e. g. C for control, LD for low dose and HD for 
high dose) and animal number. The data points and labels are colour-coded by treatment. 
For the loadings plot, the data points are labelled according to the clinical chemistry 
parameters that they represent. 
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Figure 6.1 PCA scores plot for the first two components of the Day 2 plasma clinical 
chemistry of the three hepatotoxin-dosed samples. 
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Principal component analysis of the Day 2 data set revealed some dose-related structure to 
the variation in the data with the thioacetamide-treated animals being separated from the 
control animals along the second principal component and the high dose allyl formate 
animals separated from the controls along the first principal component (Figure 6.1). The 
first principal component describes the variation between the high dose allyl formate and 
chlorpromazine-treated animals and the controls animals. The high dose animals are well 
separated from the controls except for chlorpromazine dosed animals which are partially 
separated from the controls along the first principal component. The second principal 
component describes the variation between the high dose thioacetamide-treated animals 
from the controls. In addition the control animals for the two studies are separated along the 
second principal component indicating some biochemical variations between the two 
groups of control animals. 
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Figure 6.2 PCA loadings plot for the first two components of the Day 2 plasma clinical 
chemistry of the three hepatotoxin-dosed samples. 
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The corresponding loadings plot of the PCA model (Figure 6.2) indicated that the high dose 
of allyl formate caused increases in y-glutamyl transferase and bilirubin, which are markers 
of hepatobiliary damage. Another important feature observed in the loadings plot along the 
first principal component is the generalised increase in both aminotransferases, ALAT and 
ASAT, which are indicative of hepatocellular damage in the high dose allyl formate-dosed 
animals. Animals treated with high dose of allyl formate also showed decreases in plasma 
albumin, protein and triglycerides as compared to the control animals. 
However, animals treated with high dose of thioacetamide showed increases in plasma bile 
acids, 5NT, ALP and ASAT, which contributed to the separation along the second principal 
component. These changes are orthogonal to that observed in the allyl formate-treated 
animals. In addition, animals treated with high dose of thioacetamide also showed decrease 
in plasma glucose, which contributed to the separation along the second principal 
component. 
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6.3 Global Pattern Recognition of Day 2 Standard 1D MAS NMR Spectra of Liver 
PCA and PLS-DA analysis were performed on all standard ID NMR spectra of Day 2 liver 
samples for all three hepatotoxins. The data were combined, normalised and mean-centered 
prior to modelling. In the scores plots, the data points are labelled so as to identify the 
treatment (C for control, LD for low dose and HD for high dose) and animal number. These 
data points and labels are also colour-coded by treatment. For the loadings plot, the data 
points are labelled according to the bucket or spectral segment that they represent. 
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Figure 6.3 PCA scores plot for the first two components of the Day 2 standard 1D 
IH 
MAS NMR spectra of the three hepatotoxin-dosed liver samples. 
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Principal component analysis of the Day 2 data revealed some treatment-related structure to 
the variation in the data. The first principal component describes most of the treatment- 
related variation (Figure 6.3). However, most of the animals treated with the low dose of 
allyl formate are separated from their controls along the second principal component. The 
high dose animals are well separated from the controls along the first principal component 
except for the chlorpromazine-dosed animals where three out of five animals are well 
separated along the first principal component. Some separation in animals treated with the 
three different compounds can be observed along the second component but this is partly 
explained by inter-study differences, as revealed by the controls. Thus, the high dose allyl 
formate animals are clearly separated from the high dose thioacetamide animals. However, 
the positions of the high dose chlorpromazine animals on the second principal component 
are not explainable simply by inter-study variation. 
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Figure 6.4 Corresponding PCA loadings plot for the first two components of the Day 2 
standard ID 1H NUS NMR spectra of the three hepatotoxin-dosed liver samples. 
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The corresponding PCA loadings plot (Figure 6.4) indicated that increases in liver lipids 
and decreases in liver glucose are the main contributors to the separation between the 
control animals and the dosed-animals along the first principal component. In addition, 
some increase in the level of liver lactate can also be observed along the first principal 
component, which contributed to the separation between the dosed and control groups. 
Variation in the level of liver TMAO is the major contributor to the separation among the 
three hepatotoxin-groups on the second principal component, with the allyl formate group 
showing the highest TMAO level situated on the upper half of the scores plot, and the 
thioacetamide-dosed animals situated on the lower half of the scores plot showing lower 
liver TNIAO level. However, there is also a clear difference in liver TMAO between the 
two control groups and so the TMAO difference between the high dose allyl formate and 
thioacetamide groups may not be especially significant. On the other hand, the lower level 
of TMAO in the high dose chlorpromazine group compared to the high dose allyl formate 
group is more likely to be significant as these data came from the same study. 
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6.3.2 PLS-DA ofLiver NMR Data 
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Figure 6.5 PLS-DA cross validated scores plot of the Day 2 standard ID 111 MAS 
NMR spectra of the three hepatotoxin-dosed liver samples. 
To further refine the information recovery, a PLS-DA model was constructed on the 
standard ID MAS NMR data of liver tissues. Figure 6.5 shows the X matrix cross validated 
scores of the first two components of the Day 2 tissue MAS NMR data. Overall the pattern 
observed is almost identical to that observed in the PCA scores plot (Figure 6.3). The 
scores plot shows some treatment-related separation along the first component. Compound- 
related structure can be observed along the second component with allyl formate-dosed 
animals situated in the upper half of the scores plot, thioacetamide-dosed animals situated 
in the lower half of the scores plot and chlorpromazine-dosed animals situated in both 
halves of the plot. However, the control groups of the two studies remain separated along 
the second PLS component and this separation parallels that of the allyl formate and 
thioacetamide dosed animals. 
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Figure 6.6 Corresponding PLS-DA loadings plot for the first two components (A and 
B) of the Day 2 standard 1D 1H NL4, S NMR spectra of the three hepatotoxin-dosed 
liver samples. 
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The corresponding X block PLS loadings shown in Figure 6.6 indicates that the first 
component, describing the general effects of dosing on the animals, is due to increases in 
liver lipid profiles and decreases in liver TMAO, glucose and glycogen levels. However, 
the second component mainly describes variation in the liver TMAO level, which is partly 
study-related as evidenced by the separation of the two sets of controls. Animals treated 
with high dose of chlorpromazine are separated into two sub-groups with animals 407 and 
410 being more like the controls for the two studies and animals 406,408 and 409 showing 
changes typical of the high doses of allyl formate and thioacetamide. The latter are the ones 
that showed chlorpromazine-induced ketosis. 
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6.4 Global Pattern Recognition of Day 2 CPMG NMR Spectra of Plasma 
PCA and PLS-DA analysis were performed on all CPMG ID NMR spectra of Day 2 
plasma samples for all three hepatotoxins. The CPMG NMR spectra were used in 
preference to the standard ID NMR spectra because experience indicated that better 
discrimination is provided by the former in pattern recognition analysis. The data were 
combined, normalised and mean-centred prior to modelling. In the scores plot, the data 
points are labelled and colour-coded so as to identify the treatment and animal number. For 
the loadings plot, the data points are labelled according to the plasma spectral segment that 
they represent. 
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Figure 6.7 PCA scores plot for the first two components of the Day 2 plasma CPMG 
1H NMR spectra of the three hepatotoxin-dosed liver samples. 
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Figure 6.7 shows the scores plot for the first two components of the control/dose Day 2 
plasma CPMG NMR data. Little separation between the two control groups can be seen in 
the scores plot as compare to the scores plot of the tissue MAS NMR data (Figure 6.3). The 
scores plot shows clear treatment-related separation along the first principal component 
especially between the high dose and control animals. Some compound-related variation 
can also be observed along the second principal component. In addition, the scores plot also 
revealed four outliers, animals CPHD 406 and 409, animal THD408 and control animals 
TC9. Spectral inspection revealed that both animals CPHD 406 and 409 have higher plasma 
3-D-hydroxybutyrate and lower plasma lactate content. Animal THD408 showed higher 
lactate content as compared to the rest of the high dose thioacetamide-treated animals. 
Control animal TC9, on the other hand, showed higher plasma VLDL content as compare 
to the rest of the control animals. 
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Figure 6.8 Corresponding PCA loadings plot for the first two components of the Day 2 
plasma CPMG 1H NMR spectra of the three hepatotoxin-dosed liver samples. 
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The corresponding loadings plot of the PCA model (Figure 6.8) indicates that decreases in 
plasma lipid profiles are the major contributor to the separation between the dosed and 
control animals along the first principal component. The loadings plot also shows changes 
in plasma lactate, acetoacetate and 3-D-hydroxybutyrate levels as the contributors to 
compound-related variations along the second principal component. The changes observed 
in the loadings plot agrees with the changes observe in the plasma NMR spectra whereby 
visual inspection of the corresponding NMR spectra reveals that both animals CPHD 406 
and 409 showed signs of ketosis represented by elevated 3-D-hydroxybutyrate and 
acetoacetate. Visual inspection of the NMR spectra of animal TH408 shows clear increase 
in plasma lactate and control animal TC9 showed higher plasma lipids content as compare 
to the rest of the control animals. 
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Figure 6.9 PLS-DA cross validate scores plot of the Day 2 plasma CPMG 
1H NMR 
spectra of the three hepatotoxin-dosed liver samples. 
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Figure 6.9 shows the X matrix cross validated scores plot for the first two components of 
the Day 2 plasma NMR data. Animals treated with high dose of all three hepatotoxins were 
clearly separated from the control animals along the first component. The second 
component describes the variation between the different compounds with animals dosed 
with high dose thioacetamide situated on the lower left quadrant of the scores plot. Animals 
treated with high dose allyl formate are located between the thioacetamide and 
chlorpromazine high dose animals along the second component. The scores plot also 
showed some degree of overlap between the high dose chlorpromazine animals and the 
high dose allyl formate animals. However, in the high dose of chlorpromazine, animals 
showing ketosis (animals 406,408 and 409) are clearly separated from the remaining two 
animals along the second PLS component. 
The corresponding loadings plot (Figure 6.1 OA) indicated that a decrease in plasma lipids is 
the ma or contributor to the separation between the dosed animals and the control animals 
along the first PLS component. The second component (Figure 6.10B) is partly related to 
changes in plasma lactate. Animals treated with thioacetamide showed higher levels of 
plasma lactate and alanine as compared to that of allyl formate and chlorpromazine. In 
addition, the loadings plot also reveals higher plasma acetoacetate and 3-D- 
hydroxybutyrate levels in chlorpromazine-dosed animals 406,408 and 409, which 
contributed to the separation along the second PLS component. 
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Figure 6.10 PLS-DA loadings plot of the Day 2 plasma CPMG 1H NMR spectra of the 
three hepatotoxin-dosed liver samples. 
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6.5 Global Pattern Recognition of Combined Day 2 Liver and Plasma NMR Data 
6.5.1 PCA ofLiver and Plasma NMR Data 
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Figure 6.11 PCA scores plot of Day 2 liver tissue and plasma 1H NMR spectra of the 
three hepatotoxins. 
PCA was performed on concatenated liver and plasma NMR data and Figure 6.11 shows 
the resulting scores and loadings plots. The high dose animals are largely separated from 
the controls along the first principal component. In addition, the high dose thioacetamide 
animals are separated from the high dose allyl formate animals along the second principal 
component, which corresponds to the separation between their control groups. The high 
dose chlorpromazine animals are separated into two sub-groups with the three ketotic 
animals (animals 406,408 and 409) separated from the two non-ketotic animals. The non- 
ketotic high dose chlorpromazine animals were clearly separated from the rest of the high 
dose animals along the second principal component. 
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Figure 6.12 Corresponding PCA Loadings plot of Day 2 liver tissue and plasma 1H 
NMR spectra of the three hepatotoxins. 
The corresponding PCA loadings plot (Figure 6.12) revealed that a decrease in plasma 
lipids in toxin-related animals is the major contributor to the separation along the first 
principal component whereas increases in liver lipids and decreases in liver TMAO, 
glucose and glycogen as well as increase in plasma lactate are the major contributors to the 
separation along the second principal component. The loadings plot also indicates that the 
high dose thioacetamide-treated animals have higher liver lipids and plasma alanine and 
lactate content as compared to that of the allyl formate and chlorpromazine treated animals. 
The general effects of high dose allyl formate seems to be increases in liver lipids and 
decreases in glucose and glycogen content as well as decrease in plasma lipids. The 
loadings plot also showed that increases in plasma 3-D-hydroxybutyrate and acetoacetate 
(ketone bodies) are the major contributor to the separation within the high dose 
chlorpromazine animals. Although chlorpromazine inhibits the formation of TMAO in the 
rats, the loadings plot does not reflect its effect. However, looking at the separation 
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between the two control groups in the PCA scores plot (Figure 6.11), the loadings plot 
indicated that variation in the liver TMAO level is the major contributor to the separation of 
the two control groups and visual inspection of the corresponding liver NMR spectra 
showed that all thioacetamide control animals have lower TMAO levels as compare to the 
other control animals. The results indicated that both groups of control animals are 
biochemically non-identical and that they have different biological starting point prior to 
the commencement of the study. 
6.5.2 PLS-DA ofLiver and Plasma NMR Data 
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Figure 6.13 PLS-DA cross validated scores plot of Day 2 liver tissue and plasma 
1H 
NMR spectra of the three hepatotoxins. 
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The Day 2 liver and plasma NMR data was analysed using PLS-DA approach to further 
refine the information recovery. The data was mean centered prior to modelling. Figure 
6.13 shows the cross validated scores plot for the first two components of the data set. The 
scores plot shows an improvement in the separation between the dosed animals and the 
control animals as well as the separation in animals treated with the three different 
hepatotoxins as compare to the PCA scores plot in Figure 6.11. Clear separation can be 
seen among animals treated with the different hepatotoxins along the second component 
although some overlap can still be seen. Animals treated with high dose of thioacetamide 
are separated from the rest of the high dose animals along the second PLS component. 
Animals treated with high dose of allyl fonnate are partially separated from animals treated 
with high dose of chlorpromazine along the second PLS component. The control animals of 
study 98053 are clearly separated from the control animals of study 99057 along the second 
PLS component. 
The corresponding first component PLS weight showing the contribution from liver and 
plasma (Figure 6.14A and B respectively) indicated that increase in liver lipids and 
decreases in liver glucose and glycogen as well as decrease in plasma lipids are the major 
contributors to the separation between the dosed animals and the control animals along the 
first component. The corresponding second component PLS weight showing the 
contribution from liver and plasma (Figure 6.15A and B respectively) indicated that 
differences in liver TMAO level as well as changes in plasma glucose, creatine, alanine, 
lactate, glutamine and pyruvate are the major contributors to the separation in animals 
treated with the three different hepatotoxins. Again, animals treated with high dose 
thioacetamide showed higher lactate, alanine, glutamine and pyruvate content as compared 
to animals treated with allyl formate and chlorpromazine respectively. The difference in 
liver TMAO content in the control animals dominates the second component loadings plot 
thus shadowing the effects of chlorpromazine on the biological samples. 
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Figure 6.14 First component PLS weight (W[I]) from the PLS-DA model attributed to 
(A) standard 1D 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG IH 
NMR data of Day 2 plasma samples (-). 
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Figure 6.15 Second component PLS weight (W[2]) from the PLS-DA model attributed 
to (A) standard ID 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG 
1H 
NMR data of Day 2 plasma samples (-). 
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6.5.3 PLS ofLiver and Plasma NMR Data 
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Figure 6.16 PLS cross validated scores plot of Day 2 liver tissue and plasma 1H NMR 
spectra of the three hepatotoxins. 
The Day 2 liver and plasma NMR data was further analysed using PLS approach by 
treating the liver NMR data as the X matrix and the plasma NMR data as the Y matrix in 
order to find correlations between the changes observed in the liver and the changes 
observed in the plasma. The data was mean centered prior to modelling. Figure 6.16 shows 
the cross validated scores plot for the first two components of the data set. The scores plot 
shows no improvement in the separation achieved as compared to the PCA scores plot in 
Figure 6.13. The first component describes the variation between the dosed animals and the 
control animals. In addition, the high dose chlorpromazine animals were separated into two 
sub-groups, with animals 406,408 and 409 separated from animals 407 and 410 along the 
first PLS component. The second PLS component is dominated by the inter-study 
variations. 
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The first component PLS weights (Figure 6.17A and B respectively) indicated that increase 
in liver lipids and decreases in liver glucose and glycogen as well as decreases in plasma 
lipids are the major contributors to the separation between the dosed and the control 
animals along the first component. The loadings also showed a correlation in lipid changes 
between the liver samples and the plasma samples. In addition, the loadings indicated that 
increases in plasma 3-D-hydroxybutyrate and acetoacetate are the major contributors to the 
separation within the high dose chlorpromazine-treated rats. The corresponding second 
component PLS weights (Figure 6.18A and B respectively) indicated that differences in 
liver TMAO level as well as changes in plasma glucose, creatine, alanine, lactate, 
glutamine and pyruvate are the major contributors to the separation in the second PLS 
component. The difference in liver TMAO content of the control animals dominates the 
second component loadings plot. 
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Figure 6.17 First component PLS weight (W*c[l]) from the PLS model attributed to 
(A) standard ID 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG 
1H 
NMR data of Day 2 plasma samples (-). 
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Figure 6.18 Second component PLS weight (W*c[21) from the PLS model attributed 
to (A) standard ID 1H MAS NMR data of Day 2 liver tissues (-), and (B) CPMG 
1H 
NMR data of Day 2 plasma samples (-). 
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6.6 Global Pattern Recognition of Day 2 Standard ID NMR Spectra of Urine 
6.6.1 PCA of Urine NMR Data 
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Figure 6.19 PCA scores plot for the first two components of the Day 2 urine 1H NMR 
spectra of the three hepatotoxin-dosed liver samples. 
Principal components analysis shows that the animals were separated into two groups, 
Study 98053 (allyl formate and chlorpromazine) and Study 99057 (thloacetamide) on a 
diagonal as can be seen by the green arrow in the scores plot (Figure 6.19). The 
corresponding loadings plot (Figure 6.20) indicated that difference in urinary TMAO is the 
major contributor to the separation between the two clusters of animals. Animals in Study 
98053 have higher urinary TMAO level as compare to that of Study 99057. The differences 
in urinary TMAO level dominated the PCA model therefore rendering the model less 
interpretable although some dose related variation can still be observed along the second 
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principal component. The loadings plot indicated that changes in urinary endogenous 
metabolites are the major contributors to the separation along a diagonal from high 
PC I /PC2 to low PC 1 /PC2,, as indicated by the black arrow in the scores plot, with increases 
in taurine and creatine, and decreases in urinary citrate, hippurate and 2-oxoglutarate 
featuring strongly. 
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Figure 6.20 Corresponding PCA loadings plot for the first two components of the Day 
2 urine 1H NMR spectra of the three hepatotoxin-dosed liver samples. 
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Figure 6.21 Resultant PCA scores plot for the first two components of the Day 2 urine 
1H NMR spectra of the three hepatotoxin-dosed liver samples with bucket 3.28 
removed. 
Due to the dominating effect of TMAO on the interpretability of the PCA model, the 
buckets representing TMAO was removed and the data were renormalised and mean 
centre-scaled prior to PCA analysis. Figure 6.21 shows the resultant PCA scores plot for 
the first two components after the removal of TMAO bucket. The scores plot shows 
improved interpretability of the PCA model with the two sets of controls overlapping and 
dose-variation seen in the first principal component. Clear separation between the dosed 
and control animals can be observed mainly along the first principal component. In 
addition, variation in the high dose animals can be observed on the second principal 
component. 
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Figure 6.22 Resultant PCA loadings plot for the first two components of the Day 2 
urine 111 NNM spectra of the three hepatotoxin-dosed liver samples with bucket 3.28 
removed. 
The corresponding loadings plot (Figure 6.22) indicated that changes in urinary endogenous 
metabolites are the major contributors to the separation along the first principal component 
with increases in taurine and creatine, and decreases in citrate, hippurate and 2-oxoglutarate 
as major factors. Additionally, a change in urinary PAG was also detected but was not as 
clear as the other changes. Variation in the urinary creatine level also contributed to the 
separation along the second principal component with animals AHD 203, AHD 205, THD 
402 and CPHD 401 showing lower levels of this metabolite than the rest of the high dose 
animals. 
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6.6.2 PLS-DA of Urine NMR Data 
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Figure 6.23 PLS-DA cross validated scores plot of the Day 2 1H NMR spectra of the 
three hepatotoxin-dosed urine samples with bucket 3.28 removed. 
In order to improve interpretability and information recovery from the urine NMR data a 
PLS-DA model was constructed using the normallsed mean centre-scaled data set with the 
TMAO bucket removed. Figure 6.23 shows the PLS-DA cross validated scores plot for the 
first two components of the Day 2 urine NMR data. The first X matrix PLS component 
describes the dose related variation between the dosed animals and the control animals of 
study 98053 whereas the second X matrix PLS component describes the dose related 
variation between the dosed animals and the control animals of study 99057. In addition, 
some separation between the two studies can still be seen along the second component. 
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Figure 6.24 Corresponding PLS-DA loadings plot of the Day 2 1H NMR spectra of the 
three hepatotoxin-dosed urine samples with bucket 3.28 removed. 
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The corresponding loadings plot (Figure 6.24) indicated that changes in urinary endogenous 
metabolites are the major contributors to the separation along the first PLS component with 
increases in taurine, creatine and PAG, and decreases in urinary citrate, hippurate and 2- 
oxoglutarate. The change in urinary PAG was not as clear as the rest of the endogenous 
metabolites. In addition, the corresponding loadings plot of the second PLS component 
indicated that differences in urinary hippurate, lactate and glucose levels contributed to the 
separation between the thioacetamide-treated and the allyl formate- and chlorpromazine- 
treated animals along the second PLS component. Thioacetamide-treated animals showed 
higher urinary lactate and glucose levels and lower urinary hippurate level as compare to 
the rest of the high dose animals. The appearance of urinary glucose in thioacetamide- 
treated animals indicates impaired kidney function in these animals. 
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6.7 Discussion 
The application of pattern recognition methods has enabled the visualisation and 
comparison of the effects of the three hepatotoxins i. e. allyl formate, chlorpromazine and 
thioacetamide on the rats. The integrated approach to analysing biological samples renders 
it possible for pattern recognition techniques to highlight important dose- and compound- 
related differences in the animals. The use of unsupervised method such as PCA allows 
visualisation of intrinsic clustering behaviour that is unique to each of the hepatotoxins i. e. 
chlorpromazine, an FAD inhibitor, reduces TMAO level in biological samples. This 
approach has revealed changes that are common to all the hepatotoxins administered such 
as their effects on liver and plasma lipids and has enabled cross-correlation of changes 
occurring in different biological matrices. 
The difference in TMAO level in the control animals appears to dominate majority of the 
models. Changes in the levels of methylamine intermediates can be directly related to the 
diet since TNIAO is mostly dietary derived, synthesised from its precursor, choline, in the 
diet by the gut microflora. TMAO is involved in methane metabolism. The differences in 
TMAO could reflect the biochemical status of the control animals during the course of the 
study. TMAO has an osmoregulatory role in animals, and may be involved (in a redox 
fashion) within disulphide/thiol linkage formation/equilibrium. Zethof et aL (1994) showed 
that animal handling can affect the colonic temperature, a condition termed stress-induced 
hypothermia, which may affect the metabolism in particular the metabolism of 
methylamines in the gut microflora. The difference in TMAO level in the control rats also 
highlights the problem of using genetically identical animals which exhibit dissimilar 
biochemical starting point in toxicological studies. 
In pattern recognition analysis of drug-induced toxicity, it is mainly perturbations of the 
endogenous metabolites that are of interest. Therefore, it is imperative that the NMR 
spectral data used does not contain any xenobiotic metabolites which will interfere in 
analysis. Fortunately, all the Day 2 NMR data of allyl formate, chlorpromazine and 
thioacetamide were free from these interfering peaks. However, it is still possible albeit 
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time consuming to analyse the data even if the metabolites were present by removing the 
metabolite peaks and renormalizing the data set. The use of statistical total correlation 
spectroscopy (STOCSY) could also help in identifying such peaks (Cloarec et al. 2005) 
Another potential problem with pattern recognition analyses is the segmentation or 
bucketing of the original spectra into 'buckets'. In biofluld, the bucket size used was 0.04 
ppm, therefore, for samples analysed using a 600 MHz spectrometer, the bucket size of 
0.04 ppm corresponds to 24 Hz. It is clear that each bucket will include contributions from 
several NMR peaks instead of just one specific NMR peak. It is vital that the bucket 
identified by pattern recognition methods be compared with visual inspection of the actual 
NMR spectra to ensure the results obtained are true representative of the actual effects of 
the drugs being tested. The use of smaller bucket size i. e. in liver tissue NMR spectra 
minimises this problem. However, the use of smaller bucket size in biofluids such as 
plasma and urine NMR spectra is impractical as the later suffers from pH-induced peak 
shifts. In addition, global pattern recognition tends to involve data acquired over a long 
period of time and possibly from different laboratories. Therefore, it is of utmost 
importance to ensure that a set of standard operating procedures including sample 
preparations, NMR acquisition parameters and pattern recognition steps were practiced to 
ensure minimal systematic error, which will contribute to the variation in the results 
obtained. 
The application of supervised pattern recognition techniques such as PLS-DA enhanced the 
separation between the dosed animals and the controls. It also enables construction of 
mathematical models that can predict the class of each sample. One important feature of 
PLS-DA is the validity of the models created using this technique can be determined by 
cross validation. This allows statistical evaluation as to whether the distinction between the 
classes is significant or not. Cross-validation uses an internal test set of observations to test 
for the models forecasting veracity. The idea of cross-validation is to remove a portion of 
the data set, usually one third, out of the model development and then developing a number 
of parallel models from the remaining data. The removed data is then used to predict the 
classification of each observation in the test set. The predicted values can then be compared 
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to the actual values to validate the predictive ability, accuracy and significance of the PLS- 
DA model. However, due to the small sample size cross validations were not carried out for 
each model hepatotoxin. The use of PLS analysis by treating the liver NMR data as the X 
variable and the plasma NMR data as the Y variable has enabled the identification of 
changes in the liver, which correlates with the changes in the blood plasma. In this case, the 
increase in liver lipids correlates to a decrease in plasma lipids in all the high dose treated 
animals. This indicates that all three compounds used in this project caused a decrease in 
lipid transport from the liver to the blood. 
Despite all the potential problems, the application of pattern recognition techniques to 
NMR data had helped enormously in simplifying the analysis and visualisation of changes 
in complex biological data especially in identifying small changes that are not easily 
distinguished by eye. The use of standard operating protocols, good laboratory practice 
(GLP) and good design of experiment as well as having a consistent set of NMR 
parameters are paramount in ensuring good quality NMR spectroscopic data are obtained 
for analysis. 
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Chapter 7: Summary and Conclusions 
7.1 Summary 
In this project, the integrated metabonomic approach has been applied in conjunction with 
conventional toxicological techniques to examine the effects of three model hepatotoxins in 
rats. This comprehensive analysis provided a complex data set but the use of pattern 
recognit on techniques such as principal components analysis and partial least squares 
analysis has simplified the analysis and enabled a better understanding of the effects 
produced. An interesting and novel aspect of this work is that the diverse biochemical 
profiles generated from the different matrices (liver, plasma and urine) were compared to 
find interrelationships between the matrices and to gain insights into the toxicological 
processes. 
Table 7.1 Summary of the average levels of certain clinical chemistry parameters in 
plasma (24 hours post-dose). 
Level relative to controls in plasma 24 hours after dosing 
Hepatotoxin 
ASAT ALAT Bilirubin 5NU TBA GGT 
Allyl Formate 
45.3X 43.2X 2.2X 1.9x 4.3X 6.2X 
(75 mg/kg) 
Chlorpromazine 
1.9x 1. Ox 1.3X 0.6X 0.5X 2. OX 
(60 mg/kg) 
Thioacetamide 
30AX 9.3X 1.2X 2.8X 26.1X 1.3X 
(200 mg/kg) 
Key: The levels are expressed as a multiple of the average control level at the same time 
point. ASAT = aspartate aminotransferase, ALAT = alanine aminotransferase, 5NU = 59 
nucleotidase, TBA = total bile acids, GGT = y-glutamyltransferase. 
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All three toxins were found to produce some hepatic damages by the conventional 
methodologies but there was substantial variation in the nature and extent of this damage 
with allyl formate and thioacetamide producing major effects and chlorpromazine 
producing minor effects. Table 7.1 summarises some relevant plasma chemistry changes at 
24 hours after dosing. Despite substantial variation in the extent of the damage caused by 
the different toxins, each toxin produced some common biochemical effects (Table 7.2). 
Table 7.2 Distinguishing and common toxicological factors induced by the three 
hepatotoxins. 
Hepatotoxins Distinguishing Factors Common Factors 
Allyl Formate 
(75 mg/kg) 
- Changes in TMAO levels . Chlorpromazine Presence of ketone bodies in 
- Disruption in energy and lipid (60 mg/kg) the blood plasma indicating 
metabolism. 
ketosis. 
- Perturbations in TCA cycle Thioacetamide Presence of lactate and intermediates. 
(200 mg/kg) alanine in the blood plasma 
indicating gluconeogenesis. 
The fundamental mechanism that connects all three hepatotoxins together in biochemical 
terms, through the analysis of the NMR-generated metabolic data sets, appears to be 
disruption of energy supply. Tissue MAS NMR data analysis revealed decreases in liver 
glucose and glycogen and biofluids NMR data analysis revealed decreases in urinary TCA 
cycle intermediates namely, citrate, succinate and 2-oxoglutarate, which all indicate 
disruption in energy metabolism. Supporting this, all three compounds administered (allyl 
fonnate, chlorpromazine and thioacetamide) are known to cause mitochondrial dysfunction 
(Rees and Tarlow 1967, Pang et al. 1997, Medina et al. 1964, Dawkins et al., 1960, Moller 
and Dargel, 1985, Cascales et al. 1982). The increases in liver lipids and the decreases in 
plasma lipids are also consistent with disrupted energy supply. Under conditions Of low 
cellular ATP concentrations, glycogenolysis and glycolysis would be expected to be up- 
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regulated in order to provide ATP which would account for the decreases in liver glucose 
and glycogen storage. Disruption in mitochondrial functions often leads to disruption in 
fatty acids metabolism due to impaired fatty acid oxidation and electron transport chain 
processes, both highly dependent on mitochondria structural integrity and therefore 
mitochondrial compartmentalisation. Thus, the increases in liver lipid moeties might arise 
simply through an inability to metabolise it in the mitochondria but ATP depletion will also 
inhibit protein synthesis and will, thereby, reduce the secretion of lipoproteins from the 
liver to the blood. This latter explanation for the increases in liver lipids is more convincing 
because of the concomitant decreases in plasma lipids. 
Impaired protein synthesis through ATP-depletion and/or inhibition of protein synthesis by 
the compounds administered would also impair apolipoprotein synthesis. Impaired 
apolipoprotein synthesis would lead to reduced transport of triglycerides out of the liver 
thus leading to increase triglycerides in the liver and decreases in plasma lipid 
concentration as observed by NMR spectroscopy of both liver tissues and plasma. In 
addition, increase in intracellular bile acids concentrations was known to inhibit the 
secretion of VLDL-associated triglycerides from hepatocytes as well as the secretion of 
apolipoprotein associated with transport of VLDL namely apoB-100 as demonstrated by 
Lin et aL (1996). Of the three compounds administered, allyl formate and thioacetamide are 
known to cause biliary damage and the plasma clinical chemistry results in the current 
study indicated an increase in total bile acids (TBA). Mitochondria dysfunction will 
incapacitate ATP synthesis. Moreover, it will also waste the remaining sources of ATP 
because depolarisation of the inner membrane of mitochondria, which forces the ATP 
synthase to function in the reverse mode, as an ATPase, will hydrolyse ATP. Glycolysis 
can even be compromised by the insufficient ATP supply to the ATP-driven glycolytic 
enzymes. 
If the metabolic disorders evoked by the toxic agent is so extensive that most or all of the 
mitochondria were disrupted, a complete bioenergetic catastrophe ensues with severe 
depletion of ATP, degradative processes such as oxidative and hydrolytic degradation, and 
intracellular disintegration will go to completion thus causing complete failure in cellular 
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structure and functions leading to cell lysis or necrosis. ATP availability also determines 
the form of cell death. Apoptosis is regarded as tissue repair because it intercepted the 
process leading to necrosis, which is a more hannful sequala than apoptosis and it intercept 
the process leading to neoplasia by eliminating the cells with potentially mutagenic DNA 
damage. In apoptosis, the cell shrinks and the nuclear and cytoplasmic materials condense 
and break into membrane bound fragments, which can then be phagocytosed. In 
comparison to necrosis, this process is considered to be more orderly as necrosis normally 
results in the cells and intercellular organelles swelling and disintegrating with membrane 
lysis, which ends with cellular debris in the extracellular environment. The constituents of 
necrotic cells attract aggressive inflammatory cells, and the ensuing inflammation amplifies 
cell in ury. However, apoptosis requires ATP. Depletion of ATP by hepatotoxins would 
deny urgently needed energy to execute apoptotic program, which involves ATP-driven 
steps to form complexes required for apoptosis. Thiaocetamide is known to induce 
apoptosis in the low dose thus facilitating tissue repair (Klaassen, 2001). However, at a 
high dose, thioacetamide induced necrosis. This suggests that necrosis occurs because the 
injury overwhelms and disables the repair mechanisms including repair of damaged 
molecules, elimination of damaged cells by apoptosis and replacement of lost cells by cell 
division. 
Elevated and altered triglycerides level in the liver could also be influenced by the 
toxicological end point of hepatotoxicity. Cells which experienced widespread damage are 
usually removed through the ATP-dependent process of apoptosis or programmed cell 
death. During apoptosis, the contents of the damaged dell are digested and packed into 
vesicles for re-absorption. Necrosis is thought to occur in the same pattern except with the 
absence of ATP as energy source. Increase in triglycerides could be attributed to 
accumulation of cytoplasmic lipid bodies in cells undergoing cell death (lorio et aL 2003). 
Inter-group differences in liver and urinary TMAO levels were an important and common 
observation in these studies. As well as seeing toxin-induced changes in liver/urinary 
TNIAO there were also differences in liver/urinary TMAO between the control groups from 
the two studies. As explained in Chapter 6, TMA is synthesised from dietary choline by the 
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gut microflora. This trimethylamine is then normally oxidised in the liver by the flavin 
monooxygenase system (FMO) to TMAO and the TMAO excreted in the urine. TMAO and 
DMA may play an osmotic role in renal medulla, where they counteract the gap, due to the 
high urea concentrations, between intracellular and extracellular fluids. Table 7.3 
surnmarises the observed changes in liver and urine TMAO levels on Day 2 after dosing. 
Table 7.3 Summary of the observed hepatotoxin-induced change in liver and urinary 
TNUO levels on Day 2. 
Hepatotoxin Liver TMAO Level Urinary TMAO Excretion 
Allyl Formate 
0.64X 0.59X 
(75 mglkg) 
Chlorpromazine 
0.55X 0.39X 
(60 mg/kg) 
Thioacetamide 
0.54X 0.77X 
(200 mg/kg) 
Key: The quoted TMAO values are the group averages expressed relative to the appropriate 
control groups at the same time point. 
As discussed earlier, urinary TMAO can either come from the oxidation of TMA, which is 
derived from dietary choline, or directly from intestinal bacteria (Nicholls et aL 2003). In 
the current work, the diet was kept the same for both studies; therefore it is unlikely that the 
source of TMAO variation was due to diet. In the case of chlorpromazine, a known 
inhibitor of FMO (Yagi et al. 1956, Lasslo and Meyer 1959, Ayesh and Smith 1990), an 
inhibition of FMO by chlorpromazine will lead to decreased formation of TMAO in the 
liver as well as reduced excretion of this metabolite in the urine. The metabolism of 
thioacetamide to thioacetamide-S-oxide requires FMO, thus, competition for FMO could 
account for the decrease TMAO levels observed in the liver and urine of animals treated 
with thioacetamide. However, decreased fonnation of TMAO would lead to increased 
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urinary TMA, which was not detected in the current work. The mammalian gut microflora 
have been shown to exerts significant effects on tissue and biofluid metabolic profiles and 
thus the control of host mammalian system (Nicholson and Wilson, 2003, Xu et al. 2003, 
Beale. 2002). It is possible that the source of TMAO variation could be due to colonisation 
and subsequent redistribution of gut microflora, and/or a change in gut microflora excretion 
(Nicholls et al. 2003). Inter-group differences in liver and urinary TMAO levels as well as 
urinary hippurate level observed in the present studies could be the result of different gut 
microflora populations as suggested by Nicholls et al. (2003). 
Hippurate is normally synthesised in the liver and kidney from glycine and benzoic acid. 
This is then excreted by the renal tubular cells in the urine. Decrease in the level of 
hippurate in the urine may be indicative of reduced tubular excretion efficiency or 
metabolic alteration. The hippurate level in the urine is highly dependent on gut microflora 
(Nicholls et al. 2003), and hormonal and environmental influences, the later being diet- and 
stress-related. Therefore, hippurate presents substantial inter-animal and inter-day 
variability. Hippurate is also the product of shikimic acid (quinic acid) degradation through 
the action of intestinal gut microflora. Thus, it is not possible to exclude the influence of 
food intake and different gut microflora populations in the gastrointestinal track on changes 
in urine hippurate concentrations. 
In the current studies, increased urinary PAG and plasma tyrosine level were observed in 
allyl formate and chlorpromazine-dosed animals whereas a decrease in urinary PAG and 
plasma tyrosine level were observed in the thioacetamide-dosed animals as shown in Table 
7.4. Under normal conditions, phenylalanine is metabolised to tyrosine by hydroxylation. 
Phenylalanine is also a well-known source of phenylacetic acid. As discussed previously in 
Chapter 3, phenylacetic acid and benzoic acid are metabolic precursors of PAG 
(phenylacetylglycine) and hippurate (benzoylglycine) respectively and both these aromatic 
acids are normally detoxified via such conjugation with glycine. If glycine was channelled 
into glutathione and/or PAG production as a defence mechanism, the reduction in urinary 
hippurate might be explained by insufficient glycine for the conjugation of benzoic acid. In 
addition, changes in urinary PAG level could be attributed to variability in the gut 
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microflora, (Nicholls et aL 2003). P-Oxidation of free phenyl- substituted fatty acids derived 
from excess lipids may also be one possible source of phenylacetic acid or it might be 
derived from metabolism of phenylalanine as proposed by Nicholls et al. (2000). 
Table 7.4 Summary of the observed changes in urinary PAG and plasma tyrosine 
levels on Day 2. 
Hepatotoxin Urinary PAG Excretion Plasma Tyrosine Level 
Allyl Formate 
1.31X 1.97X 
(75 mg/kg) 
Chlorpromazine 
1.63X 1.25X 
(60 mg/kg) 
Thioacetamide 
0.85X 0.78X 
(200 mg/kg) 
Key: The quoted PAG and tyrosine values are the group averages expressed relative to the 
appropriate control groups at the same time point. 
292 
7.2 Conclusions 
Disruption of hepatic energy metabolism appears to be a common effect of the hepatotxins 
studied. Coen et al. (2003) observed similar metabolic effects in studies of acute 
paracetamol toxicity in mice. Paracetamol induces centrilobular necrosis. Similarly, Craig 
(2004) showed that administration of methapyrilene, a periportal necrotic agent, in the rats 
caused disruption in energy metabolism. Although the end point of all the toxins are not 
entirely equivalent, these common responses seems to suggest that the metabolic changes 
evidenced here and elsewhere may represent a bigger more common disruption to energy 
metabolism induced by hepatotoxins. Allyl formate, chlorpromazine, thioacetamide, 
paracetamol and methapyrilene are compounds which induce mitochondrial dysfunction. 
The glycogen, glucose and lipid changes appear to be related to mitochondrial disruption 
which reduces the availability of ATP. This disruption will trigger a switch into 
carbohydrate catabolism thus resulting in the decreased/disabled utilisation of fatty acids. 
It is noteworthy that inter-animal variations were observed in the metabolic profiles of 
animals from the same dosing groups although these animals are subjected to tight 
regulation of environmental conditions. These effects were evident in the scores plots of all 
the treated animals. Historically, these effects have always been observed in studies making 
single measurements. The concentration of a single compound may be altered in response 
to more than one disease whereas a combination of metabolic perturbations is more likely 
to be specifically diagnostic for any particular condition. These inter-animal variations 
again highlighted the danger of relying on single compound biomarkers, as is the case with 
other biochemical screening techniques, in that one cannot say for certain, that the single 
compound change is a marker for the disease or organ dysfunction, or individual 
susceptibility to disease or toxic insult, which in turn could be related to the gut microbiota. 
In conclusion, the work presented in this thesis has demonstrated the applications of NMR- 
based metabonomic techniques in toxicological studies and the advantage of integrated 
metabonomic approach to the study and understanding of drug-induced liver toxicity. The 
integrated metabonomic approach enabled a thorough and enhanced characterisation of an 
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array of biological samples. The integration of 'omics' technologies could also be adapted 
to investigate model pharmaceutical toxins or diseases within whole mammalian 
biosystems as well as the gut microbiota in order to obtain a global view into the 
biochemical and molecular interactions of the host and its commensal in response to 
toxicological insult or disease processes. 
7.3 Future work 
In order to ascertain the exact mechanism that is at work here, a more focused study using 
13C labelled metabolites would be required. This will enable more accurate assessment of 
changes in metabolic fluxes by identifying candidate pathways such as gluconeogenesis, 
glycolysis, fatty acid degradation and fatty acid synthesis in response to toxic insult. Such 
studies complemented with measurements of up or down regulation of mRNA and key 
proteins levels within each pathway would allow the determination of the hepatotoxin- 
induced metabolic changes and its relation to the concerted changes in the expression 
pathway components and/or its relation to flux changes in the pathway at the metabolic 
level. Additionally, it is crucial to understand the dynamics and influences of the gut 
microbial composition on mammalian metabolism and its relation to the development and 
expression of disease processes as well as toxic insult (Nicholson and Wilson 2003). 
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Appendices 
Appendix 1. Experimental Materials and Suppliers. 
Material Supplier Address 
D20 
Fancy Lane 
NaCl 
Poole 
Na2HP04 
Sigma-Aldrich Dorset 
NaH2PO4 
BH17 7BR 
NaOH 
UK 
TSP 
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Appendix 11. Phosphate Buffer Solution. 
Preparation of O. IM Sodium Phosphate Buffer (pH 7.4) for lH NMR Urinalysis 
Stock Solution A: 0.2M NaH2PO4 (aq) 
4.80g of monosodium dihydrogen phosphate monohydrate (NaH2PO4. H20) into 200ml of 
deionised water. 
Stock Solution B: 0.2M Na2HP04(aq) 
5.68g of disodium monohydrogen phosphate heptahydrate (Na2HP04.7H20) into 200ml of 
deionised water. 
Buffer Solution Preparation 
Prepare a 0.2M stock solution A of NaH2PO4 in H20 
Prepare a 0.2M stock solution B of Na2B? 04 in H20 
Mix 19ml of stock solution A (0.2M NaH2PO4 ) with 81ml of stock solution B (0.2M 
Na2IIPO4) 
The pH was measured and adjusted to pH 7.4 by the drop wise addition of either solution A 
(if too basic) or solution B (if too acidic). The final volume was made up to 200ml with 
deionised water. 
Preparation of the TSP/D20 solution 
Take 0.0948 g of TSP and make up to 50ml with D20 in a volumetric flask 
TSP = 3-tiimethyIsiIyI-(2,2,3,3- 
2 H4)-I -propionate. 
318 
Appendix 111. Deuterosaline Solution. 
Preparation of Deuterosaline Solution 
6.3g of Sodium Chloride (NaCl) into 63ml of deionised water and 7ml D20, 
This resulted in a 9: 1 ratio of H20to D20. 
The overall product was 0.9% NaCl (w/v) 
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